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Abstract 
 
In this PhD thesis, we report for the first time, new methodology for the synthesis of 
angucycline antibiotic natural products. In particular, for the synthesis of 1,8-
dihydroxy-3-methyltetraphene-7,12-dione, commonly known as tetrangulol. We also 
report on the synthesis of 1,10,12-trimethoxy-8-methylbenzo[c]phenanthridine in our 
quest to synthesise phenanthroviridone from an intermediate product in the synthesis 
of tetrangulol. 
The Suzuki-Miyaura coupling reaction between 1,4,5-(trimethoxynaphthalen-2-
yl)boronic acid and 2-iodo-3-methoxy-5-methylbenzaldehyde afforded intermediate, 
3-methoxy-5-methyl-2-(1,4,5-trimethoxynaphthalen-2-yl)benzaldehyde. Conversion 
of this benzaldehyde into the alkyne, 2-(2-ethynyl-6-methoxy-4-methylphenyl)-1,4,5-
trimethoxynaphthalene was accomplished utilizing the Corey-Fuchs reaction. 
Exposure of the derived acetylene to a catalytic platinum(II)-mediated ring closure 
yielded the required tetracyclic aromatic product, 1,7,8,12-tetramethoxy-3-
methyltetraphene which was converted into tetrangulol. Exposure of the related 3-
methoxy-5-methyl-2-(1,4,5-trimethoxynaphthalen-2-yl)benzaldehyde O-phenyl 
oxime to microwave irradiation in an ionic liquid yielded 1,10,12-trimethoxy-8-
methylbenzo[c]phenanthridine, instead of the desired natural product 
phenanthroviridone.  
We also report on the unexpected synthesis of the benzonaphthopyranone core found 
in other classes of angucycline antibiotics from oxygen analogs of 2-naphthylbenzyl 
alcohols when exposed to N-bromosuccinimide. Treatment of (2-(1,4-
dimethoxynaphthalen-2-yl)phenyl)methanol and related analogues with N-
bromosuccinimide under an oxygen atmosphere afforded 12-methoxy-6H-
dibenzo[c,h]chromen-6-one, 2-Methoxy-6H-benzo[c]chromen-6-one and of 6H-
benzo[c]chromen-6-one. An investigation into possible mechanisms for this 
transformation was also conducted. 
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CHAPTER 1: Angucycline Antibiotics – Introduction and Literature Review 
 
1.1 Background and introduction on antibiotics 
Antibiotics have been used for treatment of a number of diseases and ailments for 
more than 50 years and are regarded as one of the most successful forms of 
chemotherapy in the history of medicine.
1-2
 They are defined as chemical substances 
of microbial origin that in low concentrations have the capacity to inhibit the growth 
of or kill other microorganisms.
3
 Although the management of microbial infections is 
well documented in ancient Chinese, Greece and Egypt civilisations, the modern use 
of antibiotics mainly began with the serendipitous discovery of penicillin from the 
culture filtrate of a fungus by Sir Alexander Fleming in 1928.
4
 Since this discovery, 
other more effective antimicrobials have been discovered and developed through 
better understanding of the drug target interactions.
5
 As a result, they have changed 
the landscape of modern medicine and saved millions of lives across the globe.
6
 
Furthermore, they have played a critical role in achieving significant advances in 
surgery through prevention or treatment of infections in patients who have undergone 
complex surgical procedures like organ transplants or cardiac surgery.
7
 In developing 
countries where infectious diseases are rampant due to poor sanitation, the morbidity 
and mortality rates due to food-borne and other poverty-related diseases, have been 
significantly decreased as a result of antibiotics.
8
   
 
1.2 Classification and modes of action of antibiotics 
Antibiotics are the only class of medical agents whose primary target is not the 
human tissue or its products.
7
 They are classified on the basis of their cellular 
component or the systems they affect. Additionally, they are also categorised on the 
basis of the effect they have. Some antibiotics induce cell death (bactericidal) while 
others simply inhibit cell growth (bacteriostatic).
5
 A variety of mechanisms of action 
have been postulated for antibiotics. Some antibiotics like β-lactams and 
glycopeptides interfere with the homeostatic cell wall biosynthesis.
5
 Successful 
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inhibition of cell wall synthesis can result in changes to cell shape and size, leading to 
induced cellular stress responses. This eventually culminates in cell lysis.
9
  Other 
antibiotics like tetracyclines, aminoglycosides and macrolides target the protein 
synthetic machinery through interaction with ribosomal subunits.
4
 These antibiotics 
are also referred to as 50S or 30S ribosome inhibitors. 50S inhibitors include 
macrolide (erythromycin), amphenicol (chloramphenicol) and lincosamide 
(clindamycin). Examples of 30S ribosome inhibitors include the tetracycline and 
aminocyclitol families of antibiotics. 
10-11
  The 50S inhibitors physically block the 
initiation of protein translation or translocation of peptidyl-tRNAs.
12-13
 On the other 
hand, 30S inhibitors work by blocking the access of the aminoacyl-tRNAs to the 
ribosome.
14
 Another group of antibiotics, for example fluoroquinolone 
(ciprofloxacin) interfere with nucleic acid synthesis hence inhibiting DNA replication 
whereas rifamycin inhibits RNA replication. As a result of the inhibition of 
replication of nucleic acids, prokaryotic nucleic acid metabolism of the bacteria is 
affected inducing bacterial cell death.
15
 
 
1.3 Antibiotic resistance 
Although antibiotics largely enjoyed unprecedented successes since early 1940s, the 
successes however have been overshadowed by the emergence and dissemination of 
antimicrobial resistance (AMR) which is the greatest threat to human health world-
wide.
16
 Antibiotic resistance from a microbiological point of view can be defined as a 
phenotype which makes the microorganism less susceptible than other members of 
the same species, irrespective of any level of resistance. On the other hand, when the 
resistance reaches a certain critical level so as to interfere with the pharmacotherapy 
of a clinical problem caused by the bacterium, this is then referred to as clinical 
resistance.
17
 Among Gram-positive pathogens, Staphylococcus aureus and 
Enterococcus spp. are the species which currently pose the biggest challenge in 
antibiotic resistance.
8
 The accretion of resistance traits to multiple classes of 
antibiotics, resulting in strains with multidrug-resistance (MDR) phenotypes, has over 
time reduced the available treatment options for some pathogens.
8
 More recently, the 
Chapter 1: Angucyclines – An Introduction 
 
 
 
3  
 
emergence of methicillin-resistant Staphylococcus aureus (MRSA) has been reported 
to kill more Americans every year than emphysema, HIV/AIDS, Parkinson’s disease 
and homicides combined.
18
 Furthermore, the mortality rates due to multidrug-
resistant bacterial infections are on the increase. Each year, about 25,000 patients in 
the EU die from an infection with the selected multidrug-resistant bacteria.
19
 
Globally, 3.7% of new cases and 20% of previously treated cases of tuberculosis are 
estimated to be caused by strains that are resistant to isoniazid and rifampicin.
16
 
Furthermore, the emergence of drug resistance has led to an increase in health care 
costs. It is estimated that the direct cost to health care systems resulting from 
antibiotic resistance in Europe is €9 billion.20 Smith and Coast further demonstrated 
that £20,000 could be the additional cost of resistance per patient episode in hospital. 
In the same study, they further reported that the highest cost of antimicrobial 
resistance in the US is $55 billion emanating from $20 billion health services cost and 
$35 billion from loss of productivity.
21
  
 
1.4 Causes of multi-drug resistance of bacteria 
One of the most likely causes of multi-drug resistant bacteria is over-prescription of 
antibiotics.
22
 Epidemiological studies have indicated a direct relationship between 
consumption of antibiotics and development and dissemination of resistant strains.
23
 
Read et al. noted that antibiotics through a natural selective process remove drug-
sensitive competitors, leaving behind drug-resistant ones. Typically, resistance 
develops through mutations.
24
 The problem of over-use has been compounded by the 
fact that antibiotics are not regulated and are available over the counter without 
prescription in a number of countries.
25
 Furthermore, it has been reported that 
inappropriate antibiotic prescriptions promote bacterial resistance.
6
 Development of 
antibiotic resistance has also been attributed to extensive agricultural use of 
antibiotics.
22, 25
 Antibiotics are used as growth supplements in animals both in the 
developed and developing world. It is further estimated that 80% of all antibiotics 
sold in the US are used in animals.
26-27
 These antibiotics which bio-accumulate in the 
animals are eventually ingested by humans.
28
 Thirdly, the limited availability of new 
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antibiotics has been observed to also contribute to the development of resistance.
22
 
The development of new antibiotics by the pharmaceutical industry has been 
hampered by both economic and regulatory obstacles.
27
 The dwindling funding for 
academic research on antibiotics due to the economic crisis and mergers between 
pharmaceutical companies has led to fewer new antibiotics being developed and this 
resulted in less diversity to the range of antibiotics. Finally, stringent regulatory 
measures have acted as barriers in the development of new antibiotics.
22
 For 
companies having an interest in development of new drugs, obtaining regulatory 
approval is often difficult leading to fewer drugs being developed.
29
 Figure 1 
highlights the decline of new antibacterial drug approvals over the past three 
decades.
22
 Additionally, changes made by the US Food and Drug Administration 
(FDA) on new standards for clinical trials design, have consequently made clinical 
trials more challenging. This has stifled progress towards development of new leads.  
 
Figure 1: Trends in antibacterial new drugs application approvals 
 
In view of these challenges with the current antibiotics, there is a need for the 
development of new and more effective antibiotic drug candidates. Traditionally, 
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natural products, i.e., genetically encoded small molecules produced by bacteria and 
fungi, have been the dominant source of clinically used antibiotics.
30
 One class of 
such antibiotic natural products that has been reported to possess therapeutic 
properties is the angucycline antibiotics. Although this class of natural product 
belongs to the antibiotic family, their therapeutic potencies are not limited to 
antibacterial activities. As it will be demonstrated in the forthcoming sections, they 
are even more potent as anticancer agents. 
 
1.5 Angucycline antibiotic natural products 
Angucyclines belong to a relatively new and large group of antibiotic natural 
products featuring an angularly assembled carbotetracycle and have been isolated 
from the culture broths of different microorganisms.
31
 In general, the angucyclines 
possess a benz[a]anthracene as a common structural framework (Figure 2) that bears 
oxygen functionalities at both C-1 and C-8, along with a single alkyl group or a 
combination of alkyl group and oxygen functionality at C-3. The main differences 
among them are found in the aromatic or hydro-aromatic nature of the A and/or B 
rings as well as the presence, in some cases, of oxygens at C-4, C-4a and/or C-12b. 
Glycosides are often found attached to some of the oxygen substituents and typically 
attached to C-3. However, C-glycosidic moieties can also be present at C-9 or C-2.
31
 
By definition, angucyclines include those compounds with hydrolysable carbohydrate 
moieties while angucyclinones are those without the carbohydrate moiety attached to 
the aromatic nucleus. 
 
 
Figure 2: Carbon skeleton of angucycline antibiotics 
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The first members of this class of antibiotics, tetrangomycin 1 and tetrangulol 2 
(Figure 3) were first isolated in 1965 and 1966 respectively.
32-33
 Ochromycinone 3 
was later isolated in 1967.
34
 Since then, a number of other antibiotic natural products 
have been isolated with different therapeutic targets and potency.
35
 The diverse 
biological activities include antibacterial, anticancer, enzyme inhibitory, antiviral and 
antifungal activity; as well as platelet aggregation inhibition.
36
  
Figure 3: First angucycline antibiotics to be isolated 
 
1.6 Biological activities of natural angucycline antibiotics  
Since the first angucycline antibiotics were isolated, biological activity evaluations of 
different classes of these natural products have been undertaken. The next section 
highlights the therapeutic potencies of some classes of angucyclines such as 
landomycins, urdamycins, kinamycins and other new isolates of angucycline 
antibiotics.  
1.6.1 Landomycin antibiotics 
Landomycins are a sub-group of the angucycline antibiotics. They are characterised 
by a linear oligosaccharide conjugated to the angular carbotetracyclic quinone on the 
C-8 oxygen
37
 as shown in Figure 4.  
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Figure 4: Structures of Landomycin Antibiotics 
 
Landomycins have received a lot of interest and attention because of their antitumour 
activities, in particular against the NCI 60 human cancer cell line.
38
 Landomycin A 
(LA) 4 was reported to exhibit activities against prostate cancer cell lines as well as 
cell cycle disruption activities. It was also reported to disrupt thymidine uptake in 
animal models.
39
 Landomycin E (LE) 5 on the other hand, which was isolated from 
the Streptomyces globisporus strain,
40
 showed promising activity in multiple drug 
resistant cell lines as an inducer of apoptosis (IC50 0.76 mg/mL for MDA-MB-231 
human breast cancer cell line, with mean GI50 at 1 mg/mL of 1 mM). This activity 
was still less than that of LA 4. In a study by Korynevska et al. in understanding the 
mechanism of anticancer activities of LE 5 in human carcinoma cell model KB-3-1, 
they observed morphological signs of programmed cell death like cell shrinkage, 
chromatin condensation and formation of apoptotic bodies. Apoptotic cell death 
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induced by 5 was further characterised by caspase (substrate) cleavage and intense 
mitochondrial membrane depolarisation.
37
 Interestingly, it was observed that 
landomycins with the hexasaccharide intact exhibited better activity in MCF-7 
(estrogen responsive) and MDA-231(estrogen refractory) breast cancer cell lines than 
landomycins with shorter oligosaccharidal chains. Krohn and Rohr also reported that 
the cytostatic properties of particular members of the landomycin family were shown 
to depend on the length of the oligosaccharide chain.
41
 Surprisingly though, 11-
deoxy-landomycinone 6 and landomycinone 7 (Figure 5) demonstrated excellent 
activity in cancer cell lines as well, despite the absence of an oligosaccharide chain 
(IC50 2.1 mM and 1.2 mM in MCF-7 and MDA-231cell lines respectively for 6 and 
IC50 2.9 mM and 2.9 mM in MCF-7 and LL/2 murine cancer cell lines respectively 
for 7).
38, 42
 
 
 
Figure 5: Landomycins without an oligosaccharide chain 
 
1.6.2 Urdamycin antibiotics 
Urdamycins were first isolated in the mid-1980s from the culture broth of 
Streptomyces  fradiae Tü2717.
43
 While members in other classes of glycosidic 
antibiotics differ mainly in the amounts and kinds of sugar units attached, urdamycins 
differ with respect to their aglycones, as shown in Figure 6 for urdamycin A 8, C 10 
and D11. On the other hand, urdamycin B 9 does not have hydroxy groups at the C-
4a and C-12b positions.
43
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Figure 6: Examples of Urdamycins 
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Urdamycins were reported to exhibit strong antibacterial activities against both gram-
positive and gram-negative bacteria equivalent to that of tetracenomycin and 
elloramycin. In the same study, urdamycin A 8 was reported to show activity against 
L1210 leukaemia cells.
44
 Kirschning et al. also reported several new glycomodified 
urdamycin-type angucyclines such as 12 and 13 (Figure 7) with poor antitumour 
activity, but surprisingly having superior xanthine oxidase inhibition activities 
compared to allopurinol, one of the most potent inhibitors, with IC50 values of 0.42 
µM for both 12 and 13.
45
 
 
 
 
 
Figure 7: Glyco-modified urdamycins 
 
1.6.3 Kinamycin antibiotics 
Kinamycins were first isolated from S. murayamaensis and more recently, they have 
been isolated from the spiramycin producer S. ambofaciens.
46-47
 This class of 
angucycline antibiotics contains a 6-6-5-6 ring system with a highly oxygenated 
cyclohexyl (ring D) moiety. Although this subunit has a different structural motif, 
they are related to the other angucycline antibiotics because they share the same 
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dehydrorabelomycin intermediate in their biosynthesis. Examples of compounds in 
this class include kinamycins A 14, C 15 and F 16 which are given in Figure 8. 
 
 
Figure 8: Examples of Kinamycin antibiotics 
 
Kinamycins have recently attracted attention because of their antiproliferative 
activities. O’Hara et al. have recently reported that kinamycin F 16 downregulates 
cyclin D in human leukaemia K562 cells and it induced erythroid differentiation, a 
rapid apoptotic response.
48
 Kinamycin C 15  was also reported by Omura et al. to 
exhibit antitumour activity in vivo.
47
 Furthermore, kinamycins A 14 and C 15 also 
demonstrated K562 cell growth inhibition activities at submicromolar levels and they 
both induced apoptosis in Chinese hamster ovary (CHO) cancer cells with IC50 values 
in the ~10 nM range and 0.3 µM range, for 14 and 15 respectively.
49-50
 Additionally, 
both antibiotics showed potency in abolishing topoisomerase IIα decatenation activity 
(IC50 value of 7.6 mmol/L for 14 and 9.2 mmol/L for 15).
50
 
 
1.6.4 Other new angucyclinone antibiotics 
New angucyclinones in this context are antibiotics that have been discovered between 
1997- 2010.
36
 These compounds, just as those discovered earlier, have continued to 
show promising biological activities and could thus provide potential leads for drug 
development. In this section, some biological activities of selected new compounds 
are highlighted. 
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Brasiliquinone compounds A-C (17-19, Figure 9) were isolated from the 
actinomycete Nocardia brasiliensis IFM 0089.
51
 These were shown to be potent 
against gram-positive bacteria including Mycobacterium sp. Furthermore, they also 
showed promising activities against multiple drug-resistant P388/ADR tumour 
cells.
52
 
 
 
Figure 9: Brasiliquinone angucyclinones 
 
8-O-Methyltetrangulol 20, 8-O-methyl-7-deoxo-7-hydroxytetrangomycin 21 and (-)-
8-O-methyltetrangomycin 22 in Figure 10 were isolated from Streptomyces sp. 
AC113.
53
 These angucyclinones were reported to be active against Bacillus cereus 
and Listeria monocytogenes. When four cancer cell lines were subjected to these  
three natural products, compound 21 exhibited the most potent anticancer activity 
with an IC50 value of 0.054 mg/mL against a murine cancer cell line B16.
36
 
 
 
Figure 10: New Angucylinones
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The wide range of biological activities and complex and challenging structures of 
some of these natural products have stimulated a lot of interest in developing 
synthetic methodologies for their formal synthesis, synthesis of their analogues and 
indeed the development of strategies to access the angular carbotetracyclic core of 
these antibiotics. The next section will highlight some of the strategies that have been 
developed for their synthesis. 
 
1.7 Synthetic strategies towards angucycline antibiotics 
Some of the strategies reported widely include, as a key step, the Diels-Alder 
reaction, the Friedel–Crafts reaction (electrophilic addition), nucleophilic additions, 
free radical annulations and more recently, transition metal catalysed cross coupling 
and intramolecular cyclisation strategies. Details of some of these strategies will be 
discussed in the subsequent sections. 
 
1.7.1 Diels-Alder reaction 
The synthesis of the tetracycline skeleton of angucycline antibiotics has been 
achieved using the Diels-Alder reaction as a key step. This reaction was pioneered by 
Guingant in the regioselective construction of the tetracycline skeleton of the racemic 
ochromycinone 3.
54
 This was accomplished by a boron triacetate-mediated Diels-
Alder reaction between juglone 23 and methoxyvinylcyclohexenone 24 as shown in 
Scheme 1.  
 
 
 
Scheme 1: Reagents and conditions; (i) B(OAc)3, CH2Cl2, 20 °C, 75%. 
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This approach was also utilised by Krohn and co-workers in the synthesis of (±)-6-
deoxybrasiliquinone 29, a C-3 ethyl analogue of ochromycinone 3.
55
 In this synthesis 
illustrated in Scheme 2, juglone 23 was subjected to a Diels-Alder reaction with 
diene 25 to give the olefin product 26, which was treated with dimethyldioxirane to 
afford the cis-epoxide 27 in good yield. Epoxide ring opening and rearomatisation 
gave acetate 28 albeit in a very modest yield. Saponification of the acetate followed 
by photooxidation of the resulting alcohol furnished the target compound 29. 
 
 
 
Scheme 2: Reagents and conditions; (i) B(OAc)3, CH2Cl2, 0 °C, 15 min, 71%; (ii) cat. 0.08 M dimethyldioxirane, 
CH2Cl2, Acetone, 0 °C, 15 h, 83%; (iii) B(OAc)3, THF, 20 °C, 15 h, 23%; (iv) NaOMe, MeOH, THF, 20 °C, 15 min, 
then hν, 52%. 
 
    
The synthesis of enantiopure (+)-ochromycinone 3 and its structural analogue (+)-
rubiginone 30 using a Diels-Alder promoted reaction as a key step was also reported 
by Kaliappan and Ravikumar.
56
 This was realised by treating 1,3-diene 31 with 5-
acetoxy-2-bromo-1,4-naphthoquinone 32 in toluene at 80 °C to yield a tetracyclic 
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compound 33. The irradiation of the tetracycle under positive pressure of oxygen 
afforded (+)-ochromycinone 3, which was methylated under mild conditions to give 
(+)-rubiginone 30. This is presented in Scheme 3. 
 
 
Scheme 3: Reagents and conditions; (i) Toluene, 80 °C, 16 h; (ii) K2CO3, MeOH, 45% over two steps; 
(iii) hν, O2, benzene, 20 h, 82%; (iv) Ag2O, MeI, CH2Cl2, rt, 5 h, 82%. 
 
 
Although the Diels-Alder reaction has been successfully used in the synthesis of 
angucycline antibiotics, Hsu and co-workers noted that these reactions require harsh 
conditions and a long time for completion, because styrenes typically act as 
dienophiles rather than dienes. In their work, a boron triacetate promoted Diels-Alder 
reaction of juglone adduct with a styrene in the presence of 2,3-dichloro-5,6-
dicyanobenzoquinone was successfully carried out at room temperature in the 
synthesis of tetrangulol 2.
57
 In their approach highlighted in Scheme 4, Diels-Alder 
reaction of O-methylnaphthazarin 34 and a substituted styrene 35 mediated by boron 
triacetate afforded the tetracyclic compound 36 where the C-11 hydroxy group was 
protected to give triflated tetracyclic compound 37 in excellent yield. Palladium 
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mediated debromination and deoxygenation of 37 gave quinone 38 which was 
deprotected by BBr3 to afford tetrangulol 2, thus completing the formal synthesis. 
 
 
 
Scheme 4: Reagents and conditions; (i) B(OAc)3, DDQ, CH2Cl2, rt, 72 h, 63%; (ii) Tf2O, py, CH2Cl2, 
0 °C, 1 h, 95%; (iii) PdCl2(PPh3)2, HCOOH, i-PrNEt2, DMF, 80 °C, 24 h, 86%; (iv) BBr3, 
CH2Cl2,  −78 °C, 3 h, 97%. 
 
 
1.7.2 Nucleophilic Addition strategies 
Intermolecular nucleophilic addition strategies are useful for the regioselective 
synthesis of the benz[a]anthraquinone core of angucyclines. This is then followed by 
the condensation of suitable components to effect the ring-closure to the tetracyclic 
framework.
58
 The Hauser-Kraus or phthalide annulation reaction is the convenient 
method employed because of its regiochemical integrity and convergence. The 
reaction proceeds via an intermolecular Michael-type addition followed by 
cyclisation between a base-generated, stabilised anion from substituted phthalides 
with α,β-unsaturated carbonyl compounds.36 The strategy was pioneered and 
successfully used by Mal and co-workers in the synthesis of benz[a]anthraquinones 
39a-d.
59
 In this approach, reaction of a phthalide sulfone 40 with naphthoquinone 
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monoketals 41 under basic conditions resulted in the direct formation of 
benz[a]anthraquinone skeletons 39 a-d as displayed in Scheme 5. 
 
 
Scheme 5: Reagents and conditions; (i) t-BuOLi, −60 °C to rt, 12 h, a:77%, b: 66%, c: 88%, d: 43% 
 
 
This strategy was extended by the same authors to non-aromatic A ring angucycline 
42. To achieve this, an enone 44 prepared by phenyliodine diacetate (PIDA) 
oxidation of hydroxytetralin 43 was subjected to an annulation reaction with a cyano-
phthalide (a Kraus phthalide) 45 in t-BuOLi to furnish the annulated product 46.  
Introduction of a ketone function at C-1 was achieved by exposure to sunlight to give 
the angucycline 42.
60
 This is presented in Scheme 6. 
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Scheme 6: Reagents and conditions; (i) PIDA, MeOH, 67%; (ii) t-BuOLi, 85%; (iii) sunlight, CHCl3, 
88%. 
 
1.7.3 Friedel-Crafts acylation reactions 
Friedel Crafts reactions have also been explored as a strategy in the synthesis of 
angucycline antibiotics. Use of Friedel-Crafts acylations, however, requires previous 
assembly of an appropriate tricyclic system and the tetracyclic skeleton is achieved 
through two successive acylation reactions.
58
  This strategy was described by 
Deshpande and co-workers in the synthesis of a non-aromatic ring A brasiliquinone B 
18.
61
 Using this synthetic route, previously assembled tetralin derivative 47 was 
subjected to an acylation reaction with benzoyl chloride 48 in the presence of 
aluminium chloride to furnish the acylated intermediate 49. Attempted cyclisation of 
49 using a combination of boric and sulfuric acids achieved the cyclisation, but 
equally so led to the undesired aromatisation of ring A to give the untargeted product 
50, as summarised in Scheme 7. 
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Scheme 7: Reagents and conditions; (i) AlCl3, CH2Cl2, 0 °C to rt, overnight, 70%; (ii) B(OH)3, H2SO4, 
80 °C, 50 min, 45%. 
 
In order to synthesise the desired hydro-aromatic ring A angucycline, brasiliquinone 
B 18, the same authors modified the sequence of Scheme 7. In this modification, 
initial Friedel Crafts alkylation between tetraline derivative 47 and 3-bromo-4-
methoxy-phthalide 51 afforded the lactone intermediate 52 which underwent 
reductive ring opening with zinc (1 M in NaOH) and cupric sulfate to furnish the acid 
53. A second intramolecular Friedel-Crafts acylation reaction in the presence of 
TFAA followed by benzylic oxidation afforded 54, which underwent demethylation 
in the presence of AlCl3 to yield the desired natural product 18 (Scheme 8), albeit in a 
racemic manner. 
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Scheme 8: Reagents and conditions; (i) SnCl2, CH2Cl2, 0 °C, 84%; (ii) Zn, NaOH, pyridine, CuSO4, 
reflux, 10 h, 85%; (iii) TFAA, CH2Cl2, 64%; (iv) CrO3, HOAc, 0 °C to rt, 93%; (v) AlCl3, CH2Cl2, −78 
°C, 80%. 
 
1.7.4 Transition metal catalysed strategies 
Transition metal mediated reactions have recently taken prominence in the synthesis 
of the benz[a]anthraquinone structure of the angucycline antibiotics. The use of this 
strategy was first reported by Groth and co-workers where the cobalt-mediated 
[2+2+2] cycloaddition of a triyne was employed.
62
 This strategy was also reported in 
the asymmetric synthesis of (+)-rubiginone B2 30 starting from a commercially 
available (R)-(+)-citronella 55,
63
 as illustrated in Scheme 9. To achieve this, the 
aldehyde of citronella 55 was functionalised via the Corey-Fuchs olefination reaction 
to afford the TMS- protected alkyne 56. Ozonolysis of the alkyne 56 followed by a 
second Corey-Fuchs olefination reaction of the resulting aldehyde 57 furnished the 
diyne 58.   Addition of the lithiated derivative of 58 to the substituted benzaldehyde 
59 gave the triyne 60. Deprotection of the triple bonds followed by TBDMS 
protection of the hydroxy group furnished the intermediate triyne 61. Subjecting the 
triyne 61 to the cobalt mediated [2+2+2] cycloaddition as a key step in the synthesis 
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afforded the anthracene 62, which was subjected to both metal and photooxidation to 
furnish the desired (+)-rubiginone B2 30. 
 
Scheme 9: Reagents and conditions; (i) CBr4, PPh3, CH2Cl2, 0 °C, 30 min, then 25 °C, 2 h; (ii) a)      
n-BuLi, THF, −80 °C, 1 h; b) TMSCl, −80 °C to rt, 18 h, (76%, 2 steps); (iii) O3, CH2Cl2, −80 °C, 15 
min, Me2S, AcOH, −80 °C to rt, 18 h; (iv) a) CBr4, PPh3, CH2Cl2, 0 °C, 30 min, then 25 °C, 2 h; b)    
n-BuLi, THF, −80 °C, 1 h, (74%, 3 steps); (v) n-BuLi, THF, −80 °C to −30 °C, 4 h (93%); (vi) a) 
NH4F, Bu4NHSO4, CH2Cl2, rt, 48 h (96%); b) TBDMSOTf, 2,6-lutidine, CH2Cl2, 25 °C, 2 h, 95%; (vii) 
10% CpCo(CO)2, toluene, hν, reflux, 4 h, 74%; (viii) a) [Ag(Py)2]MnO4, CH2Cl2, 25 °C, 8 h, 62%; (b) 
hν, air, CHCl3, 25 °C, 18 h, 67%. 
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The palladium mediated Heck coupling reactions have also been used in the synthesis 
of angucycline antibiotics. Herzon and co-workers reported the use of this strategy for 
the assembly of the diazofluorene moiety during the convergent and enantioselective 
total synthesis of kinamycin F 16.
64
 This strategy commenced with the 
tris(diethylamino)sulfonium trimethyldifluorosilicate [TASF(Et)] promoted 
desilylative Michael addition reaction between naphthoquinone derivative 63 and β-
(trimethylsilylmethyl)-cyclohexenone 64 to afford methylene bridged coupled 
intermediate 65. The intermediate 65 was then subjected to palladium mediated Heck 
coupling reaction to furnish the tetracyclic benzofluorene 66. Introduction of the 
diazo functionality with trifluoromethanesulfonyl azide, followed by α-oxidation, 
carbonyl reduction and global deprotection produced the desired target kinamycin F 
16 as displayed in Scheme 10.  
 
 
 
Scheme 10: Reagents and conditions; (i) TASF(Et), CH2Cl2, −78 °C, 79%; (ii) Pd(OAc)2, polymer-
supported PPh3, Ag2CO3, toluene, 80 °C, 66%; (iii) TfN3, DIPEA, CH3CN, 24 °C, >99%; (iv) 
TIPSOTf, DIPEA, CH2Cl2, 0 °C; DMDO, CH2Cl2/CH3OH, −40 °C, 76%; (v) BH3•THF, THF, −20 °C, 
58%; (vi) AcCl, CH3OH, −12 to 0 °C, 65%. 
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In recent times, olefin metathesis
65-67 
has proven to be a versatile tool in organic 
synthesis due to the availability of air-stable metathesis catalysts.
68
 Kaliappan and 
Ravikumar were the first to explore the use of sequential intramolecular enyne 
metathesis and intermolecular Diels-Alder reactions in the synthesis of YM-181741 
(67).
56, 69
 In this strategy (Scheme 11), enyne derivative 68 was subjected to 
intramolecular metathesis reaction catalysed by Grubbs second generation catalyst to 
afford the diene 69.  
 
 
 
Scheme 11: Reagents and conditions; (i) Grubbs (II), ethylene, toluene, 80 °C, 12 h, 88%; (ii) 
toluene, 80 °C, 12 h; (iii) K2CO3, MeOH, 71% (over two steps); (iv) hν, O2, benzene, 70%; (v) TBAF, 
THF, rt, 2 h, 68%.  
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Diels-Alder reaction of the diene 69 with a naphthoquinone derivative 32 furnished 
the tetracyclic adduct 70 which was subsequently aromatised and deacetylated to give 
the intermediate tetracyclic compound 71, albeit as a mixture with its regioisomer in 
9:1 ratio. Photooxygenation of the inseparable mixture of 71 and the regioisomer 
afforded the ketone 72 and the other regioisomer which was separated by column 
chromatography. The ketone 72 was deprotected to furnish the desired natural 
product 67.   
 
1.7.5 Development of other transition metal catalysed strategies 
The Organic Chemistry Research Group at Wits University became interested in 
developing new methods to access the angular tetracyclic skeleton of the angucycline 
antibiotic natural products by application of other transition metal mediated 
strategies.  Dr. Myron Johnson, a former PhD student, pioneered these efforts. It was 
envisioned that Suzuki-Miyaura and ring closing metathesis (RCM) reactions could 
be key steps in assembling the carbotetracyclic skeletons of the natural products. The 
proposed retrosynthetic analysis is shown in Scheme 12. 
 
 
Scheme 12: Retrosynthetic analysis of benz[a]anthraquinone 
Chapter 1: Angucyclines – Development of New Synthetic Methodology 
 
 
 
25  
 
It was envisaged that Suzuki-Miyaura cross coupling reaction of a boronic acid 73 
and the bromonaphthalene 74 would furnish the biaryl benzaldehyde 75. The 
aldehyde could then be functionalised to the alkene 76 through the Wittig reaction, 
followed by isomerisation of the allylic double bond to furnish the dialkene 77. 
Subjecting the resulting dialkene to a ruthenium mediated ring closing metathesis 
allowing the construction of a new benzene ring could furnish the tetracyclic skeleton 
78, which, upon CAN oxidation, would give the desired quinone 79.   
 
The next sections give brief overviews of the two key reactions for the assembly of 
the carbotetracyclic skeleton of the angucyclines, i.e. the palladium mediated Suzuki-
Miyaura cross coupling reaction and the ruthenium catalysed ring closing metathesis 
reaction. These reactions, and particularly the Suzuki-Miyaura cross coupling 
reactions, were extensively used in this PhD research project. 
 
1.7.5.1 Palladium mediated Suzuki-Miyaura cross coupling reaction 
The Suzuki-Miyaura (SM) reaction is one of the most versatile carbon-carbon bond 
forming reactions used in organic synthesis. The reaction involves palladium 
catalysed cross coupling of aryl halides or pseudohalides with boronic acids in the 
presence of a base, as shown in Scheme 13.   
 
 
Scheme 13: General Suzuki-Miyaura reaction 
 
This reaction is particularly useful for the assembly of biaryls.
70
 The aryl-aryl bonds 
are found in numerous biologically active natural products. Although there are other 
metal mediated carbon-carbon bond forming coupling strategies like the Kumuda, 
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Negishi, Stille, Himaya and the Kharash reactions, the Suzuki-Miyaura reaction 
offers distinct advantages over the rest. Some of these include the mild reaction 
conditions and the commercial availability of a diversity of boronic acids that are 
environmentally safer than the other organometallic reagents. Furthermore, the 
handling and the subsequent removal of boron containing by-products is relatively 
easy. Finally, the reaction has a high tolerance towards functional groups and steric 
constraints.
71-73
  
 
1.7.5.1.1 Mechanism of Suzuki-Miyaura cross coupling reaction 
As exhibited in Scheme 14, the basic catalytic cycle of the palladium catalysed SM 
cross coupling reaction is thought to follow a sequence involving the oxidative 
addition of an aryl halide 80 to a Pd(0) complex to form an arylpalladium(II) halide 
intermediate 81. This intermediate undergoes a base-halogen exchange to generate 
the oxo-palladium(II) complex 82.  If a carbonate base is used, the hydroxy base is 
generated in situ by reacting with water. The reactive oxo-palladium compound 
generated then complexes with an arylboronic acid before undergoing intramolecular 
transmetalation to form the diarylpalladium complex 83.  In the final step of the 
catalytic cycle, the diarylpalladium complex undergoes reductive elimination to 
afford the cross coupling product 84, and the reactive palladium(0) species is  
regenerated.
74
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Scheme 14: Catalytic cycle of Suzuki-Miyaura Cross Coupling reaction 
 
Sodium carbonate is a base commonly used in the SM cross coupling reaction 
although it is less effective with sterically demanding substrates where in such cases 
Ba(OH)2 or K3PO4 are preferred. Other bases utilised include Cs2CO3, CsF, K2CO3, 
TlOH, KF and NaOH.
75
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1.7.5.1.2 Supporting ligands 
In the initial years of the SM reaction, triarylphosphines were used as supporting 
ligands. However, increased reactivity and stability of the metal catalysts by use of 
other more efficacious supporting ligands has led to improvements of the Suzuki-
Miyaura coupling reactions.
76
 The most common ligands used are monodentate, 
bulky, and electron-rich dialkylbiarylphosphine ligands, although others like N-
heterocyclic carbenes (NHC) have also been utilised.
77
 The ability to satisfy the 
diverse requirements of different SM cross coupling reactions with a single ligand, 
however, remains a challenge.
76
 
 
1.7.5.2 Ruthenium catalysed ring closing metathesis (RCM) reactions  
The application of carbon-carbon bond forming strategies to make ring systems 
remains a core theme in natural products synthesis. Cyclisation reactions are 
commonly used in this regard. The ring closing olefin metathesis reaction (RCM) is 
one such cyclisation strategy that has gained popularity because of its versatility.
78
 
Olefin metathesis is a unique carbon skeleton redistribution strategy that proceeds via 
carbene exchange between a metal carbene and an alkene through a 
metallocyclobutane (MCB) as exhibited in Scheme 15.
79
 Grubbs (I and II) ruthenium 
based catalysts developed by Grubbs are commonly used, although other catalysts 
have also been developed.
80
 
 
Scheme 15: General [2+2] ring closing metathesis reaction and associated catalysts 
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1.7.5.2.1 Mechanism for ring closing olefin metathesis 
In terms of the mechanism of the reaction, the commonly accepted view is that the 
metathesis reactions occur as postulated by Chauvin in 1971.
81
 Essentially, the 
metathesis cascade is promulgated by way of a series of [2+2] cycloadditions and 
cycloreversions as depicted in Scheme 16. 
 
 
Scheme 16: Mechanism and catalytic cycle of ring closing metathesis 
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 A diene e.g. 85 is treated with a catalyst metal alkene and undergoes a [2+2] 
cycloaddition reaction to give the metallocyclobutane 86. The cyclobutane derivative 
86 then undergoes cycloreversion to generate the metal alkylidine 87 which 
undergoes intramolecular [2+2] cycloaddition with the reactive terminal alkene on the 
same molecule to give a second metallocyclobutane intermediate 88. Cycloreversion 
of this metallocyclobutane furnishes the RCM product, in this case, cyclohexene 89, 
with the regeneration of the metal alkene catalyst.  
 
1.7.5.2.2 Applications of RCM in assembly of new benzene rings 
The ring-closing metathesis reaction has been used in a number of synthetic 
transformations. We decided to use RCM as a key step in the synthesis of 
angucycline antibiotics by building on previous work done by our group on the 
construction of benzene rings using the RCM reaction. de Koning and co-workers 
have reported the use of RCM as a key step in the assembly of a new benzene ring in 
the synthesis of ring-fused carbazoles.
82
 In the synthesis, previously assembled bis-
indole 90 was formylated to give the dialdehyde 91. Boc-protection of 91 afforded 
the biscarbamate 92, which was then functionalised to the divinyl intermediate 93 
using the Wittig reaction. Exposure of 93 to the Grubbs second generation catalyst 
afforded the desired fused-carbazoles 94 as shown in Scheme 17. 
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Scheme 17: Reagents and conditions; (i) POCl3, DMF, 0 °C, 83%; (ii) Boc2O, DMAP, 25 °C, 89%; 
(iii) MePPh2Br, n-BuLi, 0 °C; (iv) 8% Grubbs II, toluene, 25 °C, 64% (over two steps). 
 
 
As a second example, Yoshida and Imamoto also demonstrated the versatility of the 
RCM in the synthesis of a range of phenol derivatives using Grubbs second 
generation catalyst as shown Scheme 18.
83
  
 
 
 
Scheme 18: Yoshida’s synthesis of phenol derivatives using RCM 
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The upcoming Chapter in this PhD thesis discusses our results on the development of 
new methodology for the synthesis of angucycline analogues, utilising the two key 
reactions outlined. Our attempted application of the methodology to synthesise a 
natural product and finally, the results of our formal synthesis of tetrangulol 2 are 
also discussed.  
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CHAPTER 2: Results and Discussion on Angucyclines 
 
2.1 Overview 
The starting point to this project was to revisit the model studies conducted by Dr. 
Myron Johnson, a former PhD student in our group, in using the palladium catalysed 
Suzuki-Miyaura cross coupling reaction and ruthenium catalysed ring closing 
metathesis as key steps in the synthesis of angucycline antibiotic analogues. 
Following this, application of the methodology used in the model studies to 
synthesise a natural product is presented. Finally, results of our novel method for the 
synthesis of the natural product tetrangulol 2 will be presented and discussed.  
 
2.2 Model studies on the synthesis of angucycline antibiotic analogues 
Two model studies were undertaken to synthesise the desired benz[a]anthraquinone 
skeleton of the angucyclines. These are discussed in the next section. 
 
2.2.1 Synthesis of tetraphenes 79a and 79b 
Model studies were done utilising the Suzuki-Miyaura cross coupling reaction and 
the ring closing metathesis reaction as key steps for the synthesis of tetraphene-7,12-
dione 79a and methoxytetraphene-7,12-dione 79b. The synthetic scheme for the 
assembly of these two angucycline antibiotic analogues is illustrated in Scheme 19. 
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Scheme 19: Key synthetic steps for the assembly of angucycline analogues 
 
The synthesis commenced with the preparation of the bromonaphthalene precursor 74 
that would subsequently be coupled utilising the Suzuki-Miyaura reaction to two 
different boronic acids, 73a and 73b, to give the biarylbenzaldehydes 75a and 75b. 
2.2.1.1 Synthesis of 2-allyl-3-bromonaphthalene 74 
 
 
 
Scheme 20: Reagents and conditions: (i) Vinyl acetic acid, (NH4)2S2O8, AgNO3, H2O-MeCN, 65 °C, 
18 h, 71%; (ii) Me2SO4, Na2S2O4, TBAI, aq. KOH, THF, rt, 70%. 
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Our synthesis as shown in Scheme 20 started with allylation of commercially 
available 2-bromo-1,4-naphthoquinone 95. This was achieved by using a modified 
Minisci reaction where the allyl group is introduced via a radical process.84 To the 
naphthoquinone 95 in acetonitrile was added vinyl acetic acid and silver nitrate, 
followed by the dropwise addition of ammonium persulfate in distilled water. The 
reaction mixture was maintained at 65 °C for 18 hours. Purification of the crude 
product on silica gel gave 96 as a yellow solid in 71% yield. The 
1
H NMR spectrum 
unequivocally proved that we had formed the allylated 
product with the presence of 2 allylic protons at δ 3.64 ppm 
(H-1′), one vinylic proton at δ 5.87 ppm (H-2′) followed by a 
pair of vinylic protons between δ 5.27 and δ 5.22 ppm (H-3′).  
Analysis of the 
13
C NMR spectrum showed the appearance of 
three additional carbon signals. The most upfield signal at δ 35.8 ppm corresponded 
to the allylic carbon C-1′ and the two signals at δ 118.8 and δ 134.9 ppm were 
consistent with the vinylic carbons C-3′ and C-2′ respectively. 
 
Pleased with the successful synthesis of the allylated quinone 96, our next step was to 
reduce and protect the quinone through methylation. To achieve this, sodium 
dithionite and tetrabutylammonium iodide (TBAI) were added to a clear solution of 
96 in tetrahydrofuran. This was followed by the addition of an aqueous solution of 
potassium hydroxide and dimethyl sulfate and the reaction mixture was stirred for 18 
hours. Chromatographic purification of the residue afforded 74 as a yellow, low 
melting solid in 70% yield. The presence of two methoxy protons signals at δ 3.98 
and δ 3.92 ppm in the 1H NMR spectrum clearly proved that product 74 was formed. 
This was further confirmed through 
13
C NMR spectroscopy by the disappearance of 
the two carbonyl carbon signals and the appearance of four new signals at δ 160.0 and 
150.2 ppm consistent with ArC-O and at δ 62.7 and 61.4 ppm which corresponded to 
the two methoxy group carbons.  
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2.2.1.2 Synthesis of vinylphenylnaphthalene 76a and 76b 
 
 
Scheme 21: Reagents and conditions; (i) Method 1:  Pd(PPh3)4, CsF, DME, MW 150 °C, 150 W, 
30  min,75a: 49%, 75b: 45%; Method 2: (i) Pd(PPh3)4, aq. Na2CO3 (2 M), DME, reflux, 18 h, 75a: 
60%, 75b: 65%; (ii) MePPh3Br, n-BuLi, THF, 76a: 81%, 76b: 94%. 
 
With the reduced quinone 74 in hand, we then turned our attention to the first key 
step which was to use the palladium mediated Suzuki-Miyaura reaction to couple 74 
to the commercially available boronic acids 2-formylphenyl boronic acid 73a and 2-
formyl-5-methoxyphenyl boronic acid 73b (Scheme 21). Initially we explored the 
use of microwave irradiation to facilitate the coupling. Use of microwave conditions 
for Suzuki-Miyaura cross coupling reactions has been reported by Sharma et al. One 
advantage this method offers is the reduction of the reaction times from 24 hours in 
conventional methods to 20 minutes under microwave conditions due to the increase 
in the reaction rates.
85
 Using this method, the allylated dimethoxynaphthalene 74, 
boronic acid 73a or 73b, cesium fluoride, tetrakis(triphenylphosphine)palladium(0) 
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and dimethoxyethane were added in a sealed microwave tube. The reaction mixture 
was irradiated at 150 W and 150 °C for 30 minutes by a microwave reactor. Upon 
completion of this time, TLC confirmed that the starting material was consumed. The 
crude products were purified by column chromatography to furnish 75a as a yellow 
compound in 49% and 75b as an off-white solid in 45% yield. For 75a, the presence 
of eight signals due to aromatic proton in the 
1
H NMR spectrum unambiguously 
proved that the coupling had taken place, although specific assignment of the protons 
was difficult owing to most of the aromatic protons appearing in the same region of 
the spectrum.  Additionally, the presence of the aldehydic 
proton at δ 9.74 ppm in the 1H NMR spectrum was further 
evidence. The appearance of the aldehydic protons 
corresponded with the aldehyde carbonyl carbon signal at δ 
192.2 ppm in the 
13
C NMR spectrum.  The 
biarylbenzaldehyde intermediate 75b on the other hand was 
unmistakably verified to have been made owing to the presence of signals due to the 
three methoxy protons at δ 3.97, δ 3.93 and δ 3.46 ppm and, just as in compound 75a, 
the presence of the aldehydic proton at δ 9.67 ppm in the 1H NMR spectrum.  
 
Although the biarylbenzaldehydes 75a and 75b were assembled, the yields were 
moderate. All our attempts to optimise the microwave conditions did not improve the 
yields obtained. At this point, we then decided to explore the use of a conventional 
method for the Suzuki-Miyaura cross coupling reaction. In using this approach, 
tetrakis(triphenylphosphine)palladium(0) and  boronic acids 73a or 73b were added 
to a deoxygenated solution of  2-allyl-3-bromo-1,4-dimethoxynaphthalene 74 in 
dimethoxyethane followed by the addition of a deoxygenated aqueous sodium 
carbonate solution and the reaction mixture was heated at reflux for 18 hours. Upon 
chromatographic purification, compound 75a was obtained in 60% yield and 
compound 75b in 65% yield. The moderate yields from microwave reactions were 
attributed to possible decomposition of the products. Going forward, we decided to 
adopt the conventional method for all the Suzuki-Miyaura cross coupling reactions.  
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Satisfied with the yields of the Suzuki product, our next step was to convert the 
aldehyde of 75a and 75b to an alkene. This was accomplished smoothly by subjecting 
the aldehydes to Wittig conditions using methyltriphenylphosphonium bromide as the 
ylide source to afford the vinyl adducts 76a and 76b in 81% yield and 94% yield 
respectively. The disappearance of the signals due to the aldehydic protons and the 
appearance of three new olefinic signals in the 
1
H NMR spectrum at δ 6.41 ppm, δ 
5.76–5.59 ppm (overlapping) and δ 5.07 ppm for 76a and δ 6.37 ppm, δ 5.76–5.61 
ppm (overlapping) and δ 5.05 ppm for 76b undoubtedly confirmed the assembly of 
the alkenes. Analysis of the 
13
C NMR spectra also showed the disappearance of the 
aldehyde carbon signals and the appearance of two olefinic carbon signals in each 
spectrum which provided further evidence for the synthesis of the alkenes. 
2.2.1.3 Synthesis of dimethoxytetraphenes 78a and 78b 
 
 
 
Scheme 22: Reagents and conditions: (i) KOtBu, THF, rt, 4 h, 77a: 73%, 77b: 88%; (ii) Grubbs (II), 
toluene, reflux, 18 h, 78a: 92%, 78b: 88%. 
 
Pleased with the conversion of the aldehyde to the alkene using the Wittig reaction, 
the allylic double bond in both 76a and 76b was isomerised (Scheme 22). The idea in 
the subsequent step was to assemble a new benzene ring. If the allylic double bond 
was left unisomerised, a seven-membered ring would be formed.  To isomerise the 
bonds, the alkenes 76a and 76b were subjected to potassium tert-butoxide in 
tetrahydrofuran at room temperature. Purification of the crude product by column 
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chromatography furnished the dialkenes 77a and 77b in 73% and 88% yields 
respectively. 
1
H NMR spectroscopy unequivocally established the identity of the 
isomerised products by the appearance of a doublet of doublets at δ 1.65 ppm for 77a 
and δ 1.69 ppm for 77b, each integrating for 3 protons, which correlated with the 
appearance of a methyl substituent after isomerisation. The doublet of doublets signal 
arises from a J-3 coupling with the adjacent olefinic proton and a J-4 coupling with 
the other olefinic proton. The disappearance of the allylic protons signals at δ 3.13 
ppm and δ 3.14 ppm for 77a and 77b, respectively, correlated to the shifting of the 
double bond. 
Pleased with our isomerisation reaction, we then embarked on our next synthetic step 
of forming a new benzene ring using ruthenium catalysed ring closing metathesis. 
This reaction was key as it could lead to the assembly of a carbotetracyclic skeleton 
found in the angucycline antibiotic natural products. To achieve this, Grubbs II 
catalyst was added to each of the dialkenes 77a and 77b in toluene and the reaction 
mixtures were heated under reflux for 18 hours. Upon chromatographic purification 
of each of the reaction mixtures, products 78a and 78b were isolated as off-white 
solids in excellent yields of 92% and 88% respectively. 
1
H NMR spectroscopy clearly 
established the identity of the tetraphenes formed by the disappearance of all signals 
due to the olefinic protons between δ 6.46 ppm and δ 5.03 ppm for 78a and between δ 
6.46 ppm and δ 5.06 ppm for 78b. Additionally, the appearance of new signals in the 
aromatic region of the spectrum noted through the increase in total number of 
aromatic proton signals from eight to ten in 78a and from seven to nine in 78b further 
confirmed the assembly of a new benzene ring.   
With the assembly of the benz[a]anthracene skeletons, we were able to demonstrate 
that the transition metal mediated methods of the Suzuki-Miyaura and the ring 
closing metathesis reactions could be used as key steps in the synthesis of 
angucycline antibiotic analogues. The last step was then to oxidise the 
benz[a]anthracene skeletons to the target benz[a]anthraquinone analogues.   
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2.2.1.4 Synthesis of angucycline analogues 79a and 79b 
 
 
 
Scheme 23: Reagents and conditions; CAN, MeCN/H2O, rt, 30 min, 79a: 79%, 79b: 81%. 
 
The oxidation was accomplished by subjecting the benz[a]anthracene derivatives 78a 
and 78b (Scheme 23) to the cerium ammonium nitrate (CAN) mediated oxidation 
reaction in acetonitrile and water at room temperature for 30 minutes to furnish the 
desired quinones 79a and 79b in 79% and 81% yield, respectively. The products were 
undoubtedly confirmed using 
1
H NMR spectroscopy by the disappearance of the two 
signals due to the methoxy group at δ 4.12 and δ 3.97 ppm for 79a, and the 
disappearance of two of the three methoxy group signals in 79b.  Further proof was 
provided by the appearance of two carbonyl carbon signals in the 
13
C NMR spectra at 
δ 186.2, and δ 184.0 ppm for 79a and δ 186.4 and δ 183.8 ppm for 79b. 
Having accomplished the synthesis of the benz[a]anthraquinone framework of 
angucycline natural products, we then decided to use this methodology for the 
synthesis of 1,8-dihydroxy-3-methyltetraphene-7,12-dione, commonly known as 
tetrangulol 2, a natural product. This work will be discussed in the following section. 
 
 
Chapter 2: Angucyclines - Results and Discussion 
 
 
 
41  
 
 
2.3 Attempted synthesis of tetrangulol using SM and RCM reactions 
In order to synthesise the natural product tetrangulol 2, we envisaged the following 
retrosynthetic pathway given in Scheme 24.  
 
Scheme 24: Retrosynthetic Analysis for tetrangulol 
It was evident from the retrosynthetic analysis that we needed to assemble the 
naphthalene boronic acid 97 and the substituted benzaldehyde 98 precursors. We 
envisioned that the boronic acid 97 could be assembled from juglone. Owing to the 
high price of juglone, we decided to synthesise the required juglone derivative. Its 
synthesis is described in the next section. It must be highlighted that although the 
boronic acid could be made on either precursor, we opted to place it on the 
naphthalene derivative, i.e. 97, and place an iodine substituent on the benzaldehyde, 
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i.e. 98. We foresaw some difficulties in carrying out the Suzuki-Miyaura cross 
coupling reaction with these precursors that necessitated this strategic decision. This 
will be further elaborated on in the relevant section.  
 
2.3.1 Synthesis of the precursor boronic acid 97 
There are some reports in the literature on the synthesis of bromo juglone derivatives, 
which in our case, could be functionalised to the desired boronic acid.
86-87
 We 
decided to adopt the Jung approach to the synthesis of 2-bromo-5-
methoxynaphthoquinone 99 from 1,5-dihydroxynaphthalene 100 as indicated in 
Scheme 25, with a few modifications.
87
 Having synthesised the juglone derivative, 
we planned to use a modified Minisci reaction to introduce the allyl group as shown 
in Scheme 26. 
 
 
 
Scheme 25: Reagents and conditions; (i) Ac2O, pyridine, rt, 18 h, 97%; (ii) NBS, AcOH, H2O, 65 °C, 
1 h, 91%; (iii) 3 N aq. H2SO4, EtOH, reflux, 30 min, 81%; (iv) Ag2O, MeI, CH2Cl2, rt, 24 h, 96%. 
2.3.1.1 Synthesis of 2-bromo-5-methoxy-1,4-naphthoquinone 102 
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The synthesis started from commercial 1,5-dihydroxynaphthalene 100. Acetylation of 
100 using acetic anhydride in pyridine at room temperature for 18 hours gave the 
desired acetoxynaphthalene 101 as a light brown solid in 97% yield. The 
1
H NMR 
spectrum, through the appearance of a singlet at δ 2.45 ppm, unambiguously 
confirmed that the acetylated product was made. Additionally, the appearance of a 
signal due to an ester carbonyl at δ 169.3 ppm in the 13C NMR spectrum further 
supported the synthesis of 101.  Pleased with the assembly of acetylated product 101, 
our next step was to undertake an NBS mediated oxidative bromination of 101 to 
make the desired quinone 32.  To achieve this, N-bromo succinimide (NBS) was 
dissolved in a mixture of acetic acid and water and to this solution, the 
diacetoxynaphthalene 101 was added dropwise and the reaction was stirred at 65 °C 
for a further 1 hour. Chromatographic purification of the crude product furnished the 
quinone 32 as a yellow solid in 91% yield. The identity of the product 32 was 
confirmed by 
1
H NMR spectroscopy which showed four aromatic signals. The 
doublet of doublets signal at δ 8.14 ppm was consistent with H-8. 
The J values of 7.8 and 1.3 Hz were consistent with both ortho 
coupling to H-7 and meta coupling to H-6. The triplet at δ 7.77 
ppm was assigned to H-7 and the doublet of doublets at δ 7.42 
ppm was assigned to H-6. Finally, the singlet at δ 7.39 ppm was 
indicative of the H-3 proton. It is worth noting that the reaction 
was carried out in high dilution to prevent potential multiple bromination. The initial 
acetylation step was equally important for the bromination reaction as the 
nucleophilicity of the powerful phenolic groups was masked, thereby preventing 
multiple brominations. One challenge we faced was the instability of the quinone 32, 
which decomposes on exposure to air. To circumvent this challenge, the quinone was 
immediately subjected to the subsequent deacetylation step. 
Deacetylation of 32 was smoothly accomplished by refluxing in 3 N aqueous sulfuric 
acid and ethanol for 30 minutes to furnish the hydroxyquinone 102 in an excellent 
yield of 91%. The identity of the quinone 102 was confirmed by the disappearance of 
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both the signal due to ester carbonyl in the 
13
C NMR spectrum at δ 169.2 ppm and the 
singlet signal of the methyl protons at δ 2.44 ppm in the 1H NMR spectrum. 
Furthermore, the appearance of a signal due to the phenolic proton at δ 11.77 ppm 
was additional evidence of the deacetylation. The phenolic group of the quinone was 
then protected as the O-methyl ether. To accomplish this, the quinone 102 was 
exposed to silver(I) oxide and methyl iodide and the mixture stirred at room 
temperature for 24 hours. Chromatographic purification afforded the desired 
methoxyquinone 99 in an excellent yield of 96%.  The synthesis of 99 was 
unmistakably confirmed by the appearance in the 
1
H NMR spectrum of a signal due 
to the methoxy protons at δ 4.02 ppm and the disappearance of the phenolic proton 
signal at δ 11.77 ppm.  
 
2.3.1.2 Synthesis of allylated boronic acid 97 
With the quinone 99 in hand, the insertion of the allyl group to assemble the allylated 
quinone adduct 103, and subsequent reduction of the allylated quinone to furnish 
naphthalene 104 followed by the assembly of the boronic acid 97 were accomplished 
as highlighted in Scheme 26.  
 
Scheme 26: Reagents and conditions; 3-butenoic acid, (NH4)2S2O8, AgNO3, H2O-MeCN, 60 °C, 18 h, 
72%; (ii) Me2SO4, Na2S2O4, TBAI, aq. KOH, THF, 75%; (iii) n-BuLi, B(OiPr)3, −78 °C, 1 h, 94%.  
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The protocols for the first two synthetic transformations above were similar to those 
discussed in the synthesis of benza[a]anthraquinone analogues in Sections 2.1.1.1 
and 2.1.1.2 and so will not be repeated in this section. The synthesis of the allylated 
bromonaphthoquinone 103 was accomplished in a very good yield of 72% and its 
subsequent reduction furnished the bromonaphthalene derivative 104 in 75% yield. 
Finally, we needed to convert the bromonaphthalene 104 into the boronic acid 97 for 
the palladium catalysed cross coupling reaction. To accomplish this, n-BuLi was 
added dropwise to a solution of bromonaphthalene 104 in tetrahydrofuran at −78 °C 
followed by the addition of triisopropylborate and stirred for 30 minutes. The reaction 
mixture was acidified with 10% aqueous hydrochloric acid solution and extracted 
with diethyl ether. The organic layer was then poured into hexane upon which a solid 
precipitated out of solution and the mixture was filtered to furnish the boronic acid 97 
as an off-white crystalline solid in 94% yield. The boronic acid was used without 
further purification or characterization. It must be mentioned that there was a 
possibility for the isomerisation of the allyl substituent by n-BuLi and this could only 
be established in the next step.  
With the synthesis of the naphthalene boronic acid precursor 97 completed, we turned 
our attention to the synthesis of the second precursor for the Suzuki-Miyaura reaction, 
the substituted benzaldehyde 98.   The next section will highlight how the synthesis 
of 98 was accomplished. 
 
2.3.2 Synthesis of 2-iodo-3-methoxy-5-methylbenzaldehyde 98. 
One challenge we envisaged in our intended Suzuki-Miyaura reaction was steric 
hindrance, as we realised we would be forming a tetra-ortho-substituted biaryl axis 
intermediate.  One of the halogens needed to be easily displaceable like iodine to 
facilitate the Suzuki-Miyaura reaction given the steric constraints. As a consequence, 
we opted to synthesise the required substituted benzaldehyde, containing an iodine in 
the appropriate position. 
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For the synthesis of the iodo substituted benzaldehyde precursor 98, we adopted a 
method developed by Takahashi and co-workers where they synthesised the 
substituted benzaldehyde as an intermediate in the assembly of the landomycin 
antibiotics skeleton.
88
 Owing to the difficulties we encountered in one of the steps, 
we decided to modify their method. This modified synthetic route is given in Scheme 
27. 
The synthesis commenced utilising an NBS mediated benzylic bromination of 3,5-
dimethylanisole 105.  We initially applied Takahashi’s conditions where 1 equivalent 
of NBS and a catalytic amount of benzoyl peroxide were added to the anisole 105 and 
the mixture refluxed for 4 hours. After this period, the reaction mixture was poured 
into diethyl ether and water and the aqueous layer was extracted with diethyl ether. 
The residue was used for the next reaction without further purification. To 
accomplish the next hydroxylation stage, calcium carbonate was added to a stirred 
solution of the residue in dioxane and water and the reaction mixture stirred at reflux 
for 12 hours. Chromatographic purification of the crude product furnished 
phenylmethanol 106 as a light-yellow oil in a very modest yield of only 19%. From 
the 
1
H NMR spectrum, it was evident by the appearance of a singlet signal at δ 4.57 
ppm integrating for two protons, that the product was formed. This signal is 
consistent with the two benzylic protons. Further evidence was provided by the 
appearance of a broad singlet at δ 2.28 ppm which was attributed to the OH group.  
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Scheme 27: Reagents and conditions; (i) Method 1:  NBS, (PhCO2)2 or AIBN, CCl4, reflux, 4 h; (ii) 
CaCO3, 1,4-dioxane, reflux, 16 h; 70% (over two step); Method 2: NBS, AIBN or (PhCO2)2, EtOAc, 
MW 300 W, reflux, 1 h; (ii) CaCO3, 1,4-dioxane, reflux, 16 h; 72% (over two step); (iii) n-BuLi,−78 
°C, THF, 2 h, 94%; (iv) n-BuLi, Et2O, −78 °C to rt, 4 h, then I2, THF, 0 °C, 30 min, 70%; (v) MnO2, 
CH2Cl2, rt, 18  h, 97%. 
 
Although we had evidence that the desired phenylmethanol 106 had been synthesised, 
we were not satisfied with the yields and we decided to try and optimise the 
conditions. Takahashi using this protocol reported a 42% yield over the two steps. 
We undertook a number of initiatives, among them; increased reaction times, change 
in radical initiators, increased initiator loading from 1%-20%, changed reagents for 
the hydroxylation reaction to sodium bicarbonate in acetone instead of calcium 
carbonate, but none of these initiatives were helpful in improving the yields. We 
further explored the use of a microwave assisted green method of conducting the 
benzylic bromination in ethyl acetate which was reported by Jursic,
89
 and the yields 
improved only marginally. Hence, we decided to isolate the initial product after the 
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NBS reaction to ascertain that we were indeed brominating the benzylic carbon atom. 
To our surprise, we isolated the para brominated anisole 107 in 77% yield. This was 
confirmed using 
1
H NMR spectroscopy by the reduction in the number of aromatic 
proton signals from three to two. What was interesting about this reaction on this 
particular substrate was that even under radical conditions, nuclear bromination took 
preference over benzylic bromination. We searched the literature for precedence of 
this and discovered a report by Bickelhaupt. In the report, they analysed nuclear 
versus side chain bromination of a number of substituted anisoles, including our 
substrate 105, on treatment with NBS. A key finding in their research was that when 
the two methyl substituents are in any position other than 3 and 5, benzylic 
bromination dominated. Nuclear bromination dominates when the two methyl 
substituents are in the 3 and 5 positions.
90
 In their bromination of 3,5-dimethylanisole 
using NBS in carbon tetrachloride, they isolated the nuclear brominated product 107 
in 75% yield and 25% of the side chain bromination product. Our findings, where we 
isolated the nuclear brominated product 107 in 77% yield were consistent with these 
reported results. Following this discovery, we then decided to modify Takahashi’s 
protocol. To this end, we envisaged that adding another mole equivalent of NBS 
would facilitate benzylic bromination as the most reactive nuclear positon will have 
been occupied by initial bromination. This would be followed by the same 
hydroxylation conditions as before. When this was done, to our delight, we isolated 
the bromophenylmethanol derivative 108 as a white, low melting solid in 72% yield 
over two steps and 21% yield of the phenylmethanol adduct 106. Formation of 
product 108 was unequivocally proved by the appearance of a broad singlet at δ 2.85 
ppm and a signal due to the two benzylic protons at δ 4.64 ppm in the 1H NMR 
spectrum. Aromatic debromination of 108 was smoothly accomplished by subjecting 
the compound 108 to n-BuLi in tetrahydrofuran −78°C for 2 hours to furnish the 
desired phenylmethanol derivative 106 in an excellent yield of 94%. Effectively using 
our modified procedure, we were able to synthesise the substituted phenylmethanol 
derivative 106 in 87% yield over three steps. 
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Pleased with the assembly of the phenylmethanol 106, we then used the directed 
ortho metalation strategy to insert an iodine regioselectively at the C-6 position. We 
postulate that the oxygen on both the C-5 methoxy group and on the C-1 benzyl 
alcohol would coordinate to lithium, leading to directed lithiation and subsequent 
iodination at the C-6 position. To accomplish this, n-BuLi was added to a solution of 
106 in diethyl ether at −78 °C. This was followed by the slow addition of iodine 
dissolved in tetrahydrofuran and the reaction being stirred for a further 30 minutes. 
The crude product was purified by chromatography on silica gel to afford 
iodophenylmethanol 109 as a white crystalline solid in 70% yield. The 
1
H NMR 
spectrum clearly proved that the product 109 was formed by the disappearance of one 
aromatic proton signal. The position where the iodine substituent was placed was 
established by the HMBC spectrum where the methyl protons signal δ 2.31 ppm 
correlated to two aromatic carbon signals each carrying a proton three bonds away at 
δ 121.8 ppm and δ 111.2 ppm. This suggested that the protons on the two carbons 
were ortho to the methyl substituent. Consequently, this implied that the iodine 
substituent was placed para to the methyl substituent, which was the required 
position. Happy with this step, our final phase of the synthesis was to oxidise the 
benzyl alcohol to an aldehyde. This was easily accomplished by subjecting the 
alcohol 109 to manganese dioxide (MnO2) in dichloromethane for 18 hours to furnish 
the desired benzaldehyde precursor 98 in 97% yield. The synthesis of 98 was 
unmistakably confirmed by the appearance of a signal due to the aldehydic proton at 
δ 10.16 ppm and the disappearance of both the signal due to the benzylic protons and 
the broad singlet in the 
1
H NMR spectrum. The appearance of a signal due to the 
carbonyl carbon in the 
13
C NMR spectrum at δ 196.6 ppm was further evidence of the 
synthesis of the benzaldehyde 98.  
 
Having assembled the two precursors 97 and 98, the next step was to couple the two 
precursors using the palladium mediated Suzuki-Miyaura cross coupling reaction as 
shown in Scheme 28. 
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2.3.3 Synthesis of substituted benzaldehyde 110 
 
 
Scheme 28: Reagents and conditions: Pd(PPh3)4, aq. Na2CO3 (2 M), DME, reflux, 18 h, 12%. 
 
The critical step for us was to ascertain if we could utilize the Suzuki-Miyaura 
conditions we had used thus far for the coupling of the two precursors 97 and 98. To 
this end, a deoxygenated solution of 97 and 98 in dimethoxyethane was added to 
tetrakis(triphenylphosphine)palladium(0) followed by the addition of deoxygenated 
aqueous sodium carbonate solution. The mixture was then heated at reflux for 18 
hours. The crude product was purified by column chromatography on silica gel to 
afford the biarylaldehyde 110 as an off-white solid in a poor yield of 12%. 
Conclusive evidence for the formation of the compound was provided by both 
1
H 
NMR and 
13
C NMR spectroscopy. There were five signals due to aromatic protons in 
the 
1
H NMR spectrum which were all assigned and were consistent with the 2-
naphthylbenzaldehyde structure. The most deshielded singlet signal at δ 9.55 ppm 
was assigned to the aldehydic proton. One proton 
appearing as a doublet of doublets at δ 7.71 ppm was 
assigned to H-8′ with J = 8.4 Hz derived from ortho 
coupling with H-7′ and J = 1.0 Hz from meta coupling 
with H-6′. A triplet signal at δ 7.4 ppm with J = 8.4 Hz 
was assigned to H-7′. A doublet signal at δ 7.48 ppm 
with J = 0.8 Hz from meta coupling with H-4 was assigned to H-6, and similarly the 
doublet signal at δ 7.04 ppm with J = 0.9 Hz from coupling with H-6 was assigned to 
H-4. A doublet of doublets at δ 6.93 ppm with J = 7.8 and 1.0 Hz was assigned to H-
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6'. The appearance of four signals due to the methoxy groups at δ 4.04, 3.86, 3.74 and 
3.45 ppm unmistakably established the identity of the desired product 110. The 
absence of another methyl proton signal and the presence of the benzylic protons 
signal at δ 3.86 ppm suggested that the allyl substituent was intact and had not 
isomerized in the process of preparing the boronic acid precursor 97. The carbonyl 
carbon was clearly observed in the 
13
C NMR spectrum as a signal at δ 192.7 ppm, 
and this functional group was further confirmed by FTIR with a C=O stretch at 
1690.6 cm
-1
.  Upon examination of the HRMS, a molecular ion peak was observed at 
406.1759 amu which was in good agreement with the expected mass of 406.1775 for 
C25H25O5. 
 
Although we were pleased that we had obtained our Suzuki product, the yield was a 
major concern. Hence, we spent a long time trying to optimise the reaction 
conditions. However, our attempts to improve the yields by varying conditions, 
preparing the palladium catalyst in situ, changing the supporting ligands from 
triphenyl phosphine to Xantphos, changing bases from Na2CO3 to CsF, K3PO4 and 
Cs2CO3, and finally using microwave conditions instead of the conventional method, 
were all unsuccessful. We rationalised the difficulty with this particular Suzuki-
Miyaura reaction arises from the steric hindrance resulting from the four ortho 
substituents hindering the reaction in allowing for the formation of the tetra-ortho 
substituted biaryl axis intermediate 110.  
Over and above the difficulties encountered in coupling the two precursors, we also 
envisaged that the ruthenium mediated ring closing metathesis reaction to assemble a 
new benzene ring, would also pose a challenge. For that reaction to be successful in 
our case, we needed the dialkenes in the biaryl axis intermediate to align so that the 
orbitals can overlap for the [2+2] cycloaddition reactions as highlighted in Section 
1.7.5.2.1. We hypothesised that the two rings forming the biaryl axis would not be 
flat to align the dialkenes, due to steric repulsions from the adjacent ortho groups on 
the rings. The lowest energy and most stable conformation would be achieved if the 
Chapter 2: Angucyclines - Results and Discussion 
 
 
 
52  
 
groups are directed away from each other, implying that the alkenes on each side of 
the biaryl axis are not close enough for the necessary overlap of the orbitals to 
facilitate the [2+2] cycloaddition reactions.  With this in mind, we decided to revisit 
our synthetic strategy.  
2.4 Development of a new synthetic route 
We needed to find a solution to the poor yields of our Suzuki-Miyaura coupling 
reaction and at the same time, in view of our hypothesis on the ring alignment, look at 
other metal mediated methods that could accommodate steric factors. In the literature 
we came across a report by Lakshman on platinum or gold mediated 
cycloisomerisation of alkynes to assemble fused polycyclic aromatic hydrocarbons.
91
 
In this approach, 1-(2-ethynylphenyl)naphthalene 111 was cycloisomerised to 
benzo[c]phenanthrene 112. The 1-(2-ethynylphenyl)naphthalene was prepared from 
biarylaldehyde 113 using the Corey−Fuchs two-step alkynylation method.92 The brief 
summary of the synthetic route is shown in Scheme 29. 
 
Scheme 29: Reagents and conditions: (i) PPh3, CBr4, CH2Cl2, 0 °C; (ii) n-BuLi, THF, −78 °C, 78% 
(over two steps); (iii) PtCl2 or AuCl3, PhMe, 80 °C, (Pt: 84%, Au:75%) 
 
Although this strategy has never been used in the synthesis of benz[a]anthracene 
skeletons as found in angucycline cores, we thought we could adopt the PtCl2 or 
AuCl3 cycloisomerisation reaction to our substrates. The advantage of using this 
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approach was that the allyl substituent on naphthalene boronic acid 97 was no longer 
required, and as such, a tetra-ortho substituted biaryl axis intermediate would not be 
required. Hopefully, this would result in improving the yield of the Suzuki-Miyaura 
cross coupling reaction. Furthermore, our aldehyde precursor 98 could be utilised in 
this sequence to enable alkynylation and subsequent cycloisomerisation ring closure 
via a 6-endo-dig pathway.  
In the next section, this new strategy towards the synthesis of tetrangulol will be 
discussed.  
 
2.5 PtCl2 or AuCl3 mediated synthesis of tetrangulol  
Our approach to the synthesis of tetrangulol using a PtCl2 or AuCl3 mediated 
cycloisomerisation reaction as a key step to assemble a new benzene ring is shown in 
Scheme 30. 
 
 
 
Scheme 30: PtCl2 and AuCl3 mediated route to the synthesis of tetrangulol 
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Our new synthetic route commenced with the assembly of a trimethoxynaphthalene 
boronic acid 114. This was accomplished by the reduction of previously synthesised 
bromojuglone 99 to furnish the bromonaphthalene 115 which was subsequently 
functionalised to the desired boronic acid 114 as demonstrated in Scheme 31. 
 
 
Scheme 31: Reagents and conditions; Me2SO4, Na2S2O4, TBAI, aq. KOH, THF, 79%; (ii) n-BuLi, 
B(OiPr)3, −78 °C, 1 h, 96%. 
 
The quinone 99 was smoothly reductively methylated to the corresponding 
napthalene 115 as previously described in Section 2.2.1.1 and in Scheme 20. The 
bromonaphthalene 115 was obtained in 79% yield. Analysis of the 
1
H NMR spectrum showed the appearance of three methoxy group 
proton signals at δ 3.95, 3.93 and 3.92 ppm, which was consistent 
with the naphthalene. Furthermore, one singlet signal in the aromatic 
region of the 
1
H NMR spectrum at δ 6.90 ppm was assigned to H-3 
of the naphthalene structure.  
 
Satisfied with the synthesis of the naphthalene derivative 115, we now focused on the 
next step of making the naphthaleneboronic acid 114. This synthesis was 
accomplished as described in Section 2.3.1.2 and in Scheme 26. The boronic acid 
114 was obtained as an off-white crystalline solid in 96% yield. This was then used in 
the subsequent step without further purification or characterization.  
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With the boronic acid 114 in hand, we now focused our attention on the palladium 
mediated Suzuki-Miyaura coupling reaction of the boronic acid 114 and the 
previously assembled substituted benzaldehyde 98 as illustrated in Scheme 32. 
 
 
Scheme 32: Reagents and conditions: Pd(PPh3)4, aq. Na2CO3 (2 M), DME, EtOH, reflux, 18 h, 80%. 
 
This reaction was very critical for us as we hoped the less sterically hindered boronic 
acid 114 would result in a successful Suzuki-Miyaura coupling reaction affording 
high yields of the biaryl product 116.  
 
To accomplish this, a deoxygenated solution of boronic acid 114 and the 
benzaldehyde 98 in dimethoxyethane was added to 
tetrakis(triphenylphosphine)palladium(0) followed by the addition of deoxygenated 
aqueous sodium carbonate solution. The mixture was then heated at reflux for 18 
hours. To our delight, chromatographic purification of the crude product furnished the 
2-naphthylbenzaldehyde intermediate 116 in a very good yield 
of 80%.  Analysis of the 
1
H NMR spectrum showed the 
presence of four signals due to the methoxy group protons at δ 
4.00, 3.92, 3.80 and 3.45 ppm with the most shielded of these 
being that for the C-1′ methoxy group. The most shielded 
aromatic singlet at δ 6.69 ppm was indicative of the proton H-
3′. Furthermore, there were six signals in the aromatic region of the 1H NMR 
spectrum which provided evidence that coupling of the precursors had occurred. 
Additionally, in the analysis of HRMS, a peak for the molecular ion was observed at 
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366.1452 amu (100%) which correlated with the expected mass of 366.1461 amu for 
C22H22O5. 
 
The successful assembly of the biarylbenzaldehyde 116 in very good yield proved 
that a tetra-ortho substituted biaryl axis intermediate 110 was simply too sterically 
hindered for the successful Suzuki-Miyaura coupling reaction as opposed to the tri-
ortho substituted biaryl axis intermediate as noted by the increase in yields from 12% 
to 80%. With the successful synthesis of the biaryl compound 116 we then proceeded 
to convert the aldehyde to the dibromovinyl intermediate 117 and then subsequently 
to the acetylene 118 using the Corey-Fuchs method as shown in Scheme 33. 
 
 
Scheme 33: Reagents and conditions: (i) PPh3, CBr4, CH2Cl2, 0 °C, 89% (ii) n-BuLi, THF, −78 °C, 
88%.  
To achieve this, CBr4 was added to a mixture of PPh3 in dichloromethane followed by 
slow addition of the aldehyde 116 and the mixture was stirred for 4 hours. At the end 
of this period, TLC showed that all the starting material was consumed.  
Chromatographic purification of the crude product afforded the dibromovinyl 
intermediate 117 in 89% yield, as a foamy, yellow solid. The 
unmistakable disappearance of the signal due to the aldehyde 
proton in the 
1
H NMR spectrum and the appearance of a new 
singlet signal integrating for one proton at δ 7.09 ppm which 
correlated to =CH- (H-1), was proof of its formation. 
Additionally, the HRMS showed a molecular ion peak at 
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519.9881 amu which was in good agreement with the expected mass of 519.9879 
amu for C23H22O4
79
Br2. 
The obtained dibromovinyl adduct 117 was then subjected to a debromination 
reaction by treating it with n-BuLi in tetrahydrofuran at −78 °C to smoothly furnish 
the acetylene 118 as a yellowish-brown solid in an excellent yield of 88%. The 
1
H 
NMR spectrum unequivocally proved the formation of the product by the 
disappearance of a singlet signal at δ 7.09 ppm which correlated to =CH-, and the 
appearance of the singlet signal due to an acetylenic proton at δ 2.81 ppm. The 
acetylene functional group was also observed in the FTIR by a stretching band at 
2370.8 cm
-1
.  Furthermore, analysis of the HRMS showed a molecular ion peak at 
362.1522 amu (100%) which correlated with the expected mass of 362.1512 amu for 
C23H22O4. 
  
Pleased with the synthesis of acetylene 118, we then focussed our attention on the 
PtCl2 or AuCl3 mediated cycloisomerisation reaction to assemble a new benzene ring. 
This was a key step for us as it would give us the desired benz[a]anthracene carbon 
skeleton of tetrangulol as illustrated in Scheme 34.  
 
 
Scheme 34: Reagents and conditions: Cat. PtCl2 or AuCl3, PhMe, 90 °C, 24 h, (Pt: 119-61%, Au: 
119-56%). 
 
Although PtCl2 was alluded to as being a better catalyst in the assembly of substituted 
benzo[c]phenanthrenes, we decided to use both catalysts in order to compare their 
efficiency in the assembly of benz[a]anthracene skeletons. To accomplish this, PtCl2 
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or AuCl3 was added to acetylene 118 in toluene and the mixture was stirred at 90 °C 
for 24 hours. To our delight, chromatographic purification on silica gel furnished the 
desired tetramethoxy tetraphene 119 as a yellow solid in 61% yield for platinum and 
56% for gold, along with an unknown product 120. The identity of the tetraphene 119   
was confirmed by 
1
H NMR spectroscopy. The disappearance of the signal due to the 
acetylenic proton at δ 2.81 ppm and the most shielded 
aromatic singlet at δ 6.67 ppm, along with the increase in the 
number of signals in the aromatic region of the 
1
H NMR 
spectrum from six to seven, clearly established the formation 
of the tetraphene 119. The two ortho coupled doublet signals 
integrating as one proton each at 8.03 ppm (J = 9.2 Hz) and 
7.36 ppm (J = 9.5 Hz) correlated to H-6 and H-5, respectively, in the structure. In 
addition, the HRMS showed a molecular ion peak at 362.1514 amu (100%) which 
was in good agreement with the expected mass of 362.1512 amu for C23H22O4.   
 
Satisfied that our cycloisomerisation ring closure step gave us our desired tetraphene 
119 in good yields, we decided to examine in detail the identity of unknown 
compound 120. Using both 
1
H NMR and 
13
C NMR spectroscopy, and in particular 
2D experiments such as HMBC and HSQC spectroscopy, we were able to confirm 
the identity of the unknown compound. The disappearance of the acetylene proton 
signal at δ 2.81 ppm and the increase in the number of aromatic proton signals from 
six to eight clearly showed that this compound, just like the tetraphene 119 contained 
a new benzene ring. We therefore postulated that the unknown compound 120 arose 
by an alternative cycloisomerisation reaction. Two ortho coupled proton signals at δ 
8.56 ppm and δ 7.69 ppm J = 9.1 Hz for both signals were assigned to H-5 and H-6 
respectively.  Detailed analysis of the HMBC spectrum showed that the triplet at δ 
7.56 ppm and the doublet signal at δ 7.06 ppm both correlated to a methoxy carrying 
carbon three bonds and two bonds away respectively at δ 157.4 ppm assigned C-1. 
These two signals were indicative of H-2 and H-3 protons. The proton singlet signal 
at δ 9.20 ppm correlated to one methoxy carrying aromatic carbon signal at δ 154.9 
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ppm assigned C-12 and this was indicative of the H-11 proton. The doublet at δ 8.38 
ppm, which using the HMBC spectrum, was correlating to an aromatic proton present 
as a triplet at δ 7.56 ppm two bonds away and another carbon carrying a doublet 
proton signal at δ 7.06 ppm three bonds away was consistent with H-4. Finally, the 
two meta coupled protons at δ 7.34 ppm and δ 6.92 ppm with J = 0.9 Hz were 
indicative of H-7 and H-9 respectively. Additionally, the proton signal at δ 6.92 ppm 
assigned to H-9 was correlating to a methoxy group carrying aromatic carbon two 
bonds away at δ 158.6 ppm assigned as C-10, and the methyl carrying aromatic 
carbon two bonds away at δ 136.5 ppm assigned C-8. Furthermore, in the HRMS, a 
molecular ion peak was observed at 332.1379 amu which was in good agreement 
with the expected mass of 332.1407 amu for C22H20O3. Putting everything together, 
the identity of the unknown was established as the trimethoxychrysene derivative 
120. 
 
From the results of the key step cycloisomerisation reaction, it was evident that PtCl2 
was a better catalyst than AuCl3 for this reaction. These 
results were consistent with those found by Lakshman. Our 
combined yields of the two products in either platinum or 
gold catalysed transformations was above 80%. We were 
very pleased that our desired benz[a]anthracene 119 was 
formed in a better yield than the undesired chrysene 
derivative 120. The rationale for the differences in the 
ratios of the products, and indeed why the chrysene was formed at all, has not been 
fully unravelled. However, we hypothesised that the steric interactions between the 
methoxy on C-1′ and that one on the C-3 position of the acetylene derivative 118 
leads to the ring closure that proceeds via demethoxylation of the more sterically 
hindered methoxy at the C-1′ position. 
 
In both ring closing reactions to assemble the benz[a]anthracene and the 
benzo[c]anthracene frameworks, the preferred route was the 6-endo-dig pathway. 
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Echavarren reported on the mechanistic studies and the endo-selectivity of the 
intramolecular hydroarylation of alkynes by platinum and gold.
93
 The next section 
will highlight the mechanistic pathways to the cycloisomerisation. 
2.5.1 Intramolecular cycloisomerisation of alkynes. 
The 6-endo-dig intramolecular hydroarylation pathway as proposed by Echavarren
93
 
is given in Scheme 35.  
 
Scheme 35: Mechanism for cycloisomerisation 
The postulated mechanistic pathway in this electrophilic aromatic substitution 
reaction is based on the Friedel-Crafts alkenylation reaction. In this pathway, the η2-
coordination of the MXn to 121 gives the organometallic compound 122 which 
undergoes an electrophilic aromatic substitution (EAS) reaction to furnish the 
Wheland type adduct 123 which upon a 1,3 H-shift affords the cycloisomerised 
product 124. However, the 5-exo-dig pathway of electrophilic aromatic substitution 
reaction of 122 to give 125 does not take place hence substrate 121 does not furnish 
the 5-exo-dig product 126.  
 
In the case of intramolecular hydroarylation of the acetylene 118, we have speculated 
two plausible mechanisms for the assembly of the tetramethoxytetraphene 119. The 
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first mechanism proceeds via a Friedel-Crafts-type reaction by means of 6-endo-dig 
cyclisation as illustrated in Scheme 36. 
 
 
Scheme 36: Proposed mechanism for cycloisomerisation via η2- coordination 
In this mechanism, the metal coordinates to the triple bond of the acetylene 118 to 
form the coordinated complex 127 which, upon an electrophilic aromatic substitution 
reaction driven by the lone pair of electrons on the oxygen of the C4-OMe group, 
affords the intermediate 128. A concerted 1,3-H shift and rearomatisation furnish the 
tetraphene 119. In our case, there are two factors that promote or drive this 
intramolecular cycloisomerisation reaction. Firstly, the naphthalene ring of the biaryl 
acetylene 118 is electronic rich due to electron donating methoxy groups that can 
facilitate the electrophilic aromatic substitution reaction. Secondly, the carbocation 
formed as a result of the EAS can be stabilised by the C8-OMe group, further 
promoting the cycloisomerisation reaction.   
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The alternative mechanism we have proposed proceeds via a vinylidene complex 
which then undergoes a π6–electrocyclisation to form the new aromatic ring as shown 
in Scheme 37. 
 
Scheme 37: Proposed π6-electrocyclisation mechanism 
 
In this mechanism, coordination of the metal to the triple bond of acetylene 118 gives 
the coordinated complex 127  which could form the vinylidine adduct 129. The 
vinylidine undergoes the π6-electrocyclisation to assemble tetracyclic derivative 130 
which upon rearomatisation furnish the tetraphene 119. 
 
We also made an attempt to postulate the mechanism for the formation of the 
chrysene derivative 120 as illustrated in Scheme 38. 
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Scheme 38: Proposed mechanism for assembly of chrysene via η2- coordination  
 
Under this mechanism, the metal coordinates to the triple bond of the acetylene 118 
to give the coordinated complex 127, which upon electrophilic aromatic substitution 
reaction driven by the lone pair on oxygen affords the intermediate 131. 
Demethoxylation of the intermediate 131 gives the benzo[c]phenanthridine adduct 
132 which upon aromatisation furnishes the chrysene derivative 120.  
 
We also postulated that the chrysene derivative 120 could be assembled through the 
π6-electrocyclisation as illustrated in Scheme 39. 
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Scheme 39: Proposed π6-electrocyclisation mechanism for the assembly of chrysene 
 
In this mechanism, coordination of the metal to the triple bond of acetylene 118 gives 
the coordinated complex 127 which could form the vinylidine adduct 129. The 
vinylidine undergoes the π6-electrocyclisation to assemble the 
benzo[c]phenanthridine derivative 133 which, upon demethoxylation and 
rearomatisation, furnishes the tetraphene 120. 
 
Satisfied that we were able to assemble a benz[a]anthracene skeleton of tetrangulol in 
good yields using a PtCl2 or AuCl3 intramolecular cycloisomerisation reaction as a 
key step, we embarked on the final stages of the synthesis by oxidising the 
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tetramethoxytetraphene 119 into its corresponding quinone 38, followed by 
demethylation, to furnish the targeted natural product 2 as shown in Scheme 40.   
 
 
 
Scheme 40: Reagents and conditions: (i) CAN, MeCN/H2O, 86%; (ii) BBr3, CH2Cl2, −78 °C to rt, 
93%. 
 
Tetramethoxytetraphene 119 was smoothly converted into its corresponding quinone 
38. To accomplish this, cerium ammonium nitrate (CAN) was added to the tetraphene 
119 in acetonitrile and water and the mixture stirred for 30 minutes. The crude 
product was purified by column chromatography on silica gel to give the 
benza[a]anthraquinone derivative 38 in 86% yield as a yellow solid. The 
1
H NMR 
spectrum unambiguously established the formation of the quinone by the distinct 
absence of two signals due to the methoxy group protons. Additionally, the 
13
C NMR 
spectrum explicitly showed two signals due to carbonyl carbons at δ 186.6 and δ 
182.3 ppm. The 
1
H NMR spectrum and 
13
C NMR spectrum signals were in good 
agreement with those found by Hsu and co-workers.
57
 
  
To complete the formal synthesis of tetrangulol 2, we needed to demethylate the 
quinone 38. This was accomplished by subjecting the quinone 38 to BBr3 in 
dichloromethane overnight. Chromatographic purification of the crude product 
furnished the dihydroxyquinone (tetrangulol) 2 in an excellent yield of 93% as a 
brown solid. As observed in the spectral data, the unmistakable disappearance of two 
signals due to the methoxy group protons at δ 4.03 ppm and δ 3.97 ppm and the 
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appearance of two signals arising from the phenolic protons at δ 12.24 ppm and 11.26 
ppm proved that the dihydroxyquinone 2 was successfully synthesised. This 
spectroscopic data correlated well with that obtained by Hsu.
57
 
 
2.6 Conclusion  
In summary, we have successfully developed a novel convergent method for the 
synthesis of 1,8-dihydroxy-3-methyltetraphene-7,12-dione 2, a natural angucycline 
antibiotic commonly known as tetrangulol in 16 steps and 19.5% overall yield. The 
palladium catalysed Suzuki-Miyaura cross coupling reaction and the platinum or gold 
mediated intramolecular cycloisomerisation were key steps in the synthesis. This 
method can be extended to the synthesis of other angucycline antibiotic natural 
products.  
 
2.7 Future work arising from this novel synthesis 
Having successfully developed a method for synthesising angucycline antibiotic 
natural products with a carbotetracyclic core, we wondered if we could extend this 
work to the synthesis of other natural products, particularly the nitrogen containing 
angucyclines and other alkaloids. One idea we were pondering on was; could we 
make nitrogen containing natural products or analogues of natural products from one 
of the intermediates that we used to synthesise tetrangulol? 
The next chapter of this PhD thesis gives an introduction and background to nitrogen 
containing natural angucyclines and their related alkaloids. Following this 
introduction on nitrogen containing aromatic natural products, the subsequent chapter 
will detail the work that we did on developing a synthetic method for assembling 
nitrogen containing natural product analogues. 
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CHAPTER 3: Benzo[b]phenanthridines and Benzo[c]phenanthridines: 
Introduction and Literature Review 
 
3.1 Background and Introduction 
Naturally occurring nitrogen containing secondary metabolites are commonly 
distributed in plants, fungi, marine organisms, animals and others. These natural 
products with diverse and complex structures have been shown to exhibit potent 
therapeutic properties.
94
 Some examples of aromatic natural products that incorporate 
nitrogen in their structures are the benzo[b]phenanthridines, jadomycins and 
benzo[c]phenanthridines.
95-96
 On the basis of biosynthetic origins, whilst 
benzo[b]phenanthridines and jadomycins belong to the class of angucycline antibiotic 
natural products, benzo[c]phenanthridines, which are structural analogues of 
benzo[b]phenanthridines, are typically classified as alkaloids.
95, 97
The next sections 
will discuss each of these classes in detail. 
3.2 Jadomycin antibiotics 
Jadomycins are unique members of the angucycline antibiotics and are one of the 
most studied subunits of the nitrogen containing angucyclines. The first compounds 
to be isolated from Streptomyces venezuelae ISP5230 were jadomycin A 134 and B 
135
98-99
 (Figure 11).  
3.2.1 Structure of jadomycins 
Jadomycins contain an unusual 8H-benzo[b]oxazolo[3,3-f]-phenanthridine ring 
system.
100
 Compounds in this class also exhibit two unique structural features as 
shown in Figure 11; a 2,6-dideoxysugar L-digitoxose and a five-membered oxazalone 
ring.
101-102
 It is reported that the oxazolone ring is formed from the amino acid 
isoleucine with a biosynthetic aldehyde precursor.
97
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Figure 11: Jadomycin natural products 
 
3.2.2 Biosynthesis of jadomycins 
As with all angucycline antibiotics, the starting precursors for the jadomycin 
biosynthesis are an acetate propionate and nine malonate units, which combine 
through condensation to form the decaketide intermediate 136. This subsequently 
cyclises to form the benzo[b]anthracene backbone 137 as shown in Scheme 41. 
Further oxidation, followed by dehydration across the C-4a and C-12b positions and 
subsequent aromatisation leads to the formation of the intermediate 
dehydrorabelomycin 138. Oxidative cleavage of 138 at the C5-C6 bond gives the 
aldehyde/acid intermediate 139. Non-enzymatic insertion of the L-isoleucine amino 
acid affords the aldimine moiety 140.  The non-enzymatic addition of an amino acid 
pathway has also been exploited synthetically to such an extent that almost all amino 
acids have been inserted in the jadomycin biosynthesis to create a library of 
analogues.
102
 Cyclisation, oxidation of the intermediate hydroquinone and 
decarboxylation furnishes jadomycin A 134, which, upon glycosylation, gives 
jadomycin B 135.
101, 103
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Scheme 41: Biosynthesis of jadomycins 
 
3.2.3 Biological activities 
The jadomycin class of antibiotics has been reported to show potent therapeutic 
activities. Jadomycin B 135 and other analogues demonstrated potent antibacterial 
activities against Staphylococcus aureus C623, a methicillin resistant strain of 
bacteria (MIC < 2 µg/mL).
101
 Currently, vancomycin is the only drug for the 
treatment of Staphylococcus aureus C623 infections.
101
 These results illustrate the 
potential of the angucycline antibiotics as new drug candidates. Promising activities 
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were also exhibited by jadomycin B 135 and other analogues (Figure 12) against five 
cancer cell lines. 
 
 
Figure 12: Biologically active jadomycins 
 
Jadomycin 144 showed potent activity against HepG2, IM-9 and IM-9/Bcl-2 cell 
lines, whilst Jadomycin B 135 demonstrated activity against HepG2 and IM-9 cells. 
Additionally, Jadomycin F 142 exhibited excellent activity against the H460 cell line. 
Although all the compounds could supress the proliferation of tumour cell lines in 
vitro, jadomycins 141, 143 and 145 were less active.
104
 It was further demonstrated 
by the gel mobility assay that the jadomycin derivatives may also act as DNA 
cleaving agents.
101, 104
 
 
3.3 Benzo[b]phenanthridines. 
This is a small group of angucycline antibiotics that has been isolated from different 
Streptomyces species. 
3.3.1 Structures of benzo[b]phenanthridines 
The first naturally occurring benzo[b]phenanthridine, phenanthroviridone 146 and its 
glycoside, phenanthroviridine 147 (Figure 13) were isolated from Streptomyces 
murayamaensis.
105
 This class of compounds possesses a nitrogen inserted at the C-6 
position of the benzo[b]anthracene skeleton of the angucycline, tetrangulol. Very 
recently, L-digitoxosyl-phenanthroviridine 148 has been isolated from Streptomyces 
venezuelae ISP5230.
105
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Figure 13: Common benzo[b]phenanthridine natural products 
 
3.3.2 Biosynthesis of benzo[b]phenanthridines 
Benzo[b]phenanthridines are believed to be intermediates in the transformation of 
dehydrorabelomycin 138 to the kinamycin class of antibiotics (Section 1.6.3) during 
their biosynthesis.
106
 The biosynthetic pathway is summarised in Scheme 42. Just as 
in the biosynthesis of jadomycins described earlier, compounds in this class are also 
prepared from the condensation of Acetyl-CoA units, which affords the folded 
decaketide moiety 136, which undergoes cyclisation to form the benzo[b]anthracene 
backbone 137. Dehydration across C-12b and C-4a and subsequent oxidation affords 
the key intermediate, dehydrorabelomycin 138. Oxidative cleavage results in the 
biaryl adduct 139, which, upon nitrogen insertion, ring closure and decarboxylation, 
furnishes the phenanthroviridone 146. Glycosylation of 146 affords 
phenanthroviridine 147.
106-107
 Alternatively, 148 can be prepared from 146 by 
glycosylation followed by amination of the sugar moiety.  
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Scheme 42: Biosynthesis of phenanthroviridines 146, 147 and 148 
 
3.3.3 Biological activities 
Benzo[b]phenanthridines have been reported to exhibit a broad range of therapeutic 
activities. Phenanthroviridine 147 and its aglycone 146 showed potent activities 
against lung carcinoma cell line MBA9812 in a murine model.
108
 Additionally, 
phenanthroviridone 146 demonstrated good antimicrobial activity against 
Staphylococcus aureus ATCC 29213, with an MIC value of 0.25 μg/mL and 
antibacterial activity against Escherichia coli ATCC 25922, Bacillus thuringiensis 
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SCSIO BT01, and Bacillus subtilis SCSIO BS01. When 146 was evaluated against 
three human cancer cell lines, it displayed significant in vitro cytotoxicity against SF-
268 (IC50 0.09 μM) and MCF-7 (IC50 0.17 μM).
109
 Recently isolated L-digitoxosyl-
phenanthroviridine 148 demonstrated good activity against a number of human 
cancer cell lines (NCI 60). The median range values for all the cell lines were; GI50 = 
2.14 µM for 56 cell lines, TGI = 5.75 µM for 56 cell lines and LC50 = 18.2 µM for 41 
cell lines.  
 
3.4 Benzo[c]phenanthridines 
Benzo[c]phenanthridines are a class of natural products with a unique ring system. 
These alkaloids are targets for synthetic methodology development due to their 
diversity in nature and broad range of biological activities.
110-111
 Unlike the 
previously discussed benzo[b]phenanthridine and jadomycin classes which are 
isolated from soil Streptomyces sp. of bacteria, benzo[c]phenanthridines on the other 
hand are secondary metabolites extracted and isolated from plant species.
97, 112
 
 
3.4.1 Structures of benzo[c]phenanthridines 
Members of this class of alkaloids are commonly isolated from Fumariacea, 
Papaveraceae and Rutaceae families of plants.
111
 They are usually oxygenated at C-2, 
C-3, C-7 and C-8, although others with C-9 and C-10 oxygenation have also been 
isolated.
113
 Some benzo[c]phenanthridines are quaternary alkaloids such as 
sanguinarine 149, chelerythrine 150, fagaronine 151 and nitidine 152. Examples of 
non-quaternary natural products include decarine 153 and oxyterihanine 154 (Figure 
14).  
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Figure 14: Examples of benzo[c]phenanthridines 
 
These compounds have attracted attention because of their interesting biological 
activities which range from antileukemia activity, to inhibitors of DNA 
topoisomerases and both HIV-1 and HIV-2 reverse transcriptases.
114
 The forthcoming 
section will highlight some of the biological activities displayed by these 
benzo[c]phenanthridines. 
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3.4.2 Biological activities 
The biological activities of benzo[c]phenanthridines have been studied extensively. 
Fagaronine 151 and nitidine 152 were reported to show interesting antileukemic 
activities  to the extent that they were the subject of preclinical studies at the National 
Cancer Institute in the early 1970s.
115
 It has been suggested that the antitumour 
activity of 151 and 152 is due to the inhibition of DNA topoisomerase. This action is 
credited to their conformationally rigid structures.
114
 Furthermore, chelerythrine 150, 
sanguinarine 149, nitidine 152 and fagaronine 151 also demonstrated excellent 
activities against cultured human cervical tumour cells (HeLa S3) in vitro, with 
reported IC50 values of 1.24, 0.16, 0.05 and 0.39 µg/Ml, respectively.
116
 Additionally, 
150 and 149 also inhibited protein kinase C (PKC).
117
  
Sanguinarine 149 has also been reported to be a potent and selective inhibitor of 
mitogen-activated protein kinase phosphatase-1 (MKP-1). This phosphatase can 
protect cells from apoptosis caused by DNA-damaging agents or cellular stress 
through its overexpression in many human tumours. Sanguinarine 149 inhibited 
cellular MKP-1 with an IC50 value of 10 μM. It also exhibited selectivity for MKP-1 
over MKP-3. Apart from the cellular MKP-1 inhibition, it inhibited both MKP-1 and 
the MKP-1-like phosphatase, MKP-L, in vitro with IC50 values of 17.3 and 12.5 μM, 
respectively.
118
 More interestingly, the same compound was the most effective 
inhibitor of human choline acetyl-transferase (IC50 284 nM) and was reported to 
further intercalate DNA, inhibiting DNA synthesis and HIV reverse transcriptase.
119
  
The search for new synthetic methods for preparing these classes of natural products 
has been propelled by the toxicity of the most active members of these groups, and 
the consequent desire to study structure–activity relationships. The next section 
highlights the methodologies that have been developed for the synthesis of 
benzo[b]phenanthridine, jadomycin and benzo[c]phenanthridine classes of 
compounds.
Chapter 3: Benzo[b]phenanthridines and Benzo[c]phenanthridines 
 Synthetic Strategies 
 
 
 
76  
 
3.5 Synthetic methodologies 
A number of approaches have been developed over the years to achieve the total 
synthesis of the natural products in these classes or for the assembly of the nitrogen 
incorporated tetracyclic cores.  
 
3.5.1 Synthesis of jadomycins 
There are only three recent reports in the literature on the total synthesis of 
jadomycins. These three synthetic strategies have been reported by O’Doherty’s 
group, Ishikawa’s group and finally by Yu and Young.100, 120-121 
  
3.5.1.1 Ishikawas’s jadomycin synthesis 
Ishikawa and co-workers first reported the synthesis of dimethyl jadomycin A 155 as 
a proof of concept in constructing the 8H-benzo[b]oxazolo[3,2-f]phenanthridine 
skeleton.
120
 In this strategy, they used an α-spiro-lactonedihydroquinone 160 as the 
key intermediate for the assembly of the jadomycin ring system (Scheme 43). Their 
synthesis commenced with a palladium catalysed enolate arylation coupling reaction 
of a tetralone derivative 156 and the bromobenzene derivative 157 followed by 
lactonization to assemble a benzo[b]naphthopyranone adduct 158. Exposure of 158 to 
osmium tetraoxide afforded the α-spiro-lactone-tetralone derivative 159, which, upon 
benzylic bromination, hydroxylation and subsequent 2-iodoxybenzoic acid (IBX) 
oxidation, gave the key intermediate α-spiro-lactonedihydroquinone 160.  Treatment 
of the diketone 160 with methyl isoleucinate furnished the acid 161, which was 
subsequently reduced with the BH3·THF complex, followed by the hydrolysis of the 
isoleucine methyl ester with LiOH, to give the biaryl amino intermediate 162. 
Benzylic oxidation of the alcohol to facilitate condensation gave an iminium system, 
which was subsequently trapped by the carboxylate to furnish the pentacyclic 
oxazalone derivative 155. Unfortunately, attempts to demethylate the intermediate to 
afford the target natural product jadomycin A 134 were unsuccessful.   
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Scheme 43: Reagents and conditions; (i) Pd2(dba)3, xantphos, K3PO4, Na2S2O5, o-xylene, 130 °C, 
5  h, 56%; (ii) OsO4, NMO, acetone, CH2Cl2, H2O, rt, 7 d, 95%; (iii) NBS, AIBN, benzene; (iv) TFH, 
H2O; (v) IBX, DMSO 59% (over three steps); (vi) methyl isoleucinate, Et3N, MeOH, H2O, 60 °C, 2 d, 
41%; (vii) BH3.THF, 0 °C, 15 h, 36%; (viii) LiOH, THF, H2O; (ix) MnO2, CH2Cl2, rt, 40 h, 61%.  
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3.5.1.2 O’Doherty’s jadomycin synthesis 
O’Doherty and co-workers recently reported the first ever synthesis of jadomycin A 
134 and an analogue of jadomycin B 163. The key step in the synthesis was a 6 ᴨ-
electrocyclic ring closure reaction.
100
 The synthesis exhibited in Scheme 44 started 
with a commercially available phenol 164, which was MOM protected to give the 
benzene derivative 165. Directed ortho-metallation followed by exposure to 
tributyltin chloride afforded the stannane adduct 166. Palladium mediated cross 
coupling between the stannane 166 and the benzyl-protected juglone moiety 167, 
afforded the biaryl intermediate 168, whose acetal protective group was subsequently 
cleaved to furnish an aldehyde in decent yield. Unfortunately, when this MOM 
protected aldehyde was subjected to a condensation reaction with the protected 
isoleucine amino acid 170 in the key step, the desired product was not formed owing 
to the negative ortho-ortho interactions between the quinone oxygen and the MOM 
group.  The strategy was then modified by selective cleavage of the MOM protective 
group to give the phenolic aldehyde 169, which, when subjected to the isoleucine 170 
in the imine formation electrocyclic ring closure step, afforded the hemiaminal 171. 
The phenolic group in this case contributed to the ortho-ortho positive-negative 
interaction through hydrogen bonding with the quinone. Acid hydrolysis of the tert-
butyl ester to form the oxazalone pentacyclic ring, followed by benzyl deprotection, 
furnished the desired natural product jadomycin A 134. 
In the synthesis of an analogue of jadomycin B 163 (Scheme 45), an attempt to 
introduce the previously assembled cyclitol donor 172 to the synthesised jadomycin 
A 134 via the Mitsunobu cyclitolisation was not successful. Cyclitolisation was only 
successful on the debenzylated biaryl precursor 173. Following the insertion of the 
carbasugar, the jadomycin B analogue 163 was synthesised by following the same 
scheme as used in the synthesis of jadomycin A.    
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Scheme 44: Reagents and conditions; (i) MOMCl, DIPEA, CH2Cl2, rt, 12 h, 68%; (ii) n-BuLi, 
Bu3SnCl, hexane, 0 °C, 2 h, 68%; (iii) Pd2(dba)3, CHCl3, PPh3, CuI, THF, 75 °C, 12 h, 73%; (iv) HCl 
in MeCN, rt, 4-8 min, 77%; (v) isoleucine tert-butyl ester hydrochloride, toluene, rt, 24 h, 91%; (vi) 
TFA, rt, 2 d, 74%. 
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Scheme 45: Reagents and conditions; (i) PPh3, DIAD, THF, rt, 30 min, 91%; (ii) 2.4 M HCl/MeCN 
(1:5 v/v), 8 min, 59 %; (iii) isoleucine tert-butyl ester hydrochloride, toluene, rt, 24 h, 91%; (iv) TFA, 
rt, 2 h, 55%. 
 
The proposed mechanism for the 6 ᴨ-electrocyclic ring closure of the intermediate 
imine 174 is given in Scheme 46.  
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Scheme 46: Mechanism for a 6 ᴨ-electrocyclic ring closure  
 
3.5.1.3 Yu’s synthesis 
Yu and Young have also reported a protective-group-free biomimetic synthesis of 
jadomycin A 134 which was then elaborated further to jadomycin B 135 .
121
 Their 
strategy was a simple direct condensation of a naphthoquinone aldehyde with sodium 
L-isoleucinate as exhibited in Scheme 47. To accomplish this, isoleucinate 175 was 
added to a solution of naphthoquinone aldehyde 176 in tetrahydrofuran and the 
mixture stirred for 3 hours. Upon treatment with H
+
 resin, the desired jadomycin A 
132, was isolated in a mediocre yield of 51%. Although other reaction conditions 
were tried, these conditions gave the best yield. Their initial glycosylation of 132 
with 3,4-di-O-acetyl-L-digitoxosyl iodide prepared in situ from the acetate 177 was 
not successful due to the decomposition of the iodine adduct under the reaction 
conditions. To circumvent this, they opted to use the more stable glycosyl bromide 
which was also prepared in situ from the same acetate 177 using TMSBr and this 
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furnished the glycosyl coupled adduct 179 in a moderate yield of 25%, albeit with no 
α/β selectivity.  The yield was improved to 64% with a 6:1 α/β ratio when the 
Mitsunobu conditions were applied and the amount of the donor was increased from 
1.5 to 3.0 equivalents. In this case, the condensation of acetate 178 (3.0 equivalents) 
with 132 furnished the glycosyl adduct 179. Base catalysed deacetylation of the 
glycosyl coupled adduct 179 afforded the desired jadomycin B 135 in very good 
yield. 
Scheme 47: Reagents and conditions; (i) THF, rt, 3 h, then H
+
 resin, 51%; (ii) a) TMSBr, CH2Cl2, 0 
°C, then KHMDS, [18]C-6, 4 MS, THF, 0 °C, 25%; (ii) b) PPh3, DEAD, 4 MS, toluene, -78 °C, 64%; 
(iii) 0.2 N NaOMe, MeOH/CH2Cl2, rt, 89%; 
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3.5.2 Synthesis of Phenanthroviridone  
Synthetic strategies for the assembly of the benzo[b]phenanthridine core of natural 
products have been reported in the literature, particularly in the total synthesis of 
phenanthroviridone 146.
96, 122-124
 The forthcoming sections will therefore give a 
synopsis of methods that have been developed, in particular highlighting Snieckus’s, 
Gould’s and Echavarren’s synthesis of phenanthroviridone. 
 
3.5.2.1 Gould’s synthesis of phenanthroviridone  
Gould and co-workers reported the first synthesis of phenanthroviridone 146. The 
coupling reaction of a cyano phthalide and a bromo cinnamate was a key step in the 
synthesis.
122
 To achieve this, a previously assembled bromo cinnamate 180 was 
treated with a cyano phthalide 181 to give an annulated product which was converted 
to the quinone 182 upon exposure to oxygen (Scheme 48). The quinone was then 
reduced to the corresponding biaryl naphthalene 183 and the ester substituent was 
then functionalised to give an amide 184 in 80% yield over three steps. Lithiation of 
the amide followed by a DMF quench afforded a chromatographically inseparable 1:1 
mixture of the desired aldehyde 186 and the debrominated amide 187 along with 
traces of the fluorenone 185. Subjecting the inseparable mixture to modified Hoffman 
rearrangement conditions gave a mixture of carbamates 188 and 189, which, when 
quenched with water followed by reflux, led to the cyclisation of the carbamate 188 
to afford the benzo[b]phenanthridine skeleton. This was then separated from 189 and 
oxidised to its corresponding quinone 190. BBr3 deprotection of the quinone 
furnished the desired phenanthroviridone 146 in quantitative yield.  
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Scheme 48: Reagents and conditions; (i) t-BuOLi, THF, −78°C to rt, 20 h, then O2, 68%; (ii) 
Na2S2O4, Me2SO4, K2CO3, acetone, reflux, 24 h, 77%; (iii) TBAF, THF; (iv) Tf2O, pyridine; (v) aq. 
NH3, 80 % (over three steps); (vi) t-BuLi, THF, −98 °C, then DMF; (vii) NaOMe, Br2, MeOH,−54°C 
to 55°C; (viii) H2O, NaOH, reflux; (ix) aq. NaOH, O2; (x) BBr3, CH2Cl2, −78°C, quant. 
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3.5.2.2 Snieckus’s synthesis of phenanthroviridone 
Snieckus reported on a concise method for the synthesis of phenanthroviridine 
aglycone 146. In the methodology, they used a combined Directed Ortho-Remote-
Metallation (DORM) and Suzuki-Miyaura cross coupling strategy as a key step.
123
 
The synthesis commenced with the assembly of an oxaborole 191 from a benzyl 
alcohol 106 using a directed ortho metallation approach (Scheme 49).  
 
Scheme 49: Reagents and conditions; (i) n-BuLi, Et2O, 0 to 25 °C, B(OMe)3, 42%; (ii) PdCl2(dppf), 
K3PO4, DMF, rt, 62%; (iii) NH3 (aq.), MeCN, 50%; (iv) MnO2, CH2Cl2, rt, 78%; (v) BBr3, CH2Cl2, −78 
°C, quant. 
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The oxaborole was then subjected to a Suzuki-Miyaura cross coupling with 
bromojuglone 99 to give the biaryl derivative 192, which, upon exposure to aqueous 
ammonia, afforded the aminoquinone adduct 193. Manganese dioxide mediated 
oxidation of the benzyl alcohol followed by imine condensation gave the 
benzo[b]phenanthridine skeleton 190 in good yield. BBr3 deprotection furnished the 
target phenanthroviridine aglycone 146 in quantitative yield.  
 
3.5.2.3 Echavarren’s synthesis of phenanthroviridone 
The synthesis of phenanthroviridone 146 has also been described by Echavarren. The 
use of palladium and copper catalysed coupling of organostannanes and bromo 
quinones was the key step in the synthesis.
96
 This strategy was similar to the one used 
by O’Doherty and co-workers in the synthesis of jadomycin A 134 (Scheme 5044).100 
Echavarren’s synthesis, which is summarised in Scheme 50, started from the 
commercially available benzoic acid 194. Methyl ether protection of the phenol group 
of 194, reduction of the carboxylic acid to a benzyl alcohol followed by pyridinium 
chlorochromate (PCC) oxidation gave the aldehyde 195 in excellent yield. Ortho-
metallation of the aldehyde was achieved using a protocol developed by Comins.
125
 
In this procedure, treatment of the aldehyde 195 with lithium amide of N,N,N’-
trimethylethylenediamine, followed by addition of n-BuLi gave the aryllithium 
intermediate, which was subsequently quenched with n-Bu3SnCl to afford the 
stannane  derivative 196 in good yield. The Stille coupling of the aldehyde 196 with 
bromojuglone 99 gave the biaryl aldehyde 197. Exposure of the aldehyde 197 to 
ammonia in a 1-4 Michael-type reaction with the quinone was not successful owing 
to the high reactivity of the exposed aldehyde. Instead, the benzo[c]phenanthridine 
198 was isolated. To circumvent this challenge, the aldehyde was protected as an 
acetal 166 and the Stille coupling of this acetal 166 with bromojuglone 99 proceeded 
smoothly to yield the biaryl intermediate 199. Exposure of this intermediate to 
ammonia gave a 2-aryl-3-aminoquinone which, when treated with aqueous acid, 
furnished the benzo[b]phenanthridine skeleton 200. The formal synthesis of 
phenanthroviridone 146 was achieved by deprotection of 200.  
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Scheme 50: Reagents and conditions; a) (i) MeI, K2CO3, acetone, 65 °C, 12 h, 86%; (ii) LiAlH4, THF, 
23 °C, 12 h, 90%; (iii) PCC, CH2Cl2, 23 °C, 2.5 h, 85%; (iv) N,N,N’-trimethylethylenediamine, n-
BuLi, THF, −20 °C, 15 min; then n-BuLi, THF, −20 °C, 10 h; then n-Bu3SnCl, −78 to 5 °C, 12 h, 
85%; (v) Pd(PPh3)4, CuI, THF, 70 °C, 6 h, 65%; (vi) NH4OAc, HOAc, 118 °C, 24 h, 21% b) (i) MeOH, 
H2SO4 (cat.), 23 °C, 14 h, 94%; (ii) DHP, PPTS (cat.), CH2Cl2, 23 °C, 48 h, 93%; (iii) LiAlH4, THF, 
23 °C, 13 h, 93%; (iv) PCC, NaOAc, CH2Cl2, 23 °C, 3 h, 81%; (v) 1,3-propanediol, TsOH, toluene, 
reflux, 3 h, 74%; (vi) MOMCl, iPr2EtN, CH2Cl2, 40 °C, 24 h, 80%; (vii) n-BuLi, 0 °C; then n-Bu3SnCl, 
0 °C, 97%; (viii) Pd(PPh3)4, CuI, THF, 70 °C, 12 h, 85%; (ix) NH4Cl, NaOAc, EtOH, 80 °C, 12 h; 
then aq. HCl, 1,4-dioxane, 23 °C, 3 h, 67%; (x) LiI, 2,6-lutidine, 140 °C, 6 h, 63%;  
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3.5.3 Synthesis of benzo[c]phenanthridines 
Having looked at the various methods that have been developed for the synthesis of 
jadomycins and benzo[b]phenanthridines in the preceding sections, this section will 
highlight some strategies that have been used for the assembly of 
benzo[c]phenanthridines. A number of synthetic strategies for this class of 
compounds have been reported in the literature.
95, 126-129
 In the forthcoming sections, 
the Clement and Cho approaches will be discussed.  
 
3.5.3.1 Clement’s synthesis of the benzo[c]phenanthridine core 
In this strategy, Kock and Clement explored the use of a potassium t-butoxide 
catalysed condensation reaction of 2 equivalents of a substituted benzonitrile and 
aliphatic aldehydes, to assemble the tetracyclic ring system.
95
 The approach is 
summarised in Scheme 51. Subjecting paraformaldehyde 202 to a condensation 
reaction with 2 equivalents of 2-methylbenzonitrile 201 gave an amino substituted 
tetracyclic derivative 203 in moderate yields. Diazotisation of the amino group at the 
C-6 position with t-butylnitrite in dimethyl formamide afforded the 6-oxo derivative 
204, which, upon exposure to phosphorus pentasulfide, gave the 6-thio derivative 205 
in very good yields. Desulfurisation of 205 by Raney nickel furnished the target 
benzo[c]phenanthridine 206.  
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Scheme 51: Reagents and conditions; (i) KO
t
Bu, DMPU, 35-40 °C, 19%; (ii) t-butyl nitrile, DMF, 
1 h, 55 °C, 72%; (iii) P2S5, pyridine, reflux, 2 h, 89%; (iv) Raney-Ni, DMF, EtOH, reflux, 1h, 44%.  
 
3.5.3.2 Cho’s synthesis of oxynitidine and oxysanguinarine 
Cho and co-workers also described the synthesis of benzo[c]phenanthridine 
analogues of the natural products nitidine 152 and sanguinarine 149. Their approach 
involved the toluamide–benzonitrile cycloaddition reaction as a key step in the 
synthesis.
126
 The synthesis began with the assembly of a substituted benzonitrile 208 
from a bromobenzene adduct 207 (Scheme 52). The bromobenzene 207 was exposed 
to CuCN followed by acid catalysed deacetalisation to give the benzonitrile 208 in 
excellent yield. NaBH4 reduction of the aldehyde followed by MOM protection of the 
resulting benzyl alcohol furnished the MOM protected benzonitrile precursor 209. 
Exposure of 209 to n-BuLi deprotonated N-methyl-O-toluamide 210 gave the biaryl 
lactam derivative 211 in good yield. N- alkylation of the lactam with MeI gave the 
methylated derivative 212. MOM deprotection of 212 followed by pyridinium 
dichromate (PDC) oxidation of the resulting alcohol gave the aldehyde 213. 
Subjecting the aldehyde 213 to Wittig conditions afforded the olefin intermediate 
214, which, upon hydrolysis, furnished the desired oxynitidine 215. The final 
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benzo[c]phenanthridine assembly is presumed to proceed via an enamide-aldehyde 
cyclisation as shown in Scheme 52. 
 
 
Scheme 52: Reagents and conditions; (i) CuCN, DMF, reflux, 3h, 66%; (ii) 5% aq. HCl, MeOH, 50-
60°C, 15 min, 100%; (iii) NaBH4, AcOH, rt, 2 h, 78%; (iv) MOMCl, DIEA, CH2Cl2, 0 to 25 °C, 12 h, 
92%;   (v) n-BuLi, THF, −40°C, 4 h, 50%; (vi) NaH, THF, 0 °C, 1 h; then MeI, 0 to 60 °C, 78%; (vii) 
10% aq. HCl, THF, reflux, 3 h; (viii) PDC, CH2Cl2, rt, 2 h, 85% (two steps); (ix) Ph3PCH2OMeI, n-
BuLi, THF, 0 °C to rt, 4 h, 70%; (x) 10% aq. HCl, MeOH, reflux, 3 h, 88%. 
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Having introduced nitrogen containing natural products and the synthetic routes that 
have been developed to access these aromatic natural products, the next chapter 
discusses our attempts to develop a method for constructing nitrogen containing 
aromatic compounds, and more specifically, to synthesise phenanthroviridone 146.  
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Chapter 4:  Results and Discussion benzo[b]phenanthridines and 
benzo[c]phenanthridines 
 
4.1 Overview  
The work presented in this chapter draws on the results in Chapter 2 where we 
described the development of a new method for the assembly of tetrangulol, a natural 
angucycline antibiotic. We were able to synthesise the natural product tetrangulol 
from a key biarylbenzaldehyde intermediate 116, as summarised in Scheme 53.  
 
Scheme 53: Overview of tetrangulol synthesis 
 
With the development of the above methodology, we were wondering if we could 
functionalise the same intermediate 116 to access aromatic nitrogen containing 
compounds, and particularly the phenanthroviridone 146, as illustrated in Scheme 54. 
 
Scheme 54: Proposed overview of synthesis of phenanthroviridone 
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In order to accomplish the synthesis, we needed to add a nitrogen atom either on the 
naphthalene moiety or on the benzaldehyde substituent. The next section will discuss 
the development of a method for accessing phenanthroviridone 146. 
 
4.2 Development of a new synthetic method  
From previous studies on synthetic methodologies developed for the assembly of the 
benzo[b]phenanthridine-7,12-dione skeleton 217, it could be concluded that for 
stereoelectronic reasons, ring B is best constructed by cyclisation of a 2-amino-3-
phenylnaphthoquinone 216, as opposed to an amine cyclisation onto the 3-position of 
the naphthoquinone 218, which was observed to prefer a 1,2-addition at the C-1 
positon of the quinone to give a benzo[c]phenanthridine skeleton 219,
100
 as displayed 
in Scheme 55. 
 
Scheme 55: Regioselectivity of ring B formation 
 
Since our intermediate compound 116 is a naphthalene as opposed to a 
naphthoquinone, we envisaged that the regioselectivity of 1,4- versus 1,2- additions 
might not be an issue. Hence we postulated that if we could convert the aldehyde of 
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116 to an oxime and use metal mediated amination methods to allow for the 
formation of a new nitrogen bond to an aromatic ring, this could facilitate the ring 
closure in constructing ring B. Examination of the literature for precedence in such 
protocols, we came across a report by Hartwig on the palladium catalysed amination 
of aromatic C-H bonds by oxime esters.  Hartwig applied this procedure as a route to 
the synthesis of substituted indoles 221  from oxime esters 220
130
 as shown in 
Scheme 56. 
 
Scheme 56: Reagents and conditions; Pd(dba)2, Cs2CO3, toluene, 150 °C, 24 h, 72%. 
 
With this idea in mind, we thought we could build on this method and apply it to the 
synthesis of the quinoline core which would give us the desired 
benzo[b]phenanthridine skeleton. To realise this, we planned converting the aldehyde 
116 to an oxime ester 222 which, upon application of Hartwig’s conditions, would 
furnish the desired benzo[b]phenanthridine skeleton 223, as demonstrated in Scheme 
57. 
 
Scheme 57: Proposed synthetic route for assembly of benzo[b]phenanthridine core 
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4.3 Synthesis of phenanthroviridone using the Hartwig approach. 
Having developed our proposed synthetic pathway to access the targeted 
benzo[b]phenanthridine skeleton, we then embarked on the execution of this 
synthesis by converting the aldehyde 116 to the corresponding oxime ester as the first 
step (Scheme 58). 
 
 
Scheme 58: Reagents and conditions; NH2OH.HCl, NaOAc, MeOH, reflux, 2 h, then TEA, AcCl, 
CH2Cl2, 0 °C to rt, 18 h, 86%.  
 
In order to accomplish the synthesis of the oxime ester 222, benzaldehyde 116 in 
methanol was treated with hydroxylamine hydrochloride and sodium acetate. The 
reaction mixture was heated under reflux for 2 hours and then the solvent was 
removed in vacuo. To the residue in dichloromethane and triethylamine, acetyl 
chloride was then slowly added and the reaction mixture stirred at room temperature. 
Chromatographic purification of the crude product on silica gel furnished the acetyl 
oxime 222 as a yellow solid in 86% yield.  
Examination of the 
1
H NMR spectrum showed the unmistakable disappearance of the 
aldehydic proton and the appearance of two new singlet signals. The new singlet 
signal downfield integrating for one proton at δ 8.03 ppm 
corresponded to the imine proton H-1 and the other 
singlet signal integrating for three protons at δ 2.08 ppm 
was consistent with the acetyl methyl protons H-2. The 
13
C NMR spectrum also showed the disappearance of the 
aldehyde carbonyl carbon signal and the appearance of an 
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ester carbonyl signal at δ 168.6 ppm. Another new signal at δ 19.5 ppm collated well 
with the acetyl methyl carbon of the product. Additionally, in the analysis of HRMS, 
a molecular ion peak was observed at 423.1678 amu, which was in good agreement 
with the expected mass of 423.1676 amu for C24H25NO6. 
With our oxime ester in hand, the next step was to attempt the palladium mediated 
amination to assemble our desired nitrogen containing tetracyclic skeleton 223 of 
phenanthroviridone as illustrated in Scheme 59.  
 
Scheme 59: Reagents and conditions; Pd(dba)2, Cs2CO3, toluene, 150 °C, 24 h, 62%. 
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To this end, acetyl oxime 222 in toluene was treated with 
bis(dibenzylideneacetone)palladium(0) and cesium carbonate. The reaction was 
stirred at 150 °C for 24 hours. Upon purification of the crude 
product by column chromatography on silica gel, we isolated 
the benzonitrile 224 as a yellow solid in 62% yield, instead 
of the desired tetracyclic intermediate 223. 
1
H NMR 
spectroscopy unambiguously confirmed that the benzonitrile 
was formed by the distinctive disappearance of both the 
acetyl methyl proton signals at δ 2.08 ppm as well as the 
imine proton signal at δ 8.03 ppm. While the cleavage of the oxime ester was 
expected in the ring closure reaction, the disappearance of the imine proton was 
uncharacteristic. 
13
C NMR spectroscopy also confirmed the disappearance of the ester 
carbonyl carbon signal and acetyl methyl carbon signal at δ 19.5 ppm and the 
appearance of the typical C≡N signal at δ 118.9 ppm. Furthermore, the presence of 
the nitrile was confirmed by the appearance of the C≡N stretch at 2364.7 cm-1 in the 
FTIR spectrum. Additionally, the HRMS showed a molecular ion peak at 363.1473 
amu (100%), which correlated well with the expected mass of 363.1465 amu for 
C22H21 NO4. 
 
Carefully examination of the oxime ester lead to the rational that the formation of 
benzonitrile 224 resulted from elimination of acetic acid from the oxime ester under 
the reaction conditions. The proposed mechanism is illustrated in Scheme 60. 
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Scheme 60: Mechanism for formation of benzonitrile 
 
With these results, we revisited the model studies done by Hartwig in the synthesis of 
substituted indoles.  We realised that these were conducted on ketones rather than 
aldehydes and hence the imine proton would be replaced with an alkyl substituent, 
which then made it impossible for any elimination reaction to take place. If our imine 
proton was replaced by an alkyl substituent, we believe our key reaction could have 
probably been successful. At this point, it therefore meant that the use of this 
methodology on our scaffold to access the benzo[b]phenanthridine skeleton was not 
viable and hence we needed to look at alternative strategies to construct the desired 
aromatic skeleton. We immediately embarked on the development of an alternative 
strategy. The following section will discuss the alternative synthetic route that we 
developed.  
 
4.4 Development of an alternative synthetic route 
With the failure of our strategy to use a palladium mediated amination method of an 
aromatic C-H bond, we went back to the literature to ascertain if other strategies for 
the construction of N-heterocycles from oximes existed. We came across two reports 
by Rodriguez and Walton where they used oxime esters and ethers respectively to 
assemble N-heterocycles via iminyl radicals.  
 
4.4.1 Rodriguez assembly of N-heterocycles 
Rodriguez and co-workers reported a light-induced iminyl radical cyclisation reaction 
of acyloximes derived from aldehydes to isoquinolines. Building on the principle that 
acyloximes can be used as photo initiators for UV curable coatings, they 
hypothesised that the iminyl radical so formed could cyclise to construct six 
membered heterocyclic compounds.
131
 Iminyl radicals are easily generated owing to 
the ease of the cleavage of the N-O bond upon irradiation. Using light to induce 
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radicalisation, they successfully assembled N-heterocycles using this approach as 
illustrated in Scheme 61. 
 
 
 
Scheme 61: Reagents and conditions; hν, Pyrex, t-butanol, 226-58%; 227-28%. 
 
Utilising this synthetic methodology, they found that exposure of oxime ester 225 in 
tert-butanol to UV light through Pyrex gave the desired cyclised compound 226, as 
well as the benzonitrile 227, in an almost 2:1 ratio. Although a number of solvent 
systems were evaluated for the reaction, tert-butanol gave the best yield of the 
heterocyclic compound 226 (58%) versus the benzonitrile 227 (28%). This is due to 
tert-butanol being effective in breaking intramolecular H-bonding which facilitates 
elimination of acetic acid through a pericyclic type of reaction, leading to the 
formation of the benzonitrile. Although 2-propanol gave the lowest yield of the 
undesired benzonitrile 227 (8%), the yield for the phenanthridine was also very 
modest (25%). Use of non-polar solvents like hexane led to considerably higher 
yields of the benzonitrile 227 as compared to the desired tricyclic compound 226. 
 
4.4.2 Walton’s approach to the synthesis of N-heterocycles 
Apart from UV light induced formation of iminyl radicals, they can also be easily 
generated by thermolysis. Watson and co-workers reported on the microwave assisted 
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synthesis of N-heterocycles from O-phenyl oximes which proceeded via the same 
iminyl radical.
132
 In their account, previously assembled oxime ether 228 was 
subjected to microwave irradiation in the presence of an ionic liquid and  tert-
butylbenzene to furnish the desired phenanthridine product 229  as exhibited in 
Scheme 62. 
 
 
Scheme 62: Reagents and conditions; t-BuPh, EmimPF6, MW 160 °C, 30 min, 78%. 
 
The ionic liquid EmimPF6 was added to compensate for the dielectric loss factors of 
solvents and increase the microwave absorbance level of the medium.
132
 In using this 
protocol, better yields of the phenanthridine products 229 were obtained as compared 
to the UV mediated protocol, and the elimination of the acetic acid was not observed. 
This was an interesting observation from our perspective.  
 
We decided to assess the feasibility of both methodologies for the synthesis of our 
desired benzo[b]phenanthridine skeleton.  
 
4.5 Microwave and UV assisted synthesis of benzo[b]phenanthridine 
As a starting point, we decided to test the microwave assisted method for the 
intramolecular cyclisation of an oxime ether to furnish the desired nitrogen containing 
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tetracyclic derivative. To achieve this, we needed to convert our biarylbenzaldehyde 
116 to an oxime ether derivative 230, as demonstrated in Scheme 63.  
 
Scheme 63: Reagents and conditions; NH2OPh.HCl, pyridine, rt, 18 h, 93%. 
 
O-Phenylhydroxylamine hydrochloride was therefore dissolved in anhydrous 
pyridine and the benzaldehyde 116 was added in one portion. The reaction was stirred 
at room temperature for 18 hours. The crude product was purified by column 
chromatography to furnish the O-phenyl oxime 230 as a yellowish-brown solid in 
93% yield. 
1
H NMR spectroscopy unequivocally proved the formation of the product by the 
unmistakable disappearance of the aldehyde proton signal and the appearance of a 
new singlet signal at δ 8.12 ppm, which correlated with 
the imine proton H-1. Furthermore, the increase in the 
number of aromatic proton signals from six to eleven 
confirmed the addition of the O-phenyl group. More 
evidence was provided by the 
13
C NMR spectrum as it 
showed the disappearance of the aldehyde carbonyl 
signal and the appearance of new aromatic carbon signals. Additionally, analysis of 
the HRMS showed a molecular ion mass peak at 457.1890 amu which was in good 
agreement with the expected mass of 457.1883 amu for C28H27NO5. 
 
Although the oxime ether was synthesised as a mixture of E and Z isomers, no 
attempt was made to separate the two isomers as both of them should form the same 
iminyl radical in the first step of the cyclisation reaction. With our oxime ether in 
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hand, we then embarked on the execution of the key step in our synthesis, which was 
the microwave promoted intramolecular cyclisation via an iminyl radical, as 
illustrated in Scheme 64. 
 
Scheme 64: Reagents and conditions; EmimPF6, t-BuPh, MW 300 W, 160 °C, 20 min, 231 -58% and 
224-11%. 
 
In order to achieve the intramolecular cyclisation, O-phenyl oxime 230 and EmimPF6 
were dissolved in tert-butylbenzene in a microwave reactor tube. The tube was sealed 
and the reaction mixture subjected to microwave irradiation. To our surprise, upon 
purification of the crude product by column chromatography, we isolated the 
benzo[c]phenanthridine 231 as a yellow solid in 58% yield, along with the 
benzonitrile 224 in 11% yield. We initially thought we had formed the 
benzo[b]phenanthridine, albeit with the loss of one methoxy group, but on detailed 
examination of the spectrum, it was evident that we had constructed the 
benzo[c]phenanthridine 231. 
1
H NMR spectroscopy proved that we had formed the 
benzo[c]phenanthridine skeleton. The most deshielded singlet signal integrating for 
one proton at δ 9.15 ppm correlated to H-6 and the doublet of doublet signal at δ 9.13 
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ppm (J = 8.4 and 0.7 Hz) was consistent with H-4. The singlet at δ 8.87 ppm was 
assigned to be due to H-11.  In order to ascertain which methoxy group out of the 
four was no longer present and also to further confirm the 
assignments of the two singlet signals at δ 9.15 and 8.87 
ppm, HSQC and HMBC spectroscopy were used.  Using 
HMBC spectroscopy, both H-2 and H-3 were coupling to 
a methoxy carrying carbon signal at δ 156.8 ppm, which 
was assigned to be C-1. H-9 had strong correlation with 
another methoxy carrying carbon signal at δ 157.8 ppm, 
which was assigned to be C-10. The singlet at δ 8.87 ppm was strongly correlated to 
another methoxy carrying carbon signal at δ 155.4 ppm, which we assigned to be C-
12. The proton H-7 was also observed to have a lower coupling correlation with a 
carbon at δ 149.0 ppm and from the HSQC spectrum, this carbon was carrying the 
most deshielded proton at δ 9.15 ppm and we consequently assigned that carbon to be 
C-6. Additionally, upon analysis of HRMS, a molecular ion peak was observed at 
333.1368 amu which was in good agreement with the expected mass of 333.1361 
amu for phenanthridine 231. 
 
Having obtained this unexpected result of assembling the benzo[c]phenanthridine 
skeleton as opposed to the benzo[b]phenanthridine core under microwave conditions, 
we then decided to attempt the UV mediated synthesis of N-heterocycles from oxime 
esters as shown in Scheme 65. 
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Scheme 65: Reagents and conditions; t-butanol, UV (450 W), 231 - 46% and 224 - 18%. 
 
To accomplish this, previously prepared oxime ester 222 was introduced into a UV 
reactor with tert-butanol and the reaction mixture was subjected to UV irradiation. 
Purification of the crude product by column chromatography, once again furnished 
the same benzo[c]phenanthridine 231 in 46% yield and the benzonitrile 224 in 18% 
yield.  
 
Both the microwave assisted and the UV mediated methods gave us the same 
products, albeit in different ratios. The microwave method gave a better yield of the 
benzo[c]phenanthridine compared to the UV mediated method.  
 
Having obtained these unexpected results, we wanted to find out how the 
benzo[c]phenanthridine skeleton could be formed under the radical mechanism from 
an oxime ester or ether derivative. We hoped that by unravelling a possible 
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mechanism, we could rationalise why we were not forming the 
benzo[b]phenanthridine.  
 
4.6 Mechanism for the assembly of benzo[c]phenanthridine skeleton 
Since the reaction proceeds via an iminyl radical, we postulated that the first step 
involves the homolytic cleavage of the N-O bond in the ester 222 or ether 230 
assisted by either thermolysis or UV irradiation to furnish the same iminyl radical 
232 (Scheme 66).  
 
 Scheme 66: Mechanism for assembly of benzo[c]phenanthridine 
 
The iminyl radical 232 could then cyclise by breaking the aromaticity of ring C to 
furnish the tetracyclic delocalised radical intermediate 233. Homolytic cleavage of 
the ArC-OMe bond allows for the rearomatisation of ring C to furnish the 
benzo[c]phenanthridine 231. We hypothesise that if the benzo[b]phenanthridine 
skeleton was formed, in the final rearomatisation step, it would be energetically 
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unfavorable to cleave an aromatic C6b-H bond homolytically as opposed to an ArC-
O bond cleavage by homolysis to eliminate the methoxy radical in forming a 
benzo[c]phenanthridine skeleton. The presence of the methoxy group on the C-1 of 
the naphthalene ring afforded an easier and more energetically favored pathway to the 
cyclisation. Detailed mechanistic studies however need to be carried out to confirm 
this hypothesis.  
 
4.7 Conclusion  
In summary, we had planned to develop methodology for the synthesis of nitrogen 
containing phenanthroviridone 146 by functionalising a key intermediate which we 
used in the synthesis of tetrangulol 2. Although we did not succeed in the synthesis of 
phenanthroviridone 146, in this PhD we have serendipitously found a UV promoted 
or microwave assisted radical based strategy to assemble and access the biologically 
important benzo[c]phenanthridine alkaloids and other related natural products.  
 
4.8 Future Work 
Having found a method for making the benzo[c]phenanthridine skeleton, it could be 
worthwhile to apply this method to the synthesis of natural products that possess a 
benzo[c]phenanthridine core, for example, fagaronine 151, nitidine 152 and decarine 
153. In this way, the limits and indeed the versatility of this method as a useful 
strategy could be unravelled.  
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Secondly, detailed mechanistic studies to confirm the proposed mechanism need to be 
undertaken. A number of substituents could be varied on both the C-1 and C-3 
positions of the naphthalene ring to decipher the effect of substituents on the 6-endo-
trig cyclisation that furnishes the benzo[b]phenanthridine versus the 6-exo-trig 
cyclisation that gives the benzo[c]phenanthridine core.   
 
4.9 Conception of a new project  
In section 4.2, it was highlighted during the discussion on regioselectivity of ring B 
formation that a 6-endo-trig 1,4- addition type of cyclisation of a phenyl amine onto 
the C-3 position on a naphthoquinone does not occur, and instead a 1,2 addition-type 
6-exo-trig cyclisation onto the C-1 carbon of a quinone is preferred. However, if there 
is a halogen (e.g. bromine) on the C-3 position, then a 1,4- Michael-type 6-endo-trig 
cyclisation furnishes the benzo[b]phenanthridine-7,12-dione skeleton as displayed in 
Scheme 67
133
. 
 
Scheme 67: Cyclisation of bromo quinone 
 
This cyclisation was confirmed by Dr Priyamvada Pradeep, a former PhD student in 
our group at Wits University. In this project, we wanted to build on this strategy to 
synthesise oxygen containing analogues of natural products by cyclising a benzyl 
alcohol 236 onto the bromonaphthalene motif to give the cyclised oxygen containing 
skeleton 237 as exhibited in Scheme 68. 
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Scheme 68: NBS mediated synthesis of Benzo[b]naphthopyranone 
 
Miss Chevonne Reynolds, then an MSc student in our group, pioneered this work. 
When the benzyl alcohol 235 was subjected to the NBS bromination, a 
benzo[b]naphthopyranone derivative 238 was isolated instead of the desired 
naphthylphenyl derivative 236. On examination of the literature, we were pleased to 
notice that there are a number of natural products that contain a 
benzonaphthopyranone core. What was even more interesting was that three 
subclasses of such compounds, namely gilvocarcins, ravidomycins and 
chrysomycins, belong to the angucycline class of natural products.  
Following this discovery, there were a number of questions for which we did not 
have answers. Could this discovery be a general method for the assembly of 
benzonaphthopyranone angucycline antibiotics? What would be the scope of such 
reactions? What could be the limitations of this strategy in the synthesis of 
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benzonaphthopyranone skeletons? These were some of the questions this PhD 
investigation aimed to unravel. 
Building on this previous work, the forthcoming chapter of this PhD thesis (Chapter 
5), will introduce the three sub classes of benzonaphthopyranone angucycline natural 
products and their associated biological activities. Furthermore, some selected 
synthetic strategies to these types of natural products are also highlighted. Following 
this introduction, results on the synthetic studies on the NBS mediated synthesis of 
benzonaphthopyranone skeletons are presented and discussed in Chapter 6. 
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CHAPTER 5: Benzonaphthopyranone Antibiotics: Introduction and Literature 
Review 
 
5.1 Benzonaphthopyranone natural products 
Nature is endowed with biologically active polyketide derived natural products that 
contain a benzonaphthopyranone core. These compounds are reported to exhibit 
antibacterial, antitumour and antiviral activities, among others.
134-135
 Gilvocarcins, 
ravidomycins and chrysomycins are some of the classes of aromatic polyketide 
antibiotics that share a benzonaphthopyranone moiety and are characterised by their 
intense yellow colour.
136
  
Examples of such antibiotics include arnottin I 239, hayumicinone 240, the 
gilvocarcins 241, chrysomycins 242, chartarin 243 and ravidomycin 244 (Figure 15). 
These families share the same biosynthetic origin. 
Chapter 5: Benzonaphthopyranone Antibiotics – An Introduction 
 
 
 
111  
 
 
Figure 15: Examples of benzonaphthopyranone natural products 
 
5.2 Biosynthesis of benzonaphthopyranones 
The aryl-C-glycosidal linked classes of naphthocoumarins are believed to be 
biosynthesised from acetate units via the polyketide pathway.
137
 This pathway is 
depicted in Scheme 69. Although it was initially hypothesised that the C-8 side 
chains found in these compounds resulted from secondary alkylation steps, this was 
disproved by labelling experiments done on ravidomycins and chrysomycins, which 
share the same chromophore.
134, 138
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Scheme 69: Biosynthesis of benzonaphthopyranone natural products 
 
In the proposed pathway, the condensation of one proprionate and 9 malonate units 
gives the decaketide chain 245, which cyclises to afford the tetracyclic intermediate 
246. Oxidative cleavage of 246 furnishes the dicarboxylic acid 247, which, upon 
decarboxylation and lactonization, gives the benzonaphthopyranone core 248. 
Secondary transformations of 248 like methylation, glycosidation, and 
dehydrogenation affords the various classes of the benzonaphthopyranone natural 
products.    
These classes of antibiotic compounds have aroused considerable interest in view of 
the antibiotic and antitumour activity of their members.
139-141
 The next sections 
highlight the biological potencies of these families. 
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5.3 Chrysomycins 
5.3.1 Structure of chrysomycins 
The yellow crystalline naphthocoumarin C-glycosidically linked chrysomycins A 249 
and B 250 (Figure 16) were first isolated from Streptomyces A-419 species by 
Strelitz and co-workers
142
 in 1955, but their structures were only elucidated by Weiss 
and co-workers in 1982.
143
 Vishwakarma also isolated the two chrysomycins from 
Streptomyces sporoverrucosus,
144
 together with a new compound chrysomycin C 
251. 
 
Figure 16: Structures of chrysomycin natural products 
 
5.3.2 Biological activities of chrysomycins 
The therapeutic potential of this class of antibiotics has been evaluated. The first 
isolate 249 was reported to have potent activity against Bacillus cereus with an MIC 
value of 0.01 µg/mL. It was also reported to inhibit the growth of the following fungi: 
Aspergillus niger, Chaetomium globosum, Gliomasti convuluta, Myrotecium 
verrucaria, Penicillium nototum, Phycomyces blakesleeanus and Saccharomyces 
cerevisiae.
142
 Chrysomycins A 249 and B 250 also displayed potent activity against 
lymphocytic leukaemia P388 cells in vivo.
143
 Additionally, the compounds 249-251 
were tested against five cancer cell lines A549, Colo205, PC-3, MIAPaCa-2, and HL-
60. They were all found to be potent, particularly against the human leukaemia HL-60 
cells, with IC50 values of 0.9, 0.95 and 11 µM against this cell line, respectively. 
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Furthermore, evaluation of the mode of action studies show that 250 and 251, at 1 
µM concentration, distorted the morphology of the cell and nucleus with significant 
DNA damage and apoptosis in HL-60 cells.
144
  
 
5.4 Ravidomycins 
5.4.1 Structure of ravidomycins 
Ravidomycin 244 was isolated from Guatemalan soil bacteria Streptomyces 
ravidus.
139
 This compound shares an identical chromophore with chrysomycin A 249 
and differs only in the sugar attached at the C-4 position of their aglycon. 
Ravidomycin contains the amino pyranose sugar 4-O-acetyl-D-ravidosamine while 
chrysomycins contains the branched pyranose sugar D-virenose.
36
  
 
5.4.2 Biological activities of ravidomycins 
Ravidomycin 244 was reported to exhibit marked activity against Gram-positive 
bacteria, and particularly Streptococcus faecalis with an MIC value of ˂ 0.2 µg/mL 
and Mycobacterium fortuitum with MIC value of 0.5 µg/mL.
139
 In another study, 244 
inhibited the growth of Bacillus subtilis at a concentration of 0.5 µg/mL with 100% 
inhibition at 1 µg/mL. It was  further reported that the primary mode of action of 244 
is to limit the synthesis of DNA in Bacillus subtilis.
141
 Rakhit and co-workers also 
reported that the deacetyl analogue of ravidomycin 244 was more active against P388 
leukaemia cells in vivo than 244 itself. Additionally, they postulated through 
structure-activity relationships that the vinyl group plays a role in retaining the 
inherent activity of ravidomycin.
140
 Ravidomycin analogues 252 and 253 (Figure 17) 
were also reported to be cytotoxic against U937 histiocytic lymphoma cells in the low 
nanomolar range. Furthermore, they were postulated to induce caspase-3-like 
apoptosis at concentrations above 200 nM.
145
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Figure 17: Bioactive ravidomycins 
 
5.5 Gilvocarcins 
5.5.1 Structure of gilvocarcins 
Gilvocarcins are another class of angucycline antibiotic natural products and were 
isolated from different Streptomyces sp. Just like the chrysomycins and ravidomycins, 
the members of this class contain a polyketide derived benzo[d]naphtho[1,2-b]pyran-
6-one chromophore, but family members differ by the alkyl substituents at the C-8 
position.
136
 Although compounds in this class have an identical chromophore to 
chrysomycins and ravidomycins, they differ in the type of sugar at the C-4 position. 
Whilst ravidomycins have an amino sugar moiety, gilvocarcins have a fucose moiety, 
as shown in Figure 18.
146
 Gilvocarcin V (GV) 254 is the major metabolite of 
Streptomyces griseoflavus Gö 3592 and other species and is produced with minor 
congeners gilvocarcin M (GM) 255 and gilvocarcin E (GE) 256.
134
 The  names 
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gilvocarcin V, M and E are based on their structure in which vinyl, methyl and ethyl 
groups are borne, respectively.
147
 
 
 
Figure 18: Gilvocarcins Natural products 
 
The three members of this family generally exhibit interesting biological activities as 
will be highlighted in the next section. 
5.5.2 Biological activities of gilvocarcins 
GV 254 was reported to have the most potent antitumour activities against both 
sarcoma180 induced as well as P388 lymphatic tumours in vivo, whilst GM 255 and 
GE 256 had moderate activities. GV 254 was also observed to be less toxic, with 
reported LD50 values of 1,000 mg/kg and 375 mg/kg for a single intraperitoneal and 
intravenous dose administration, respectively. GM 255 displayed an LD50 value of 
450 mg/kg by a single intravenous administration.
148-149
 The mode of action for the 
antitumour activities of these compounds appears to depend on several mechanisms. 
GV 254 has been shown to efficiently intercalate DNA strands, thus allowing UV 
mediated DNA cleavage by [2+2] cycloaddition with a thymine residue. It has also 
been reported that 254 is equally capable of cross linking between DNA and Histone 
H3.
150-152
 Structure-activity relationship studies revealed that the vinyl group is an 
important functionality in the activity of GV 254. The pivotal role of the vinyl group 
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is shown in the findings that GM 255 and GE 256, which both carry aliphatic residues 
instead of the vinyl group, are not cytotoxic.
148, 152
 
Gilvocarcins 254 and 255 also showed exceptional antibacterial activities against a 
number of organisms. GV 254 exhibited potent activities against Streptococcus 
pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus aureus 
(penicillin resistant) and Streptococcus faecalis with MIC values of 0.13, 0.13 0.06, 
0.25 and 0.016 µg/mL, respectively. For the same organisms, MIC values for GM 
255 were 0.25, 0.5, 0.13, 0.5 and 0.13 µg/mL, respectively.
148
 
As a result of their biological activities and interesting structures, a number of 
synthetic strategies have been developed for the total synthesis of these natural 
products or for the assembly of the benzo[d]naphtho[1,2-b]pyran-6-one core. The 
upcoming section will highlight some of the methodologies that have been developed 
for the synthesis of these compounds. 
 
5.1 Synthetic strategies for benzonaphthopyranone type natural products.  
Some of the strategies developed for the assembly of benzonaphthopyranone type 
natural products are highlighted, and these include among others, nucleophilic 
addition, transition metal catalysed as well as pericyclic or cycloaddition ([2+2], 
[4+2] and [2+2+2]) reactions.  
 
5.6.1 Mal’s Hauser-initiated tandem annulation synthesis of chartarin 
The Hauser-initiated tandem annulation was developed by Mai and co-workers to 
synthesise the benzonaphthopyranone core of these natural products. In principle, a 
Hauser Kraus donor is reacted with a Michael acceptor and the resulting intermediate 
undergoes intramolecular cyclisation to afford the target motif. This strategy was 
applied in a model study for the  synthesis of a benzo[d]naphtho[1,2-b]pyran-6-one 
skeleton 257 exhibited in Scheme 70.
136
 The sulfone phthalide 40 was subjected to an 
annulation reaction with a Michael acceptor 258 to afford an aryloxy anion 
intermediate 259 which underwent intramolecular cyclisation through nucleophilic 
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attack of the oxygen anion onto the cyano group to give the intermediate 260.  During 
an acid work-up, the intermediate 260 was hydrolysed to amino compound 261, 
which, upon protonation and elimination of ammonia, afforded the desired 
benzonaphthopyranone scaffold 257. 
 
Scheme 70: Reagents and conditions; t-BuOLi, −60 °C, THF then H+/H2O, 83%. 
 
Having successfully developed the method for the model study, this synthetic strategy 
was extended to the total synthesis of chartarin 262
153
 (Scheme 71).   In this 
synthesis, 5-hydroxy-2-methylbenzoate 263 was subjected to a Wittig reaction-
cyclisation sequence to give the coumarin derivative 264.  Exposure of the coumarin 
to an annulation reaction with a different phthalide, the Kraus cyanophthalide 265 
afforded the methyl chartarin derivative 266. Demethylation of 266 with a mixture of 
HBr and AcOH completed the formal synthesis of chartarin 262.      
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Scheme 71: Reagents and conditions; (i) (CH2)6N4, PPA, 100 °C, 30%; (ii) Ph3P=CHCO2Et, Et2NPh, 
reflux, 95%; (iii) t-BuOLi, −60 °C, THF, 86%; (iv) HBr, AcOH, reflux, 81%. 
 
5.6.2 Snieckus’s total synthesis of defucogilvocarcins 
Snieckus has reported methodology for the total synthesis of defucogilvocarcins V 
267, E 268 and M 269, aglycones of gilvocarcins. The key step in this synthesis was 
the directed remote metallation (DreM)-carbamoyl migration strategy. Transition 
metal catalysed cross coupling reaction strategies like Suzuki and Stille reactions 
were also used in key transformations in the synthesis.
154
 The strategy is summarised 
in Scheme 72. The iodonaphthalene 270 was coupled to a boronic acid 271 using a 
palladium mediated Suzuki-Miyaura reaction to generate the biarylcarbamate 272. 
The carbamate 272 was then subjected to the LDA induced directed remote 
metallation-carbamoyl migration. This was followed by acid hydrolysis and triflate 
protection to afford benzonaphthopyranone intermediate 273. 
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Scheme 72: Reagents and conditions; (i) Pd(PPh3)4, aq. Ba(OH)2, reflux, 99%; (ii) LDA, THF, reflux; 
(iii) AcOH, H2O, reflux, 54% (over two steps); (iv) Tf2O, CH2Cl2, Et3N, −78 °C, 81%; (a) (i) 
C2H3SnBu3, Pd2dba3, NMP, LiCl, (2-furyl)3P, 69%; (ii) BCl3, CH2Cl2, 0 °C, 95%; (b) (i)BEt3, 
PdCl2(dppf), K3PO4, THF, reflux, 75%; (ii) BCl3, CH2Cl2, 0 °C, 86%; (c) (i) MeZnCl, NiCl2(dppf), 
THF, reflux, 59%; (ii) BCl3, CH2Cl2, 0 °C, 83%. 
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The C-8 triflate was introduced because it could easily be functionalised into the 
required vinyl, methyl and ethyl substituents. Palladium mediated modified Stille 
coupling reaction of 273 using tri-n-butyl vinylstannane, followed by BCl3 
demethylation, gave the desired defucogilvocarcin V 267. Similarly, Suzuki coupling 
of 273 using BEt3 followed by a similar demethylation strategy afforded 
defucogilvocarcin E 268, while the Negishi-Quesnelle coupling conditions with 
MeZnCl followed by demethylation furnished defucogilvocarcin M 269. 
The authors extended this directed remote metallation (DreM)-carbamoyl migration 
methodology to the synthesis of arnottin I 239. 
5.6.3 Snieckus’s total synthesis of arnottin I 
Following the strategy developed earlier, synthesis of 239, illustrated in Scheme 73 
commenced with the Suzuki-Miyaura cross coupling reaction between a previously 
assembled iodonaphthalene 274 and the phenyl boronic acid 275 to give the 
biarlycarbamate 276. Selective removal of the isopropyl protecting groups of 276 
followed by the appropriate protection afforded the protected biaryl intermediate 277. 
Subjecting the protected intermediate 277 to the key LDA mediated directed remote 
metallation-carbamoyl migration reaction furnished the benzonaphthopyranone 
derivative 278 in a modest yield. This was then subjected to acid hydrolysis to give 
the catechol derivative 279. The formal synthesis of arnottin I 239 was achieved by 
the methylenation of the catechol moiety of 279.
154
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Scheme 73: Reagents and conditions; (i) Pd(PPh3)4, aq. Ba(OH)2, reflux, 95%; (ii) BCl3, CH2Cl2, 0 °C, 
89%; (iii) NaH, MOMCl, DMF, 95%; (iv) LDA, THF, reflux, 34%; (v) TsOH, MeOH, reflux; (vi) 
CH2Cl2, CsF, DMF, reflux, 39%. 
 
5.6.4 Ishikawa’s synthesis of arnottin I 
The synthesis of arnottin 239 has also been described by Ishikawa. The key strategy 
in this synthesis was the application of the Buchwald protocol on palladium mediated 
α-enolate arylation.155 To accomplish this, the dimethoxy benzoate 280 and a 
tetralone derivative 281 were subjected to a palladium catalysed enolate arylation 
coupling reaction to afford the dihydroarnottin I 282. DDQ mediated aromatisation of 
282 furnished the desired arnottin I 239, completing the formal synthesis (Scheme 
74). 
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Scheme 74: Reagents and conditions; (i) Pd2(dba)3, xantphos, CS2CO3, Na2S2O5, Toluene, 105 °C, 48 
h, 73 %; (ii) DDQ, benzene, 90 °C, 12 h, 94%.  
 
5.6.5 Suzuki’s synthesis of ravidomycin V 
The first total synthesis of ravidomycin 244 has been described by Suzuki. In this 
strategy  exhibited in Scheme 75, the regioselective [4+2] cycloaddition of a benzyne 
and a furan derivative, followed by an intramolecular palladium catalysed cross 
coupling reaction, were key steps in the assembly of the benzonaphthopyranone 
skeleton.
156
 Starting from the glycosyl donor 283 with a t-butyldiphenylsilyl 
substituent for stereocontrol, C-glycosylation with iodinated resorcinol derivative 284 
gave a C-glycoside adduct 285 in a very good yield. A regioselective [4+2] 
cycloaddition of the derivative 285 with 2-methoxyfuran 286 followed by MOM 
protection of the resulting phenol afforded the naphthyl glycoside 287. Introduction 
of an azide at the C-3′ position through an SN2 type reaction followed by LiAlH4 
reduction and N, N-methylation furnished the amino-glycoside derivative 288.  
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Scheme 75: Reagents and conditions; (i) CP2HfCl2, AgClO4, CH2Cl2, −78 °C to −10 °C, 83%; (ii) 
Tf2O,  i-Pr2NEt/CH2Cl2, −78 °C, 20 min, 88% (iii) n-BuLi, THF, −78 °C, 0.5 h; (iv) MOMCl, 
NaH/DMF,  1 h (two steps, 77%); (v) CsF/DMF, 100 °C, 3 h, 90%; (vi) (Imd)2SO2, NaH/DMF, −40 to 
0 °C, 0.5 h, 93%; (vii) NaN3, BnMe3NCl/DMF, 60 °C, 3 h, 57%; (viii) a) LiAlH4/THF, 0 °C, 0.5 h; b) 
aq. HCHO, NaBH3(CN)/CH3CN, 0.5 h, 91% (over two steps); (ix) a) 1 M HCl/acetone, reflux, 3 h; b) 
EDCI, DMAP/CH2Cl2, 2 h, 98% (over two steps); (x) Pd(OAc)2, DPPP, Bu3P, Ag2CO3/DMF, 130 °C, 
15 min, 70%; (xi) a) H2, Pd black, 2 M HCl/MeOH, 0.5 h; b) Ac2O, DMAP/pyridine, 45 min, 76% (two 
steps); (xii) H2, Pd black, 2 M HCl/MeOH, 3 h, 86%; (xiii) TMSBr/CH2Cl2, −78 °C to −15 °C, 45 min, 
59%; (xiv) MsCl /pyr, −20 °C, 0.5 h, quant.; (xv) DBN/CH3CN, 80 °C, 0.5 h, 64%. 
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Subjecting the derivative 288 to deprotection followed by a Mitsunobu reaction with 
the benzoic acid derivative 289 yielded ester-linked intermediate 290. The 
benzonaphthopyranone skeleton 291 was assembled by an intramolecular palladium 
mediated cross coupling reaction of 290.  A series of protections and deprotections 
and finally elimination to construct the vinyl group furnished ravidomycin 244. 
 
5.6.6 Suzuki’s synthesis of defucogilvocarcin M 
Suzuki and co-workers also used a strategy that exploits the use of a [2+2+2] 
cycloaddition reaction to synthesise defucogilvocarcin M 269. The approach relies on 
the ready availability of various benzocyclobutene derivatives via regioselective 
[2+2] cycloaddition of α-alkoxybenzynes and ketenes.157 This was a convergent 
synthesis of two advanced precursors, benzocyclobutenone 292 and styryl bromide 
293 (Scheme 76). Benzocyclobutenone precursor 292 was prepared in four steps 
from the aromatic triflate 294. On the other hand, the styryl bromide precursor 293 
was prepared from a different aromatic triflate 295 in six steps. The convergent 
synthesis of the target compound commenced by coupling the two advanced 
precursors 292 and 293 to yield the cyclobutane intermediate compound 296. 
Thermolysis and acetylation of the intermediate gave the biaryl adduct 297. 
Hydrolysis of the acetal moiety in 297, followed by oxidation of the resulting 
aldehyde and lactonization through methanolysis of the acetate and acidification, 
furnished the benzonaphthopyranone motif 298 in excellent yield. The synthesis was 
completed by debenzylation to give the target compound 269.  
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Scheme 76: Reagents and conditions: (i) t-BuLi, −78 °C, 10 min, quant.; (ii) toluene, 110 °C, 8.5 h; 
(iii) AC2O, DMAP, pyridine, 95% (over two steps); (iv) AcOH aq., 25 °C, 4 h, 98%; (v) NaClO2, 
NaH2PO4, 2-methyl-2-butene, Acetone, H2O, 25 °C, 15 min; (vi) K2CO3, MeOH, reflux, 4 h, then 2 M, 
HCl aq., 0 °C, 98% (two steps); (vii) H2, 10% Pd/C, THF/DMF (12:1, v/v), 25 °C, 1 h, 85%. 
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5.6.7 Findlay’s synthesis of ravidomycin aglycone (defucogilvocarcin V)  
Lastly in this section, synthesis of ravidomycin aglycone by Findlay and his group is 
highlighted. The synthetic approach, shown in Scheme 77, involves the joining of an 
appropriately functionalised Grignard reagent of naphthalene with the protected 
substituted benzoic acid derivatives via nucleophilic substitution reactions.
135
 As 
discussed in the preceding section, this is also a convergent synthesis of the 
naphthalene and benzoic acid precursors. The Grignard naphthalene precursor 115 
was synthesised from 1,5-dihydroxynaphalene 100 in four steps. The oxazoline 
precursor 299 was prepared in four steps from substituted benzaldehyde 300 derived 
from vanillin. Convergent coupling of the advanced precursors using conditions 
described by Meyers et al.
158
 gave the biaryl phenylnaphthalene adduct 301. 
Oxazoline deprotection of 301, followed by demethylation at three sites and 
lactonization, furnished the benzonaphthopyranone skeleton 302 in good yield. 
Methylation of phenolic lactone gave a mixture of adducts 303 and 304. Re-
introduction of the vinyl group on 304 by NBS mediated benzylic bromination, 
followed by elimination and deacetylation, gave the target defucogilvocarcin V 267.  
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Scheme 77: Reagents and conditions; (i) Mg, THF, cat. I2, 15 h, rt, 81%; (ii) AcOH, 47% aq. HCl, 
reflux, 9 h, 77%; (iii) K2CO3, MeI, Acetone, DMSO, rt, 2 h, then Ac2O, pyridine, cat. 
dimethylaminopyridine; (iv) NBS, CCl4, dibenzoyl peroxide, reflux, 3 h, 75%; (v) NaBH4, diphenyl 
diselenide, EtOH, THF, reflux, 2.5 h, then H2O2, 0 °C, 3 h, 40%. 
 
Having highlighted some of the synthetic strategies to access 
benzonaphthopyranones, the next chapter highlights a novel method that was 
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developed in our group for the synthesis of the benzonaphthopyranone core found in 
the gilvocarcins, ravidomycins and chrysomycin natural products. One aspect that 
will be dwelt on in the chapter is the evaluation of the versatility of the method to 
assemble different benzo-fused lactone rings systems.  
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CHAPTER 6: Results and Discussion on synthesis of fused lactone skeletons 
 
6.1 Overview 
As highlighted at the end of Chapter 4, our initial idea through the research of Miss 
Reynolds and Dr Pradeep in our research group was to conduct aromatic nuclear 
bromination of the benzylalcohol 235 using NBS, which serendipitously afforded the 
fused lactone system 238 as shown is Scheme 78, rather than the expected product 
236 
 
Scheme 78: NBS mediated synthesis of benzonaphthopyranone skeleton 
 
This finding was both unexpected and interesting. Although NBS has been used for a 
number of chemical transformations, this transformation was, however, unique. We 
needed to ascertain from the onset of this project whether this kind of reaction was 
reproducible and if so, we needed to determine if this could be a general reaction to 
access the benzonaphthopyranone skeleton which is found in natural products like the 
gilvocarcins, the ravidomycins and chrysomycins. For us to draw any conclusions on 
the generality of this methodology, we needed to understand and evaluate aspects 
such as the reproducibility, scope and conditions of this reaction. Additionally, we 
were also interested in unravelling the mechanism of this key step in the assembly of 
the fused aromatic lactone systems. 
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In the final chapter of this PhD thesis, results on the application of this new NBS 
mediated ring closure reaction for the synthesis of fused lactone systems are 
presented. Future aspects stemming from this work have also been highlighted.  
This work has been peer reviewed and accepted for publication in the journal 
Tetrahedron.
133
 
 
6.2 Reproducing the NBS mediated synthesis of 12-methoxy-6H-
dibenzo[c,h]chromen-6-one 
The starting point for this PhD was to repeat the NBS mediated reaction on the same 
substrate tested initially for the assembly of the benzonaphthopyranone skeleton, to 
ascertain if we could reproduce the results. The general synthetic approach is 
illustrated in Scheme 79. The strategy uses a Suzuki-Miyaura reaction as a key step 
to assemble the biaryl benzaldehyde 309 followed by reduction of the aldehyde to the 
alcohol 235 and finally the NBS mediated ring closure of the biaryl alcohol to furnish 
the desired product 238. 
 
Scheme 79: Synthetic pathway to access benzonaphthopyranone skeleton 
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In order to achieve this, we commenced our synthesis with the assembly of the 
bromonaphthalene 307 as shown in Scheme 80. 
 
Scheme 80: Reagents and conditions; (i) Me2SO4, Na2S2O4, TBAI, aq. KOH, THF, 87%; (ii) NBS, 
CH2Cl2, reflux, 24 h, 81%.  
 
1,4-Naphthoquinone 305 in tetrahydrofuran was treated with sodium dithionite and 
tetrabutylammonium iodide (TBAI) followed by the addition of an aqueous solution 
of potassium hydroxide and dimethyl sulfate and the reaction mixture was stirred at 
room temperature. Chromatographic purification of the crude product on silica gel 
gave the commercially available 1,4-dimethoxynaphthalene 306 as a low melting, 
off-white crystalline solid in 87% yield.  
 
The 
1
H NMR spectrum undoubtedly established that the quinone was reduced by the 
appearance of a signal at δ 3.90 ppm due to the methoxy group protons and since the 
compound is symmetrical, one methoxy signal was observed as expected. 
Additionally, the 
13
C NMR spectrum clearly showed the appearance of the 
characteristic aromatic ArC-O signal at δ 151.7 ppm and the corresponding methoxy 
carbon signal at δ 61.4 ppm. 
  
The obtained naphthalene 306 was smoothly brominated to furnish 2-bromo-1,4-
dimethoxynaphthalene 307. To accomplish this, NBS was added to a solution of the 
naphthalene 306 in dichloromethane and the resulting mixture refluxed for 30 
minutes. The crude product was purified by column chromatography to isolate the 
brominated product 307 as a low melting off-white solid in 81% yield. Analysis of 
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the 
1
H NMR spectrum showed the presence of a singlet signal integrating for one 
proton at δ 6.81 ppm which correlated with H-3. The appearance of two distinct 
signals at δ 3.90 and δ 3.84 ppm due to the methoxy protons implied 
that the original symmetry of the naphthalene was lost due to the 
bromination. Additionally, 
13
C NMR spectroscopy supported the 
formation of the desired naphthalene by the appearance of twelve 
distinct carbon signals from only six carbon signals in the starting 
material. This was further evidence of the assembly of an asymmetrical naphthalene 
due to bromination. 
 
With the bromonaphthalene 307 in hand, the next step was to subject it to an 
appropriate boronic acid under Suzuki-Miyaura reaction conditions and complete the 
synthesis of the benzonaphthopyranone framework as shown in Scheme 81. 
 
Scheme 81: Reagents and conditions; (i) Pd(PPh3)4, aq. Na2CO3 (2 M), DME, reflux, 18 h, 90%; (ii) 
LiAlH4, THF, rt, 2 h, 96%; (iii) NBS, CH2Cl2, air, 8 h, 34%. 
 
Tetrakis(triphenylphosphine)palladium(0) and  2-formylphenylboronic acid 308 were 
added to a deoxygenated solution of  2-bromo-1,4-dimethoxynaphthalene 307 in 
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dimethoxyethane. To this was added a deoxygenated aqueous sodium carbonate 
solution and the reaction mixture was refluxed for 18 hours. Upon chromatographic 
purification of the crude product, the biarylbenzaldehyde 309 was isolated as a yellow 
solid in 90% yield.  The appearance of the aldehydic proton signal at δ 9.90 ppm and 
carbon signal at δ 192.4 ppm in the 1H NMR spectrum and 13C NMR spectrum, 
respectively, unmistakably confirmed the identity of the biaryl compound 309. In 
addition, the presence of nine aromatic protons and nineteen carbon signals suggested 
the two precursors were successfully joined.  The intermediate benzaldehyde 309 was 
smoothly reduced using lithium aluminium hydride to the corresponding 2-
naphthylbenzyl alcohol 235 in an excellent yield of 96%. The successful reduction 
was confirmed through 
1
H NMR spectroscopy by the disappearance of the aldehydic 
proton signal and the subsequent appearance of a broad singlet signal at δ 3.61 ppm 
and the benzylic methylene proton signal at δ 4.40 ppm. 13C NMR spectroscopy also 
established the identity of the reduced product by the disappearance of the aldehyde 
carbonyl signal and the appearance of new signal at δ 64.1 ppm, which was consistent 
with a benzylic carbon signal. 
Satisfied that we had obtained the desired benzyl alcohol 235, the next step was to 
carry out the key NBS mediated ring closing reaction that furnished the lactone. To 
accomplish this, NBS was slowly added to a solution of the benzyl alcohol in 
dichloromethane and the reaction mixture was allowed to stir open to the atmosphere 
at room temperature. To our delight, chromatographic purification of the crude 
product furnished the desired lactone 238 as a light tan solid in a moderate yield of 
34%, together with an unknown compound in 11% yield. The 
1
H NMR spectrum 
unambiguously established that we had formed the lactone by the disappearance of 
the benzylic proton signals between δ 4.44 and 4.37 ppm, as well as the broad singlet 
signal was observed at δ 3.16 ppm. As expected, only one methoxy group proton 
signals at δ 4.12 ppm. The 13C NMR spectrum also proved the formation of the 
dibenzochromenone core by the appearance of a typical lactone carbonyl signal at δ 
161.4 ppm. The spectroscopic data was consistent with what was reported by Miss 
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Reynolds and Dr. Pradeep from our laboratory and was in good agreement with the 
data reported by Jones and Qabaja.
159
 
Pleased that the NBS reaction gave the desired lactone 238, albeit in a modest yield, 
we decided to take a closer look at the identity of the unknown compound. Using 
both 
1
H NMR and 
13
C NMR spectroscopy, the identity of the 
unknown compound was established to be a lactol, 310. The 
aromatic proton signal at δ 7.12 ppm was indicative of H-11 and 
the other singlet at δ 7.08 was consistent with H-6 proton.  
Furthermore, one methoxy group proton signal at δ 4.04 ppm 
and a broad singlet at 1.54 ppm were also observed in the 
1
H 
NMR spectrum. Further evidence was provided by the 
appearance of one methoxy carbon signal at δ 55.8 ppm and a signal at δ 92.8 ppm 
which correlated to C-6. 
Although we were pleased with the results of the NBS mediated ring closure reaction, 
TLC evidence showed the presence of other products that we could not isolate, hence 
we decided to repeat the reaction to see if the results were reproducible. In addition, if 
the reaction was conducted on a large scale, we thought it might be possible to 
characterise other products formed in the reaction. Finally, as previous evidence has 
shown that the reaction needed to be conducted under atmospheric conditions, 
oxygen in the atmosphere could be playing a role in the reaction. Hence, we 
attempted the NBS mediated lactone forming reaction under an oxygen atmosphere. 
 
As illustrated in Scheme 82, when the reaction was repeated under an atmosphere of 
oxygen, we isolated the desired lactone 238 in a yield of 42%, along with the quinone 
311 in 36% yield. Not surprisingly though, we were unable to isolate the lactol 310 
which we attributed to its instability as the hemiacetal should form the lactone 238 
under these conditions. This could have been as a result of the reaction being 
conducted under oxygen. The 
1
H NMR spectrum evidently established the formation 
of the quinone 311 by appearance of the distinct aldehydic proton signal at δ 9.94 
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ppm. Additionally, the distinct aromatic proton singlet signal between δ 6.50 and 6.70 
ppm had disappeared. This suggested that aromatic nuclear bromination had taken 
place at this C'-3 position. Analysis of the 
13
C NMR spectrum confirmed the 
appearance of the aldehyde carbonyl carbon signal at δ 191.3 ppm and two other 
carbonyl signals at δ 180.9 and 177.8 ppm. Furthermore, examination of the HRMS 
showed a molecular ion mass peak at 339.9720 amu, which was in good agreement 
with the expected mass of 339.9726 amu for C17H9O3
79
Br.  
 
Scheme 82: Reagents and conditions; NBS, CH2Cl2, O2, rt, 8 h, 238-42%; 311 -36%. 
 
Satisfied that we had been able to reproduce this novel method for the synthesis of 
the dibenzochromenone motif 238, albeit in mediocre yields, we were interested in 
unravelling the mechanism of the reaction. The upcoming sections will highlight our 
attempts to understand the mechanism of this reaction. 
6.3 Mechanistic studies of the NBS catalysed ring closing reaction 
The isolation of the quinone 311 from the preceding reaction suggested that NBS was 
oxidising both the benzyl alcohol of 235 to the corresponding aldehyde and also the 
naphthalene portion of 235 to the quinone 311. It is not uncommon for NBS to 
oxidise benzylic alcohols to aldehydes and naphthalenes to corresponding 
quinones.
160-163
  
6.3.1 Mechanist route via the benzoyl bromide intermediate  
We therefore needed to determine whether the ring closure reaction proceeded via the 
benzoyl bromide intermediate 312, as indicated in Scheme 83. 
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Scheme 83: Dibenzochromenone motif assembly via benzoyl bromine route 
 
If the assembly of the dibenzochromenone 238 proceeded via this route, oxidation 
and subsequent bromination of the benzyl alcohol would have to give the benzoyl 
bromide 312 as an intermediate, which then would cyclise to furnish the lactone 
derivative 313. O-Demethylation by formation of bromomethane would then afford 
the desired compound 238. If this was the case, we expected that treating our initial 2-
naphthylbenzaldehyde 309 with NBS should furnish the lactone 238.  
In order to verify if this was a possible mechanism for the synthesis of the lactone 
motif 238, we subjected the 2-naphthylbenzaldehyde 309 to our NBS conditions as 
illustrated in Scheme 84.   
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Scheme 84: Reagents and conditions; NBS, CH2Cl2, O2, rt, 8 h, 314-57%; 311 -28%. 
 
When the biarylbenzaldehyde derivative 309 was subjected to the NBS reaction 
conditions, the desired lactone 238 was not obtained. Instead, the bromonaphthalene 
314 and the quinone 311 were isolated in 57% and 28% yields respectively. The 
1
H 
NMR spectrum confirmed the formation of the bromonaphthalene 314 by the 
disappearance of the most shielded proton singlet signal at δ 6.74 ppm at C'-3. This 
suggested that this was the position that was brominated, as it is also the most 
activated for electrophilic aromatic substitution. Further evidence was provided by 
HRMS where a molecular ion peak was observed at 370.0188 amu which correlated 
to the expected mass of 370.0199 amu for C19H15O3
79
Br. These results suggest that 
the ring closing reaction does not proceed via the acid bromide derivative 312. A 
hypothesis that the reaction could proceed via the corresponding benzyl bromide 
intermediate 315 was also disproved by Dr. Pradeep in her PhD work.  
 
 
 
Although these results were disappointing from the point of view of our mechanistic 
study, they provided an unintended break-through in the initial project of assembling 
the oxygen containing analogues of angucycline antibiotics, as highlighted in Scheme 
68 at the end of Chapter 4. 
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During our initial attempt to reproduce the synthesis of the lactone 238, we also 
isolated an unstable lactol 310 which we were unable to isolate again in the 
subsequent reactions we undertook. This led us to question whether this could be an 
important intermediate in the formation of the lactone 238.    
6.3.2 Proposed mechanistic route via a lactol derivative 
Examination of the literature on mechanisms for the oxidation of alcohols by NBS, 
shows that two potential mechanistic pathways have been advanced. In an 
experimental and theoretical study on the oxidation of alcohols to aldehydes and 
ketones with N-bromosuccinimide by Shang and co-workers,
163
 they suggested that 
this oxidation possibly proceeds though either a reactive hypobromite species A or 
through substitution of a benzylic hydrogen by bromine to afford the intermediate B, 
presumably by means of a radical side chain bromination, as shown in Scheme 85. 
 
Scheme 85: Plausible pathways to oxidation of alcohols by NBS 
 
Using the benzyl alcohol as a model, the calculated free energy of the reactions for 
path A and B was found to be 1.18 kcal/mol and -30.8 kcal/mol respectively which 
suggested that path B was the more likely mechanism for the oxidation.  
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If this was a likely pathway for our reaction, we could indeed postulate that the 
unstable lactol 310 was an intermediate in the formation of the lactone 238, as 
suggested in Scheme 86. In this proposed mechanism, the benzyl alcohol 235 is 
initially brominated on the benzylic carbon to give the bromomethanol derivative 316 
which then cyclises to afford the methylated lactol derivative 317. O-Demethylation 
of 317 through formation of bromomethane, gives the lactol intermediate 310, which 
then easily oxidises to furnish the desired lactone 238. This proposed mechanism 
correlated well with the results reported by Shang on the reaction proceeding via path 
A. However, more detailed mechanistic studies need to be undertaken to confirm this 
proposed mechanism. 
 
Scheme 86: Proposed mechanism via a lactol intermediate 
 
Having successfully improved on the methodology and proposed the mechanistic 
route for the NBS mediated synthesis of the benzonaphthopyranone skeleton, we then 
embarked on evaluating the scope and the limitations of this methodology for the 
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synthesis of lactones. We wanted to ascertain whether this could be a general and 
versatile method to access the lactone motif of natural products. 
6.4 Expanding the scope and application of the NBS reaction 
Having established that we could assemble the dibenzochromenone 
(benzonaphthopyranone) skeleton, we expanded the application of this new method to 
the assembly of smaller benzochromenone (dibenzopyranone) ring systems. We also 
wanted to evaluate the isoelectronic effects of the rings on the reaction by increasing 
or decreasing oxygen functionalities in the rings. The following section discusses our 
endeavours to expand the scope of the NBS reaction.  
6.4.1 Synthesis of 2-methoxy-6H-benzo[c]chromen-6-one 322 
We commenced the general application of this methodology to the synthesis of 2-
methoxy-6H-benzo[c]chromen-6-one by attempting the reaction on benzene 
precursors rather than naphthalene-containing substrates. Hence, in the previous 
reaction we started from a naphthoquinone, the starting point in this reaction was 1,4-
dimethoxybenzene. This is illustrated in Scheme 87. 
In this synthesis, the same protocols used in the model studies were adopted without 
significant variations. Commercially available 1,4-dimethoxy benzene 318 was 
subjected to NBS bromination to smoothly give the bromobenzene 
derivative 319 in 93% yield. The 
1
H NMR spectrum established the 
formation of 319 by the appearance of three different aromatic signals, 
although two of them were overlapping. The doublet of doublet signal 
at δ 7.11 ppm J = 7.1, 0.8 Hz, correlated with H-5 and the overlapping 
signal between δ 6.82 - 6.79 ppm integrating for two protons was 
consistent with H-3 and H-6. Satisfied with the bromination reaction, we then 
subjected the bromobenzene derivative 319 to a palladium mediated cross coupling 
reaction with formylphenylboronic acid 308 to furnish the biarylbenzaldehyde 320 as 
an off-white solid in 88% yield (Scheme 87). Analysis of the 
1
H NMR spectrum 
showed the presence of the aldehydic proton signal at δ 9.79 ppm. Additionally, there 
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were seven aromatic protons in total, which proved that the Suzuki-Miyaura coupling 
reaction was successful. From the 
13
C NMR spectrum, the appearance of the aldehyde 
carbonyl signal at δ 192.5 ppm and six other new carbon signals established that we 
had formed the benzaldehyde 320.  
 
Scheme 87: Reagents and conditions; (i) NBS, CH2Cl2, reflux, 36 hr, 93%; (ii) Pd(PPh3)4, aq. Na2CO3 
(2 M), DME, reflux, 18 h, 88%; (iii) LiAlH4, THF, rt, 2 h, 98%; (iv) NBS, CH2Cl2, O2, 8 h, 322-46%; 
323 -36%. 
 
The benzaldehyde derivative 320 was then effortlessly reduced to the benzyl alcohol 
derivative 321 using lithium aluminium hydride in a quantitative yield. The reduction 
was confirmed by 
1
H NMR spectroscopy through the unmistakable disappearance of 
the aldehyde proton signal at δ 9.79 ppm and the subsequent appearance of the broad 
singlet signal at δ 2.50 ppm and typical benzylic methylene signals at δ 4.41 ppm. 
The 
13
C NMR spectrum also correlated with the 
1
H NMR spectroscopy results by the 
disappearance of the aldehyde carbonyl signal δ 192.5 ppm and the subsequent 
appearance of a benzylic carbon signal at δ 63.8 ppm.  
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Satisfied with the reduction reaction and with the alcohol in hand, we then attempted 
the key step by exposing the alcohol 321 to our NBS reaction conditions.  To our 
delight, the reaction furnished the desired benzochromenone 322 as a white solid in 
46% yield along with the benzaldehyde 323 in 36% yield. The 
13
C NMR spectrum 
unequivocally established the identity of the lactone 322 by the appearance of a 
typical lactone carbonyl signal at δ 161.3 ppm and only one methoxy carbon signal at 
δ 55.9 ppm. The 1H NMR spectrum also showed the presence of only one methoxy 
group proton signal at δ 3.91 ppm. Analysis of HRMS showed a molecular ion peak 
at 226.0622 amu (100%) which correlated well with the expected mass of 226.0625 
amu for C14H10O3.  
The formation of the benzaldehyde 323 was also supported by the spectroscopic data. 
The appearance of the aldehyde proton signal at δ 9.78 ppm and two aromatic proton 
singlet signals at δ 7.51 ppm (H-6′) and 7.18 ppm (H-3′) in the 1H NMR spectrum 
signified that the C-5′ position was brominated. The confirmation of the aldehyde was 
also supported by the appearance of a typical aldehyde carbonyl 
signal in the 
13C NMR spectrum at δ 192.1 ppm and the 
subsequent disappearance of the benzylic carbon signal at δ 
4.41 ppm. In the HRMS, a molecular ion peak was observed at 
320.0041 amu, which was in good agreement with the expected 
mass of 320.0043 amu for C15H13O3
79
Br. 
The results of the successful synthesis confirmed that the NBS methodology can be 
applied to the synthesis of the benzochromenone skeleton 322. What was also 
significant in these results was that in conducting the reaction on (2',5'-dimethoxy-
[1,1'-biphenyl]-2-yl)methanol 321 as compared to (2-(1,4-dimethoxynaphthalen-2-
yl)phenyl)methanol 235, there was a slight improvement in the yield of the 
corresponding lactones from 42% to 46%, respectively.  
Pleased with these results, we then decided to attempt the lactone forming reaction on 
a benzene substrate possessing one less methoxy substituent, making it less electron 
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rich. Hence, we wished to establish if the electronic effect of the ring has an impact 
on the assembly of the aromatic lactone. These results are highlighted in the next 
section. 
6.4.2 Synthesis of 6H-benzo[c]chromen-6-one 327 
In order to accomplish this, we decided to use commercially available 2-bromo 
anisole as a starting material in our synthesis. Using this starting material effectively 
reduces the electron density on the substrate in the final lactonisation reaction. The 
synthesis of 6H-benzo[c]chomen-6-one is shown in Scheme 88. 
 
Scheme 88: Reagents and conditions; (i) Pd(PPh3)4, aq. Na2CO3 (2 M), DME, reflux, 18 h, 87%; (ii) 
LiAlH4, THF, rt, 2 h, 98%; (iii) NBS, CH2Cl2, O2, 8 h, 70%; 
 
The bromobenzene 324 was again coupled with formylphenylboronic acid 308 using 
a palladium catalysed Suzuki Miyaura cross coupling reaction to give the 
benzaldehyde 325 as an off-white solid in 87%. As before, the 
1
H NMR spectrum 
confirmed the appearance of the aldehyde proton signal at δ 9.78 ppm. Furthermore, 
eight aromatic proton signals were also observed that suggested that the coupling was 
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successful. The presence of the aldehyde carbonyl signal at δ 192.5 ppm was also 
confirmed by 
13
C NMR spectroscopy. The benzaldehyde 325 was easily reduced 
using lithium aluminium hydride to the corresponding benzyl alcohol 326, which was 
isolated as a clear oil in 92% yield. The identity of the alcohol was confirmed by the 
unmistakable disappearance of the aldehyde proton signal at δ 9.78 ppm in the 1H 
NMR spectrum and the carbonyl signal at δ 192.5 ppm in the 13C NMR spectrum. 
There was also the appearance of a broad singlet signal at δ 2.66 ppm consistent with 
the -OH proton, and a typical benzylic protons signal at δ 4.36 ppm in the 1H NMR 
spectrum. The corresponding benzylic carbon signal was observed in the 
13
C NMR 
spectrum at δ 63.3 ppm.  
Satisfied with our reduction, we then subjected the benzyl alcohol 326 to our key 
NBS mediated ring closure reaction. To our delight, we smoothly isolated the desired 
benzochromenone 327 as a white crystalline solid in a good yield of 70%. The 
assembly of 327 was confirmed by the disappearance of the methoxy proton signal at 
δ 3.63 ppm in the 1H NMR spectrum. The disappearance of the corresponding 
methoxy carbon signal was confirmed by 
13
C NMR spectroscopy. Additionally, a 
typical lactone carbonyl signal was observed at δ 161.1 ppm.  
The results thus far seemed to suggest two important points. Firstly, with the 
synthesis of three different lactone skeletons, the method could be described as a 
general method for the synthesis of benzonaphthopyranone ring systems. The second 
interesting observation was that the reactions appeared to favour less electron rich 
systems owing to the trend in the isolated yields. So far, the isolated yield for 
dibenzochromenone 238 was 42%, 2-methoxybenzochromenone 322 was 46% and 
finally benzochromenone 327 was 70%. This meant that there could be some 
limitations in the scope of the lactone scaffolds that could be synthesised by this new 
methodology. We decided to probe further this limitation by using a more oxygenated 
ring system such as a juglone derivative as a starting precursor. 
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6.4.3 Attempted synthesis of dibenzochromen-6-one 330 
The synthesis commenced from our previously assembled bromonaphthalene 
derivative 115. This precursor was chosen because it is highly oxygenated, and hence, 
an electron rich ring system. This afforded us the opportunity to further explore the 
limits of the NBS reaction. This synthesis is exhibited in Scheme 89.  
 
Scheme 89: Reagents and conditions: (i) Pd(PPh3)4, aq. Na2CO3 (2 M), DME, reflux, 18 h, 81%; (ii) 
LiAlH4, THF, rt, 2 h, 97%; (iii) NBS, CH2Cl2, O2, 8 h. 
The Suzuki-Miyaura cross coupling reaction of the bromonaphthalene derivative 115 
with a boronic acid 308 easily furnished the 2-naphthylbenzaldehyde derivative 328 
as a yellow solid in 81% yield. The 
1
H NMR spectrum undoubtedly proved that the 
coupling reaction was successful by the appearance of the aldehyde proton signal at δ 
9.89 ppm and the corresponding carbonyl signal was observed in the 
13
C NMR 
spectrum at δ 192.3 ppm. Reduction of the benzaldehyde 328 was accomplished by 
reacting with lithium aluminium hydride, affording the benzyl alcohol derivative 329, 
which was obtained as a low melting solid in an excellent yield of 97%. As before, 
the disappearance of the aldehyde proton signal at δ 9.89 ppm and the appearance of a 
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methylene proton signal at δ 4.42 ppm in the 1H NMR spectrum was evidence that 
the benzaldehyde was reduced. Additionally, 
13
C NMR spectroscopy unambiguously 
established the formation of the alcohol by the disappearance of the aldehyde 
carbonyl signal at δ 192.3 ppm and the appearance of a typical benzylic carbon signal 
at δ 64.1 ppm.  
The next step was the key NBS mediated ring closure reaction to furnish the lactone 
330. To accomplish this, the benzyl alcohol 329 was exposed to our NBS reaction 
conditions. Typically, upon addition of NBS, the reaction mixture is colourless and 
slowly turns light yellow after 4-6 hours, eventually turning a dark yellowish-brown 
colour when completed. To our surprise this time, when NBS was introduced, the 
reaction immediately turned brown and within a few minutes turned a deep purple 
colour. Examination of the TLC plate at this point showed a large number of spots. 
This suggested that decomposition of the reaction materials was possibly taking 
place. Our attempts to isolate and characterise any of these spots observed on the 
TLC plate were unsuccessful. This finding suggests that the NBS mediated 
lactonization reaction favours less electron rich ring systems although more detailed  
scientific study needs to be undertaken to confirm this. The overall trend is shown in 
Figure 19. 
 
Figure 19: Yield comparisons in assembly of different ring systems 
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It would appear that this method would be useful in the synthesis of simpler and less 
oxygenated benzochromenone skeletons. We have not yet determined the reasons  
why electron rich systems are less favoured compared to less oxygenated ring 
systems in this NBS-mediated reaction.  
6.5 Conclusion 
Through the work presented in this chapter, we have established that the NBS 
mediated ring closing reaction is indeed a general method for the synthesis of 
benzonaphthopyranone ring systems. We have also established that the method has 
limitations in as far as the assembly of highly oxygenated or electron rich ring 
systems is concerned, and works best in electron deficient ring systems. Although the 
mechanism of the reaction has not been fully elucidated, we believe and have 
postulated that it proceeds via a lactol intermediate. Additionally, we hypothesised 
that the electronics in the rings play a role in the mechanism of the reaction and 
consequently in the formation of the products. 
 
6.6 Future Work 
This work has generated new scientific knowledge on the NBS mediated construction 
of benzonaphthopyranone ring systems, and at the same time, generated some 
unexpected results that could not be fully exploited due to time constraints of the 
PhD. One aspect that still needs to be studied is the mechanism of the reaction, along 
with rationalisation of the isoelectronic effect of the ring systems on the reaction.   
Having established that the NBS reaction is a general method for the assembly of 
benzonaphthopyranone ring systems, it would be imperative to apply this 
methodology to the synthesis of natural products that possess the 
benzonaphthopyranone core like chrysomycins, ravidomycins and gilvocarcins. 
Finally, one interesting aspect is that this reaction as highlighted in Section 6.1 was 
serendipitously discovered in the process of brominating a naphthalene moiety at the 
C-3 position of a biaryl alcohol.  In this study, we again serendipitously discovered 
that we were able to brominate that position of the ring on a 2-naphthylbenzaldehyde 
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scaffold as shown in Scheme 84 in Section 6.3.1.  With the bottleneck removed by 
this discovery, efforts to synthesise oxygen containing natural products such as 
lagumycin B 331 and WS-5995 A 332 could be explored.  
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6.7 Overall conclusions from this PhD work 
 
To sum up the work accomplished in this PhD, we undertook three 
projects, the first two of which were method development projects for the 
synthesis of natural angucycline antibiotics and the third project was 
based on synthetic studies in assembling benzonaphthopyranones using a 
novel reaction we discovered in our group. 
 
In the first project, we have successfully developed a novel convergent 
method for the synthesis of 1,8-dihydroxy-3-methyltetraphene-7,12-dione 
2, a natural angucycline antibiotic commonly known as tetrangulol in 16 
steps and 19.5% overall yield. In this strategy, the palladium catalysed 
Suzuki-Miyaura cross coupling reaction and the platinum or gold 
mediated intramolecular cycloisomerisation of a 2-
naphthylphenylacetylene intermediate 118 were key steps. This method 
could now be extended to the synthesis of other angucycline antibiotic 
natural products.  
 
Following this success, we then wanted to extend this work to the 
synthesis of other nitrogen containing aromatic natural products. More 
specifically, we wanted to develop a method for the synthesis of 
phenanthroviridone 146 from one of the intermediates that we used to 
synthesise tetrangulol. In our strategy, we sought to use microwave 
mediated or UV promoted intramolecular cyclisation of an advanced 
oxime ester or oxime ether precursor to give the nitrogen containing 
aromatic tetracyclic framework of phenanthroviridone. The intramolecular 
cyclisation instead furnished a benzo[c]phenanthridine skeleton. Although 
we did not succeed in the synthesis of phenanthroviridone 146, we 
serendipitously found a UV promoted or microwave assisted radical based 
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strategy to assemble and access the biologically important 
benzo[c]phenanthridine alkaloids and other related natural products 
 
The final project we undertook aimed at establishing the scope of NBS 
mediated cyclisation of 2-naphthylbenzylalcohol to assemble a fused 
chromenone skeletons. From this project, we established that the NBS 
mediated ring closing reaction is indeed a general method for the synthesis 
of benzonaphthopyranone ring systems. We further established that the 
method has limitations in as far as the assembly of highly oxygenated or 
electron rich ring systems is concerned, and works best in electron 
deficient ring systems. 
 
Through this PhD, we believe we have contributed scientific knowledge in 
the area of total synthesis of angucycline antibiotic natural products and 
the assembly of benzonaphthopyranone motifs found in other classes of 
angucyclines. This is evidenced by our recent publication in the journal 
Tetrahedron based on our work on the NBS project. Additionally, a 
manuscript on the first two projects was submitted to European Journal of 
Organic Chemistry and is currently under review. 
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CHAPTER 7: Experimental Procedures 
 
7.1 General Laboratory Procedures  
7.1.1 Laboratory solvents  
Solvents utilized for chromatographic techniques (ethyl acetate and n-hexane) were 
distilled preceding use by means of conventional distillation processes. The solvents 
employed in reactions were first dried over the suitable drying agent, followed by 
distillation under an inert atmosphere (argon or nitrogen gas). Acetonitrile and 
dichloromethane were distilled over calcium hydride, whereas tetrahydrofuran was 
distilled over sodium with benzophenone as an indicator. Toluene was distilled over 
sodium. All the required chemicals or reagents were obtained from FLUKA, SIGMA 
ALDRICH or MERCK and were used without further purification. 
7.1.2 Chromatographic techniques 
Normal chromatography was performed with silica gel 60 (Macherey-Nagel, particle 
size 0.063-0.200 mm) adsorbent, with both isocratic and gradient eluent systems 
being employed. Thin layer chromatography (TLC) of the compounds was executed 
on Macherey-Nagel Alugram Sil G/UV254 plates pre-coated with 0.25 mm silica gel 
60. The TLC plates were viewed under UV light (254 nm and 366 nm). 
 
7.1.3 Spectroscopic Analysis 
7.1.3.1 Nuclear Magnetic Resonance (NMR) 
Nuclear magnetic resonance (NMR) spectra were recorded on either a Bruker 
AVANCE 300 MHz or a Bruker AVANCE III 500 MHz spectrometer. All spectra 
were recorded in chloroform-d. All chemical shift values are reported in parts per 
million referenced against trimethylsilane which is given an assignment of zero parts 
per million. Coupling constants (J-values) are given in Hertz (Hz). 
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7.1.3.2 Infrared spectroscopy 
The infra-red spectra were recorded on a Bruker Tensor 27 standard system 
spectrometer. Measurements were made by loading the sample directly onto a 
diamond cell. The measurements are reported on the wavenumber scale (/cm
-1
). 
7.1.3.3 High Resolution Mass Spectrometry  
High resolution mass spectra were obtained with a Waters-LCT-Premier mass 
spectrometer. The sample was dissolved in methanol to a concentration of 2 ng/μl and 
introduced by direct infusion. The ionization mode was electrospray positive with a 
capillary voltage of 2500 V and a desolvation temperature of 250 °C using nitrogen 
gas at 250 L/hr. The intensity data was recorded on a Bruker APEX II CCD area 
detector diffractometer with graphite monochromated Mo K3 radiation (50 kV, 30 
mA) with temperature of measurement at 173(2) K, using the APEX 2 data collection 
software. The collection method involved 4-scans of width 0.5 and 512×512 bit data 
frames. The data reduction was achieved by means of the program SAINT+ and face 
indexed absorption corrections were made using XPRE. 
 
7.1.4 Melting points determination 
Determination of melting points was done using a Reichert hot-stage microscope, and 
remain uncorrected. All crystalline compounds were recrystallized in the appropriate 
solvents prior to melting point determination.  
7.1.5 Photochemical reactions 
Photochemical reactions were done using a UV 450 W quartz mercury vapor Arc 
Lamp with an arc length of 5 inches, overall length 27 cm, overall diameter 13 
inches, 430 mA operating current and UV output at principal wavelength of 254 nm. 
The lamp was inserted in a quartz immersion well 450 mm length. Reactions were 
undertaken in a 500 mL photochemical reaction vessel at a radiation distance of 1.5 
cm. 
7.1.6 Microwave reactions 
Microwave reactions were carried out in a CEM Discover microwave. 
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7.2 Experimental procedures pertaining to Chapter 2. 
 
7.2.1 Experimental procedures for the synthesis of angucycline analogues 
 
7.2.1.1 Preparation of 2-allyl-3-bromonaphthalene-1,4-dione 96 
In a 1000 mL round-bottom flask, 2-bromo-naphthoquinone 95 (3.15 g, 13.29 mmol, 
1.0 eq.), vinyl acetic acid (1.72 g, 1.70 mL, 19.98 mmol, 1.5 eq.) and silver nitrate 
(1.13 g, 6.65 mmol, 0.5 eq.) was added to dry MeCN (200 mL). The reaction mixture 
was heated to 65 °C and ammonium persulfate (6.07 g, 26.60 mmol, 2.0 eq.) in 
distilled water (150 mL) was added dropwise to the reaction mixture. The reaction 
mixture was maintained at 65 °C with stirring for 18 hrs under argon. Upon 
completion, the reaction mixture was quenched with H2O (100 mL) and extracted into 
EtOAc (4 × 100 mL). The combined organic phase was washed sequentially with 
NaHCO3 (2 × 100 mL) followed by brine (100 mL). The organic extract was dried 
over MgSO4, filtered through Celite and the solvent removed under reduced pressure. 
The crude product was purified by column chromatography on silica gel (20% 
EtOAc/Hexane) to yield 2-allyl-3-bromonaphthalene-1,4-dione 96 as a yellow solid 
(2.61 g, 9.44 mmol, 71%). 
 
 Rf = 0.50 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3114, 3018, 
2911, 1688, 1677, 1591, 1484, 1457, 1126,  1051, 814; 
1
H 
NMR (500 MHz, CDCl3): δ 8.21 – 8.11 (2H, m, ArH), 7.82 
– 7.72 (2H, m, ArH), 5.87 (1H, ddt, J = 16.6, 10.0, 6.6 Hz, H-2′), 5.27 (1H, ddd, J = 
17.1, 2.9, 1.4 Hz, one of H-3′), 5.22 – 5.10 (1H, m, one of H-3′), 3.64 (2H, dt, J = 6.6, 
1.4 Hz, H-1′); 13C NMR (126 MHz, CDCl3) δ 181.30, 177.66, 149.00, 139.40, 
134.17, 133.92, 131.45, 131.40, 131.09, 127.48, 127.13, 118.27, 35.45. 
 
7.2.1.2 Preparation of 2-allyl-3-bromo-1,4-dimethoxynaphthalene 74 
In a 1000 mL round-bottom flask, sodium dithionite (7.85 g, 45.11 mmol, 5.0 eq.) in 
H2O (50 mL) and TBAI (0.33 g, 0.90 mmol, 0.1 eq.) were added to a clear solution of 
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2-allyl-3-bromonaphthalene-1,4-dione 96 (2.50 g, 9.02 mmol, 1.0 eq.) in dry THF 
(100 mL). The reaction was stirred at rt under argon for 30 min and potassium 
hydroxide (5.05 g, 90.2 mmol, 10 eq.) in H2O (150 mL) was then added and the 
reaction was stirred for a further 1 hr. Finally, dimethyl sulfate (11.35 g, 28.50 mL, 
90.2 mmol, 10 eq.) was added and the reaction mixture was stirred for 18 hrs. Upon 
completion, the reaction was quenched with 25% aq. ammonia (100 mL) and the 
organic material was extracted into EtOAc (3 × 100 mL). The organic layer was 
consecutively washed with distilled water (100 mL), 10% aq. HCl (100 mL), brine 
(100 mL) and distilled water (100 mL) and was dried over MgSO4 and filtered 
through Celite. The solvent was removed under reduced pressure and the residue 
purified by column chromatography on silica gel chromatography (5% 
EtOAc/Hexane) to afford 2-allyl-3-bromo-1,4-dimethoxynaphthalene 74 as a yellow 
solid (1.94 g, 6.31 mmol, 70%).  
 
Rf = 0.67 (50% EtOAc/Hexane); IR (ν/cm
–1
): 3067, 2988, 
2812, 1636, 1258, 1058, 913; 817; 
1
H NMR (300 MHz, 
CDCl3): δ 8.13 – 8.02 (2H, m, ArH), 7.57 – 7.47 (2H, m, 
ArH), 6.07 (1H, ddt, J = 16.0, 10.2, 5.8 Hz, H-2′), 5.12 – 
4.98 (2H, m, H-3′), 3.98 (3H, s, OMe), 3.92 (3H, s, OMe), 3.79 (2H, dt, J = 5.8, 1.7 
Hz, H-1′); 13C NMR (75 MHz, CDCl3): δ 160.0, 150.2, 135.7, 128.9, 128.1, 127.9, 
126.6, 126.5, 122.7, 122.6, 116.7, 115.9, 62.7, 61.4, 34.4. 
 
7.2.1.3 General methods for preparation of Suzuki products 
Method 1: Conventional method 
Tetrakis(triphenylphosphine)palladium(0) (10% mol) and  boronic acid 73a or 73b 
(1.5 eq.) were added to a deoxygenated solution of  2-allyl-3-bromo-1,4-
dimethoxynaphthalene (1.0 eq.) in DME (100 mL) under argon atmosphere with 
stirring. To this was added a deoxygenated aq. Na2CO3 solution (2 M, 4.0 eq.). The 
reaction mixture was then heated at reflux for 18 hrs. After this time, the mixture was 
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cooled to rt and reaction quenched with H2O (50 mL). The organic material was 
extracted into EtOAc (3 × 100 mL), followed by a brine wash (100 mL). The 
combined extract was dried over MgSO4, filtered through Celite and the solvent 
removed in vacuo. The crude product was purified by column chromatography on 
silica gel (10-20% EtOAc/hexane) to afford the Suzuki products as yellow or off-
white solids.  
 
Method 2: Microwave assisted method 
To a sealed microwave vessel was added 2-allyl-3-bromo-1,4-dimethoxynaphthalene 
(1.0 eq.), boronic acid 73a or 73b (1.6 eq.), cesium fluoride (2.0 eq.) and 
tetrakis(triphenylphosphine)palladium(0) (10 mol%) in dimethoxyethane (2 
mL/mmol of bromo-compound). The reaction mixture was irradiated with 150 W at 
150 °C for 15 min by microwave reactor. The reaction was allowed to cool, diluted 
with H2O (20 mL) and extracted into EtOAc (2 × 40 mL). The organic layer was 
consecutively washed with distilled water (40 mL) and brine (40 mL) before being 
dried over MgSO4 and filtered through Celite. The solvent was removed in vacuo and 
the residue purified by flash silica gel chromatography (5% EtOAc/Hexane) to afford 
the products as yellow compounds. 
 
7.2.1.4 Preparation of 2-(3-allyl-1,4-dimethoxynaphthalen-2-yl)benzaldehyde 
75a 
Yellow solid (0.77 g, 60%); Rf = 0.45 (20% EtOAc/Hexane); 
IR (ν/cm–1): 3072, 2841, 1676, 1597, 1482, 1201, 1126, 1007, 
923; 
1
H NMR (300 MHz, CDCl3): δ 9.74 (1H, s, ArCHO), 8.18 
– 8.05 (3H, m, ArH), 7.67 (1H, m, ArH), 7.63 – 7.49 (3H, m, 
ArH), 7.38 (1H, ddd, J = 7.6, 1.3, 0.5 Hz, ArH), 5.68 (1H, ddt, J 
= 16.2, 10.1, 6.0 Hz, H-2′), 4.81 (1H, dd, J = 10.1, 1.6 Hz, one 
of H-3′), 4.56 (1H, dd, J =17.1, 1.7 Hz, one of H-3′), 3.97 (3H, s, OMe), 3.46 (3H, s, 
OMe), 3.39 (2H, dt, J = 5.8, 1.7 Hz, H-1′); 13C NMR (126 MHz, CDCl3): δ 192.2, 
150.8, 150.1, 140.2, 136.1, 134.4, 133.2, 131.7, 128.9, 128.2, 127.6, 127.5, 127.1, 
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126.8, 126.3, 122.9, 122.6, 115.9, 62.5, 61.2, 31.8; HRMS (ESI+): Found (M + H)
+
 
333.1496, C22H20O3 (M + H)
+
 requires 333.1491, m/z 333.1496 [(M + H)
+
, 100%], 
301.1233 (35), 289.1239 (50). 
 
7.2.1.5 Preparation of 2-(3-allyl-1,4-dimethoxynaphthalen-2-yl)-5-
methoxybenzaldehyde 75b 
Yellow solid (1.15 g, 65%); Rf = 0.64 (50% 
EtOAc/Hexane); IR (ν/cm–1): 3078, 2840, 1682, 1601, 
1498,  1233, 1102, 1008, 932; 
1
H NMR (300 MHz, 
CDCl3): δ 9.67 (1H, s, ArCHO), 7.62 – 7.49 (3H, m, ArH), 
7.33 – 7.18 (2H, m, ArH), 5.69 (1H, ddt, J = 16.1, 10.1, 6.0 
Hz, H-2′), 4.83 (1H, dd, J = 10.1, 1.5 Hz, one of H-3′), 4.59 
(1H, dd, J = 17.1, 1.6 Hz, one of H-3′), 3.97 (3H, s, OMe), 3.93 (3H, s, OMe), 3.46 
(3H, s, OMe), 3.40 (2H, dt, J = 5.9, 1.5 Hz, H-1′); 13C NMR (75 MHz, CDCl3): δ 
192.1, 159.4, 150.7, 150.5, 136.2, 132.9, 128.9, 128.0, 127.8, 127.6, 126.7, 126.2, 
122.9, 122.5, 121.0, 115.8, 109.6, 62.4, 61.1, 55.6, 31.9; HRMS (ESI+): Found (M + 
H)
+
 363.1588, C23H22O4 (M + H)
+
 requires 363.1574, m/z 363.1588 [(M
 
+ H)
+
, 
100%], 319.1336 (30). 
 
7.2.1.6 General method for preparation of Wittig products 
In a 50 mL two necked round-bottom flask fitted with a rubber septum, n-
butyllithium (1.5 M, 2.5 eq.) was added dropwise at rt to a suspension of 
methyltriphenylphosphonium bromide (2.5 eq.) in dry THF (10 mL). The resulting 
orange solution was stirred for a further 30 min before being cooled to 0 °C using an 
ice-bath. Aldehyde 75a or 75b (1.0 eq.) in dry THF (5 mL) was added dropwise at 0 
°C to the resulting ylide. The reaction was then warmed to rt and stirred at this 
temperature for 18 hrs. Upon completion, the reaction mixture was diluted with 
diethyl ether (50 mL) and washed with H2O (50 mL). The organic extract was dried 
over MgSO4, filtered through Celite and the solvent removed in vacuo. The resulting 
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crude product was purified by column chromatography on silica gel (5% 
EtOAc/Hexane) to afford the products as yellow oils. 
 
7.2.1.7 Preparation of 2-allyl-1,4-dimethoxy-3-(2-vinylphenyl)naphthalene 76a 
 Yellow oil (0.11 g, 81%); Rf = 0.70 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3108, 3072, 
2930, 1588, 1483, 1227, 1124, 1006,  910; 
1
H NMR (300 
MHz, CDCl3): δ 8.16 – 8.11 (2H, m, ArH), 7.72 (1H, dd, 
J = 7.7, 1.2 Hz, ArH), 7.58 – 7.47 (2H , m, ArH), 7.35 
(2H, dtd, J = 20.7, 7.3, 1.2 Hz, ArH), 7.25 – 7.20 (1H, m, 
ArH), 6.41 (1H, dd, J = 17.6, 11.0 Hz, H-1′′), 5.76 – 5.59 
(2H, m, H-2′ and one of H-2′′ overlapping), 5.07 (1H, dd, J = 11.0, 1.1 Hz, one of H-
2′′), 4.80 (1H, dd, J = 17.0, 3.4, 1.6 Hz, one of H-3′), 4.67 (1H, ddd, J = 10.1, 3.2, 1.5 
Hz, one of H-3′), 3.96 (3H, s, OMe), 3.55–3.44 (4H, m, OMe and one of H-1′ 
overlapping), 3.13 (1H, ddt, J = 14.9, 6.2, 1.5 Hz, one of H-1′); 13C NMR (126 MHz, 
CDCl3): δ 150.5, 149.8, 136.5, 136.4, 135.6, 135.1, 131.3, 131.2, 128.6, 128.4, 128.0, 
127.8, 127.2, 126.2, 125.8, 124.6, 122.9, 122.4, 115.2, 114.6, 62.4, 61.3, 31.9; 
HRMS (ESI+): Found (M + H)
+
 331.1698, C23H22O2 (M + H)
+
 requires 331.1674, 
m/z 331.1698 [(M + H)
+
, 95%], 289.1237 (50), 275.1073 (20). 
 
7.2.1.8 Preparation of 2-allyl-1,4-dimethoxy-3-(4-methoxy-2-vinylphenyl) 
naphthalene 76 b 
 
Yellow oil (0.88 g, 94%); Rf = 0.58 (20% EtOAc/Hexane); 
IR (ν/cm–1): 3087, 3012, 2928, 1603, 1490,  1231, 1196, 
1087, 913; 
1
H NMR (300 MHz, CDCl3): δ 8.12 (2H, dd, J 
= 7.2, 2.4 Hz, ArH), 7.57 – 7.47 (2H, m, ArH), 7.24 (2H, 
d, J = 3.4 Hz, ArH), 7.14 (1H, d, J = 8.4 Hz, ArH), 6.90 
(1H, dd, J = 8.4, 2.6 Hz, ArH), 6.37 (1H, dd, J = 17.5, 11.0 Hz, H-1′′), 5.76 – 5.61 
(2H, m, H-2′ and one of H-2′′ overlapping), 5.07 (1H, dd, J = 11.0, 1.0 Hz, one of H-
2′′), 4.81 (1H, dd, J = 10.1, 1.6 Hz, one of H-3′), 4.69 (1H, dd, J = 17.1, 1.7 Hz, one 
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of H-3′), 3.96 (3H, s, OMe), 3.90 (3H, s, OMe), 3.51 (3H, s, OMe), 3.49–3.44 (1H, 
m, one of H-1′), 3.14 (1H, dd, J = 14.9, 6.2, 1.6 Hz, one of H-1′); 13C NMR (75 
MHz, CDCl3): δ 159.2, 150.4, 150.2, 137.5, 136.6, 135.2, 132.3, 130.9, 128.9, 128.5, 
128.3, 128.0, 126.2, 125.8, 122.9, 122.4, 115.2, 114.7, 113.3, 109.5, 62.4, 61.3, 55.3, 
32.0; HRMS (ESI+): Found (M + H)
+
 361.1799, C24H24O3 (M + H)
+
 requires 
361.1773, m/z 361.1799 [(M + H)
+
, 100%], 279.0945 (75). 
 
7.2.1.9 General method for preparation of Isomerisation products 
A 50 mL round-bottom flask, alkene 76a or 76b (1.0 eq.) was dissolved in dry THF 
(10 mL). Potassium tert-butoxide (4.0 eq.) in dry THF (10 mL) was slowly added and 
the resulting reaction mixture was stirred at rt for 4 hrs, under argon. The mixture was 
poured into saturated aq. ammonium chloride (20 mL) and the organic material 
extracted into EtOAc (4 × 50 mL). The organic extract was washed in succession 
with H2O (100 mL) and brine (100 mL), dried over MgSO4 and filtered through 
Celite. The solvent was removed under reduced pressure and the crude product was 
purified by column chromatography on silica gel (10% EtOAc/Hexane) to yield the 
products as clear oils. 
 
 
7.2.1.10 Preparation of (E)-1,4-dimethoxy-2-(prop-1-en-1yl)-3-
(2vinylphenyl)naphthalene 77a 
 
Clear oil (0.16 g, 73%); Rf = 0.72 (20% EtOAc/Hexane); 
IR (ν/cm–1): 3066, 2984, 2813, 1626, 1480, 1269,  1190, 
910; 
1
H NMR (300 MHz, CDCl3): δ 8.17 – 8.18 (2H, m, 
ArH), 7.71 – 7.64 (1H, m, ArH), 7.55 – 7.41 (2H, m, 
ArH), 7.38 – 7.26 (2H, m, ArH), 7.21 (1H, dd, J = 7.3, 1.7 
Hz, ArH), 6.46 (1H, dd, J = 17.5, 11.0 Hz, H-1′′), 6.13 (1H, d, J = 17.1 Hz, H-1′), 
6.07 – 5.93 (1H, m, H-2′), 5.64 (1H, dd, J = 17.5, 0.9 Hz, one of H-2′′), 5.03 (1H, dd, 
J = 11.0, 0.9 Hz, one of H-2′′), 3.83 (3H, s, OMe), 3.45 (3H, s, OMe), 1.65 (3H, dd, J 
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= 6.2, 0.9 Hz, -Me); 
13
C NMR (75 MHz, CDCl3): δ 150.0, 149.6, 136.5, 136.2, 135.3, 
131.8, 131.2, 130.1, 128.9, 127.8, 127.6, 127.3, 126.8, 126.3, 126.0, 124.8), 124.6, 
122.7, 122.6, 114.3, 61.0, 60.6, 19.7; HRMS (ESI+): Found (M + H)
+
 331.1693, 
C23H22O2 (M + H)
+
 requires 331.1674, m/z 331.1679 [(M + H)
+
, 45%], 317.1543 
(85), 315.1390 (80), 289.1237 (50). 
 
7.2.1.11 Preparation of (E)-1,4-dimethoxy-2-(4-methoxy-2vinylphenyl)-3-
(prop-1-en-1-yl)naphthalene 77b 
 
Clear oil (0.75 g, 88%); Rf = 0.63 (20% EtOAc/Hexane); IR (ν/cm
–1
): , 3012, 2931, 
2837, 1602, 1492, 1228, 1181, 1025, 908; 
1
H NMR (300 
MHz, CDCl3): δ 8.19 – 8.06 (2H, m, ArH), 7.55 – 7.45 (2H, 
m, ArH), 7.25 – 7.21 (1H, m, ArH), 7.13 (1H, dd, J = 8.4, 2.9 
Hz, ArH), 6.92 (1H, dd, J =8.4, 2.4 Hz, ArH), 6.46 – 6.37 
(1H, m, H-1′′), 6.12 (1H, dd, J = 15.9, 1.9 Hz, H-2′), 6.08 – 
5.98 (1H, m, H-1′), 5.65 (1H, dd,, J = 17.5, 2.4 Hz, one of H-
2′′), 5.06 (1H, dd, J = 11.0, 1.0 Hz, one of H-2′′), 3.89 (3H, s, OMe), 3.84 (3H, s, 
OMe), 3.47 (3H, s, OMe), 1.69 (3H, dd, J = 4.8, 2.6 Hz, -Me); 
13
C NMR (126 MHz, 
CDCl3): δ 159.0, 150.0, 149.9, 137.7, 135.4, 132.3, 131.8, 129.8, 128.9, 128.8, 127.7, 
127.2, 126.3, 125.9, 124.9, 122.7, 122.6, 114.4, 113.4, 109.5, 61.0, 60.6, 55.2, 19.8; 
HRMS (ESI+): Found (M + H)
+
 361.1804, C24H24O3 (M + H)
+ 
requires 361.1773, 
m/z  361.1804 [(M + H)
+
, 100%], 345.1495 (50), 319.1352 (35), 305.1188 (15). 
 
7.2.1.12 General Method for RCM ring closure 
In a 50 mL round-bottom flask fitted with a condenser was added the di-alkene 77a or 
77b (1.0 eq.) in dry CH2Cl2 (10 mL/mmol of dialkene). To this was added Grubbs II 
catalyst (15 mol%) and the reaction was heated under reflux for 18 hrs under an argon 
atmosphere. Upon completion, the reaction was cooled to rt and the solvent removed 
in vacuo. The crude product was purified by column chromatography on silica gel 
(5% EtOAc/ Hexane) to yield the products as off white solids.  
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7.2.1.13 Preparation of 7,12-dimethoxytetraphene 78a 
 Yellow solid (0.11 g, 92%); Rf = 0.61 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3016, 
2931, 2837, 1593, 1495, 1448, 1252, 1098; 
1
H NMR (500 
MHz, CDCl3): δ 9.67 (1H, d, J = 8.4 Hz, ArH), 8.50 – 8.41 
(1H, m, ArH), 8.37 – 8.31 (1H, m, ArH), 8.14 (1H, d, J = 9.2 
Hz, ArH), 7.84 (1H, d, J = 7.3 Hz, ArH), 7.71 – 7.65 (1H, m, 
ArH), 7.65 – 7.59 (4H, m, ArH), 4.12 (3H, s, OMe), 3.97 (3H, 
s, OMe); 
13
C NMR (125 MHz, CDCl3): δ 151.1, 148.6, 132.7, 130.0, 128.4, 128.2, 
127.6, 127.4, 127.3, 127.0, 126.5, 126.0, 125.9, 124.3, 123.2, 122.3, 121.1, 120.8, 
63.2, 60.9; HRMS (ESI+): Found (M + H)
+ 
289.1010, C20H16O2 (M + H)
+
 requires 
289.1274, m/z 289.1010 [(M + H)
+
, 100%], 273.0919 (90). 
 
7.2.1.14 Preparation of 3,7,12-trimethoxytetraphene 78b 
 Yellow solid (0.38 g, 88%); Rf = 0.61 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3012, 
2933, 2843, 1606, 1494, 1267, 1201, 1109; 
1
H NMR (500 
MHz, CDCl3): δ 9.58 (1H, d, J = 9.2 Hz, ArH), 8.43 (1H, 
dd, J = 7.4, 1.8 Hz, ArH), 8.32 (1H, dd, J = 7.3, 1.8 Hz, 
ArH), 8.13 (1H, d, J = 9.3 Hz, ArH), 7.64 – 7.53 (3H, m, 
ArH), 7.31 – 7.23 (2H, m, ArH), 4.11 (3H, s, OMe), 3.98 
(3H, s, OMe), 3.96 (3H, s, OMe); 
13
C NMR (126 MHz, 
CDCl3): δ 158.3, 150.1, 148.8, 134.4, 129.9, 127.4, 127.4, 125.9, 125.6, 125.4, 123.7, 
123.7, 123.0, 122.3, 121.7, 120.9, 116.0, 110.0, 63.2, 60.7, 55.4; HRMS (ESI+): 
Found (M + H)
+
 319.1259, C21H18O3 (M + H)
+
 requires 319.1379, m/z 319.1259 [(M 
+ H)
+
, 90%], 318.1262 (100), 303.1032 (25). 
 
7.2.1.15 General Method for oxidation of naphthalenes 
In a 50 mL round-bottom flask, the arene 78a or 78b (1.0 eq.) was dissolved in 
acetonitrile (10 mL/mmol of arene). CAN (2.5 eq.) in H2O volume equivalent to 
acetonitrile was added and the reaction was stirred for 30 min. NaHCO3 was added 
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and the organic material extracted in EtOAc (3 × 10 mL). The combined organic 
layer was then dried over anhydrous MgSO4 and the solvent removed in vacuo. The 
crude product was purified by column chromatography on silica gel (20% EtOAc/ 
Hexane) to yield the products as yellow solids. 
 
7.2.1.16 Preparation of tetraphene-7,12-dione 79a 
 Yellow solid (71 mg, 79%); Rf = 0.63 (20% 
EtOAc/Hexane); IR (ν/cm–1): 3011, 2918, 1682, 1675, 
1587, 1507, 1277; 
1
H NMR (500 MHz, CDCl3): δ 9.72 
(1H, d, J = 8.8 Hz, ArH), 8.39 (1H, d, J = 8.5 Hz, ArH), 
8.29 (2H, dd, J = 24.2, 7.3 Hz, ArH), 8.21 (1H, d, J = 8.5 Hz, ArH), 7.92 (1H, d, J = 
8.1 Hz, ArH), 7.78 (3H, tdd, J = 9.4, 5.4, 4.3 Hz, ArH), 7.67 (1H, t, J = 7.3 Hz, ArH); 
13
C NMR (126 MHz, CDCl3): δ 186.2, 184.0, 136.7, 135.3, 135.1, 134.2, 134.1, 
133.5, 132.3, 130.6, 130.0, 129.4, 128.8, 128.7, 127.3, 126.5, 122.5; HRMS (ESI+): 
Found (M + H)
+
 259.0747, C18H10O2 (M + H)
+
 requires 259.0779, m/z 259.0742 [(M 
+ H)
+
, 100%], 234.2048 (25), 224.1323 (10). 
 
 
7.2.1.17 Preparation of 3-methoxytetraphene-7,12-dione 79b 
 
 Yellow solid (0.103 g, 81%); Rf = 0.61 (20% 
EtOAc/Hexane); IR (ν/cm–1): 3010, 2917, 2849, 1689, 
1670, 1610, 1503, 1264, 1201; 
1
H NMR (500 MHz, 
CDCl3): δ 9.61 (1H, d, J = 9.6 Hz, ArH), 8.34 (1H, d, J = 
8.6 Hz, ArH), 8.30 – 8.21 (2H, m, ArH), 8.06 (1H, d, J = 
8.6 Hz, ArH), 7.82 – 7.71 (2H, m, ArH), 7.38 (1H, dd, J = 9.6, 2.8 Hz, ArH), 7.18 
(1H, t, J = 5.0 Hz, ArH), 3.97 (3H, s, OMe); 
13
C NMR (126 MHz, CDCl3): δ 186.4 
183.8, 159.6, 138.9, 135.0, 134.0, 133.8, 133.5, 132.4, 132.1, 130.4, 129.5, 127.2, 
126.4, 125.7, 123.4, 122.4, 106.7, 55.4; HRMS (ESI+): Found (M + H)
+
 289.0805, 
C19H12O3 (M + H)
+
 requires 289.0874, m/z 289.0805 [(M + H)
+
, 100%]. 
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7.2.2 Experimental procedures for the synthesis of tetrangulol 
7.2.2.1 Preparation of (2-bromo-5-methoxy-3-methylphenyl)methanol 108 
 
Method 1: Green Chemistry 
To an ethyl acetate (15 mL) solution of 3,5-dimethylanisole 105 (900 mg, 6.61 mmol, 
1.0 eq.), was added benzoyl peroxide (8 mg; 0.033 mmol, 0.5 mol%) and N-
bromosuccinimide (2.47 g, 13.88 mmol, 2.1 eq.). The reaction mixture was refluxed 
for 60 min under microwave heating (magnetron power of 300 W). The crude product 
was washed with 30 mL each of 10% aq. HCl, saturated aq. NaHCO3, H2O and brine. 
The crude product was used for the next reaction without further purification.  
To a stirred solution of the above residue in dioxane (30.0 mL) and H2O (30.0 mL), 
CaCO3 (1.32 g, 13.22 mmol, 2.0 eq.) was added at rt under argon. The reaction 
mixture was stirred at reflux for 18 hrs and then cooled to rt and extracted with 
EtOAc (3 × 50 mL). The combined organic layer was washed with brine (50 mL), 
dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
column chromatography on silica gel (30% EtOAc/hexane) to afford (2-bromo-5-
methoxy-3-methylphenyl)methanol 108 as an off-white solid (1.10 g, 4.76 mmol, 
72%).  
 
Method 2: Carbon tetrachloride method 
To a stirred solution of 3,5-dimethylanisole 105 (2.07 ml, 14.68 mmol, 1.0 eq.) in 
CCl4 (30.0 mL), NBS (2.62 g, 14.68 mmol, 1.0 eq.) and benzoyl peroxide (356 mg, 
1.47 mmol) were added at rt under argon. The reaction mixture was refluxed for 4 hrs 
and the succinimide was filtered off and the filtrate was successively washed with 
100 mL each of 10% aq. HCl, saturated aq. NaHCO3, H2O and brine. The organic 
layer was dried over MgSO4 and concentrated in vacuo. The residue was used for the 
next reaction without further purification. 
To a stirred solution of the above residue in dioxane (30 mL) and H2O (30 mL), 
CaCO3 (2.94 g, 29.36 mmol, 2.0 eq.) were added at rt under argon. The reaction 
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mixture was stirred at reflux for 12 hrs and then cooled to rt and extracted with 
EtOAc (3 × 100 mL). The combined organic layer was washed with brine (100 mL) 
and dried over MgSO4 and concentrated in vacuo. The crude product was purified by 
chromatography (30% EtOAc/hexane) to afford (2-bromo-5-methoxy-3-
methylphenyl)methanol 108 as an off-white solid (2.37 g, 10.28 mmol, 70%).  
Rf = 0.42 (20% EtOAc/Hexane); 
1
H NMR (500 MHz, CDCl3): δ 
6.86 (1H, d, J = 3.2 Hz, H-6), 6.69 (1H, d, J = 3.1 Hz, H-4), 4.64 
(2H, s, -CH2OH), 3.75 (3H, s, OMe), 2.85 (1H, br-s, OH), 2.34 
(3H, s, ArMe); 
13
C NMR (126 MHz, CDCl3): δ 158.6, 141.0, 
139.2, 115.5, 115.1, 111.3, 65.3, 55.4, 23.4 (Me). 
 
7.2.2.2 Preparation of (3-methoxy-5-methylphenyl)methanol 106 
In an oven-dried 250 mL two-neck round-bottom flask equipped with a magnetic 
stirring bar was placed (2-bromo-5-methoxy-3-methylphenyl)methanol 108 (7.62 g, 
33.0 mmol) in dry THF  (150 mL) under argon atmosphere. The mixture was cooled 
to −78 °C and a 1.3 M solution of n-BuLi in hexanes (38.08 mL, 49.50 mmol) was 
added dropwise. The mixture was stirred at −78 °C for 2 hrs and was then slowly 
warmed to rt. The reaction was quenched with water (50 mL) and then extracted with 
EtOAc (3 × 100 mL). The combined organic extracts were washed with brine, dried 
over MgSO4 and evaporated under reduced pressure. The crude product was purified 
by column chromatography (20-30% EtOAc/hexane) to give 3-methoxy-5-
methylphenyl)methanol 106 as a yellowish oil (4.72 g, 31.02 mmol, 94%).  
Rf = 0.27 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3377, 2979, 1612, 
1443, 1297, 1166, 1042; 
1
H NMR (500 MHz, CDCl3): δ 6.74 
(1H, d, J = 0.7 Hz, ArH), 6.69 (1H, d,  J = 0.8 Hz, ArH), 6.63 
(1H, d, J = 0.7 Hz, ArH), 4.57 (2H, s, -CH2OH), 3.76 (3H, s, 
OMe), 2.31 (3H, s, ArMe), 2.28 (1H, br-s, OH); 
13
C NMR (126 MHz, CDCl3): δ 
159.8, 142.4, 139.7, 120.0, 114.0, 109.3, 65.2, 55.2, 21.5.  
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7.2.2.3 Preparation of (2-iodo-3-methoxy-5-methylphenyl)methanol 109 
In an oven-dried 50 mL three-neck round-bottom flask equipped with a magnetic 
stirring bar was placed (3-methoxy-5-methylphenyl)methanol 106 (500 mg, 3.29 
mmol) in dry Et2O (17 mL) under argon atmosphere. The mixture was cooled to −78 
°C and a 1.2 M solution of n-BuLi in hexanes (6.05 mL, 7.26 mmol) was added 
dropwise. The mixture was the slowly warmed to rt and stirred for 4 hrs. The solution 
was cooled to 0 °C and THF (9 mL) was then added to the solution and the mixture 
further stirred for 1 hr followed by the slow addition of I2 (1.00 g, 3.95 mmol) 
dissolved in THF (4.0 mL). After being stirred at 0
 
°C for 30 min, the reaction 
mixture was poured into aq. Na2S2O3 and extracted with EtOAc (3 × 50 mL). The 
combined organic layer was washed with brine, dried over MgSO4 and evaporated 
under reduced pressure. The crude product was purified by chromatography on silica 
gel (20% EtOAc/hexane) to afford (2-iodo-3-methoxy-5-methylphenyl)methanol 109 
as a white crystalline solid (641 mg, 2.31 mmol, 70%).  
Rf = 0.39 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3193, 2912, 1576, 
1449, 1302, 1171, 1041, 836; H NMR (500 MHz, CDCl3): δ 
6.90 (1H, d, J = 0.6 Hz, ArH), 6.58 (1H, d, J = 0.9 Hz, ArH), 
4.65 (2H, s, -CH2OH), 3.86 (3H, s, OMe), 2.34 (4H, s, ArMe and OH overlapping); 
13
C NMR (126 MHz, CDCl3): δ 157.8 (ArC-O), 144.0, 139.7, 121.8, 111.2, 85.4 
(ArC-I), 69.6 (-CH2OH), 56.5 (-OCH3), 21.4 (Me). 
 
7.2.2.4 Preparation of 2-iodo-3-methoxy-5-methylbenzaldehyde 98 
In an oven-dried 10 mL round bottom flask equipped with a magnetic stirring bar was 
placed 2-iodo-3-methoxy-5-methylphenyl)methanol 109 (360 mg, 1.29 mmol) in dry 
CH2Cl2  (5.0 mL). To this solution, MnO2 (450 mg, 5.2 mmol) was added and the 
reaction was stirred at rt for 24 hrs. The solution was then filtered through a pad of 
Celite and concentrated in vacuo. The crude product was purified by chromatography 
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on silica gel (20 % EtOAc/hexane) to give 2-iodo-3-methoxy-5-methylbenzaldehyde 
98 as an off-white solid (345 mg, 1.25 mmol, 97%). 
 Rf = 0.59 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3174, 
2912, 1703, 1576, 1457, 1309, 1116, 1041, 838; 
1
H 
NMR (500 MHz, CDCl3): δ 10.16 (1H, s, H-1), 7.31 
(1H, s, H-2), 6.88 (1H, s, H-4), 3.93 (3H, s, OMe), 2.39 
(3H, s, H-3);  
13
C NMR (126 MHz, CDCl3): δ 196.6, 
158.2, 140.0, 136.2, 122.9, 117.2, 90.1, 56.8, 21.1.  
 
7.2.2.5 Preparation of 1,5-diacetoxynaphthalene 101 
In a 250 mL round-bottom flask equipped with a magnetic stirring bar was placed 
1,5-dihydroxynaphthalene 100 (10.01 g, 62.5 mmol) followed by pyridine (50.4 mL, 
0.625 mol) and acetic anhydride (53.2 mL, 0.563 mol). The mixture was stirred at rt 
for 18 hrs followed by the careful addition of H2O to quench the reaction, causing the 
product to precipitate. The precipitate was filtered and washed with H2O (5 × 100 
mL) to afford the acetylated product 101 as a light brown solid (14.85 g, 60.6 mmol, 
97 %).  
Rf = 0.21 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3012, 2813, 1751, 
1613, 1412, 1370, 1182, 1157, 1012, 950; 
1
H NMR (300 MHz, 
CDCl3): δ 7.78 (2H, d, J = 8.6 Hz, H-4), 7.50 (2H, t, J = 8.7 Hz, H-
3), 7.29 (2H, dd, J = 7.4, 0.6 Hz, H-2), 2.45 (6H, s, -CO2Me); 
13
C 
NMR (75 MHz, CDCl3): δ 169.3 (ArC-O), 146.8, 128.2, 126.0, 119.3, 118.8, 21.0. 
7.2.2.6 Preparation of 5-acetoxy-2-bromo-1,4-naphthoquinone 32 
In a 1000 mL round bottom flask equipped with a magnetic stirring bar and fitted 
with a dropping funnel, N-bromosuccinimide (NBS) (14.63 g, 82.01 mmol) was 
dissolved in AcOH (400 mL) and H2O (200 mL) and the reaction heated to 65 °C. 
The dropping funnel was charged with 1,5-diacetoxynaphthalene 101 (5.01g, 20.50 
mmol) in warm AcOH (200 mL) and this solution was added dropwise to the NBS 
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solution. After complete addition, the reaction was maintained at 65 °C for a further 1 
hr. the cooled reaction mixture was then extracted with CH3Cl (3 × 100 mL). The 
combined organic extract was sequentially washed with H2O (4 × 200 mL) and brine 
(200 mL), dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by column chromatography on silica gel (20 % EtOAc/hexane) to afford 5-
acetoxy-2-bromo-1,4-naphthoquinone 32 as a yellow solid (5.50g, 18.7 mmol, 91%). 
 
Rf = 0.40 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3124, 
2967, 1781, 1684, 1683,  1602, 1368, 1326, 1190; 
1
H 
NMR (300 MHz, CDCl3): δ 8.14 (1H, dd, J = 7.8, 1.3 
Hz, H-8), 7.77 (1H, t, J = 7.9, Hz, H-7), 7.42 (1H, dd, J 
= 8.1, 1.3 Hz, H-6), 7.39 (1H, s, H-3), 2.44 (3H, s, -
CO2Me); 
13
C NMR (75 MHz, CDCl3): δ 180.9, 177.4, 
169.2, 149.9, 141.4, 138.5, 134.9, 132.6, 130.3, 126.3, 
21.0. 
7.2.2.7 Preparation of 2-bromo-5-hydroxy-1,4-naphthoquinone 102 
3 N H2SO4 (90 mL) was added to the suspension of 5-acetoxy-2-bromo-1,4-
naphthoquinone 32 (8.20 g, 27.82 mmol) in EtOH (300 mL). the suspension was 
heated gently under reflux for 30 min. The solution was concentrated in vacuo to 
remove EtOH and the residue extracted with CHCl3 (3 × 150 mL). The combined 
extracts were washed with H2O (4 × 200 mL) and brine (200 mL), dried over MgSO4 
and concentrated in vacuo. The crude product was purified by column 
chromatography on silica gel (15% EtOAc/hexane) to give 2-bromo-5-hydroxy-1,4-
naphthoquinone 102 as a brown-orange solid (5.70 g, 22.5 mmol, 81%).  
 
Rf = 0.68 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3326, 
3190, 1681, 1674, 1596, 1460, 1310, 1097, 815; 
1
H 
NMR (300 MHz, CDCl3): δ 11.77 (1H, s, ArOH), 7.73 
(1H, dd, J = 7.5, 1.2 Hz, H-8), 7.63 (1H, t, J = 8.4, 1.1 
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Hz, H-7), 7.49 (1H, s, H-3), 7.31 (1H, dd, J = 8.3, 1.3 
Hz, H-6); 
13
C NMR (75 MHz, CDCl3): δ 187.5, 177.2, 
161.7, 140.9, 140.3, 136.5, 130.7, 125.1, 121.0, 114.7.  
 
7.2.2.8 Preparation of 2-bromo-5-methoxy-1,4-naphthoquinone 99 
In a 100 mL round bottom flask equipped with a magnetic stirring bar was placed 2-
bromo-5-hydroxy-1,4-naphthoquinone 102 (4.70 g, 18.60 mmol) dissolved in CH2Cl2 
(60 mL) followed by Ag2O (10.80 g, 46.63 mmol). To this suspension, MeI (7.92 g, 
3.6 mL, 55.81 mmol) was added and the reaction mixture was stirred at rt for 24 hrs 
under argon. The suspension was filtered through a pad of Celite and the solvent 
removed in vacuo. The crude product was purified by column chromatography on 
silica gel (30% EtOAc/hexane) to give 2-bromo-5-methoxy-1,4-naphthoquinone 99 
as a yellow solid (5.90 g, 17.9 mmol, 96 %).  
Rf = 0.16 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3013, 
2915, 1680, 1672, 1595, 1475, 1457, 1298, 1047, 814; 
1
H NMR (300 MHz, CDCl3): δ 7.81 (1H, dd, J = 7.7, 
1.2 Hz, H-8), 7.69 (1H, t, J = 8.4 Hz, H-7), 7.39 (1H, s, 
H-3), 7.35 (1H, dd, J = 8.5, 1.2 Hz, H-6), 4.02 (3H, s, 
OMe); 
13
C NMR (75 MHz, CDCl3): δ 181.4, 178.2, 
160.0, 142.3, 136.8, 135.0, 133.0, 120.6, 119.3, 118.5, 
56.6. 
 
7.2.2.9 Preparation of 2-bromo-1,4,5-trimethoxynaphthalene 115 
To a clear solution of 2-bromo-5-methoxy-1,4-naphthoquinone 99 (6.10 g, 22.85 
mmol) in THF (380 mL) was added Na2S2O4 (19.9 g, 114.30 mmol) in H2O (100 mL) 
and TBAI (0.84 g, 2.28 mmol). The reaction was stirred at rt under argon for 30 min 
followed by the addition of KOH (12.8 g, 0.23 mol) in H2O (300 mL). The reaction 
was stirred for 1 hr and Me2SO4 (28.8 g, 21.6 mL, 0.23 mol) was added. The reaction 
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mixture was then stirred for 18 hrs before being quenched with 25% NH4OH (150 
mL) and the organic material extracted into EtOAc (3 × 200 mL). The combined 
organic extracts were washed sequentially with distilled water (200 mL), 10% aq. 
HCl (200 mL) and brine (200 mL). The organic extract was dried over MgSO4, 
filtered through Celite and concentrated under reduced pressure. The crude product 
was purified by column chromatography on silica gel (10% EtOAc/hexane) to give 2-
bromo-1,4,5-trimethoxynaphthalene 115 as a yellowish-brown solid (5.43 g, 18.1 
mmol, 79%). 
 Rf = 0.57 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3094, 2921, 
2910, 1605, 1465, 1385, 1270, 1156, 1092, 1054, 815; 
1
H 
NMR (500 MHz, CDCl3): δ 7.68 (1H, d, J = 8.4 Hz, H-8), 7.44 
(1H, t, J = 8.0 Hz, H-7), 6.90 (1H, s, H-3), 6.88 (1H, dd, J = 
7.8, 0.5 Hz, H-6), 3.95 (3H, s, OMe), 3.93 (3H, s, OMe), 3.92 (3H, s, OMe); 
13
C 
NMR (126 MHz, CDCl3): δ 157.5, 153.9, 146.7, 131.7, 127.5, 117.6 114.6, 112,6, 
109.8, 106.9, 61.1, 56.8, 56.4.  
 
7.2.2.10 Preparation of 3-allyl-2-bromo-5-methoxy-1,4-naphthoquinone 103 
To a mixture of 2-bromo-5-methoxy-1,4-naphthoquinone 99 (2.20 g, 8.24 mmol) and 
silver nitrate (0.71 g, 4.18 mmol) in dry MeCN (140 mL) was added vinyl acetic acid 
(1.42 g, 1.40 mL, 16.48 mmol). The reaction mixture was heated to 65 °C and 
(NH4)2S2O8 (3. 76 g, 16.48 mmol) in distilled water (120 mL) was added dropwise to 
the reaction mixture over 30 min. After stirring for 16 h at 65 °C under argon, the 
cooled reaction mixture was extracted with EtOAc (3 × 100 mL), washed with 
NaHCO3 (2 × 100 mL) followed by brine (100 mL) and dried over MgSO4. After 
filtering through Celite, the solvent was removed in vacuo and the crude product was 
purified by column chromatography on silica gel (20-30% EtOAc/hexane) to yield 3-
allyl-2-bromo-5-methoxy-1,4-naphthoquinone 103 as a yellow solid (1.82 g, 5.93 
mmol, 72%). 
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 Rf = 0.28 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3109, 
3008, 2917, 1684, 1675, 1591, 1496, 1126, 1108, 1051, 
817; 
1
H NMR (300 MHz, CDCl3): δ 7.80 (IH, dd, J = 
7.7, 1.1 Hz, H-8), 7.66 (1H, t, J = 8.4 Hz, H-7), 7.32 
(1H, dd, J = 8.5, 0.9 Hz, H-6), 5.94 – 5.77 (1H, m, H-2′), 5.27 (1H, dd, J = 17.1, 1.5 
Hz, H-3′), 5.12 (1H, dd, J = 10.0, 1.4 Hz, H-3′), 4.01 (3H, s, OMe), 3.60 (2H, d, J = 
6.6 Hz, H-1′); 13C NMR (75 MHz, CDCl3): δ 180.2, 178.1, 160.1, 150.6, 136.6, 
134.9, 133.3, 131.7, 120.3, 119.2, 118.2, 118.2, 56.6, 35.7. 
 
 
7.2.2.11 Preparation of 3-allyl-2-bromo-1,4,5-trimethoxynaphthalene 104 
To a clear solution of 3-allyl-2-bromo-5-methoxy-1,4-naphthoquinone 103 (1.40 g, 
4.56 mmol) in THF (80 mL) was added Na2S2O4 (3.97 g, 22.80 mmol) in H2O (25 
mL) and TBAI (0.17 g, 0.46 mmol). The reaction was stirred at rt under argon for 30 
min followed by the addition of KOH (2.56 g, 45.60 mol) in H2O (140 mL). The 
reaction was stirred for 1 hr and Me2SO4 (5.75 g, 4.32 mL, 45.6 mol) was added. The 
reaction mixture was then stirred for 18 hrs before being quenched with 25% NH4OH 
(100 mL) and the organic material extracted into EtOAc (3 × 100 mL). The combined 
organic extracts were washed sequentially with distilled water (100 mL), 10% aq. 
HCl (100 mL) and brine (100 mL). The organic extract was dried over MgSO4, 
filtered through Celite and concentrated under reduced pressure. The crude product 
was purified by column chromatography on silica gel (10% EtOAc/hexane) to give 3-
allyl-2-bromo-1,4,5-trimethoxynaphthalene 104 as a yellowish-brown solid (1.12 g, 
3.42 mmol, 75%).  
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Rf = 0.58 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3086, 2934, 2810, 1601, 1465, 1281, 
1162, 1083, 812; 
1
H NMR (500 MHz, CDCl3): δ 7.71 (1H, d, 
J = 8.4 Hz, H-8), 7.41 (1H, t, J = 8.1 Hz, H-7), 6.90 (1H, d, J 
= 7.7 Hz, H-6), 6.16 – 5.93 (1H, m, H-2′), 5.20 – 4.83 (2H, 
m, H-3′), 4.00 (3H, s, OMe), 3.94 (3H, s, OMe), 3.80 (5H, m, 
OMe and H-1′ overlapping); 13C NMR (75 MHz, CDCl3): δ 156.1, 151.2, 149.7, 
136.1, 130.4, 129.7, 126.7, 120.0, 117.5, 115.7, 115.0, 106.6, 62.9, 61.1, 56.2, 34.4. 
 
 
7.2.2.12 Preparation 3-allyl-1,4,5-trimethoxynaphthalen-2-yl-2-boronic acid 
97 
n-BuLi (1.2 M, 3.02 mL, 3.62 mmol, 2.0 eq.) was added dropwise to a solution of 3-
allyl-2-bromo-1,4,5-trimethoxynaphthalene 104 (610 mg, 1.81 mmol, 1.0 eq.) in THF 
(15 mL) at −78 °C. The reaction mixture was stirred for 30 min at −78 °C, then 
B(OiPr)3 (1.67 mL, 7.24 mmol, 4.0 eq.) was added. The resulting mixture was stirred 
at −78 °C for a further 30 min and then allowed to warm to rt. The reaction mixture 
was acidified with 10% aq. HCl solution and extracted with Et2O (3 × 30 mL). The 
organic layer was then dried with MgSO4 and concentrated under reduced pressure to 
afford 3-allyl-1,4,5-trimethoxynaphthalen-2-yl-2-boronic acid 97 as an off-white 
crystalline material (510 mg, 1.70 mmol, 94%), which was used without further 
purification or characterization. 
 
7.2.2.13 Preparation of 2-(2-allyl-1,4,8-trimethoxynaphthalen-3-yl)-3-
methoxy-5-methylbenzaldehyde 110 
A deoxygenated solution of 3-allyl-1,4,5-trimethoxynaphthalen-2-yl-2-boronic acid 
97 (310 mg, 1.03 mmol, 1.5 eq.) and 2-iodo-3-methoxy-5-methylbenzaldehyde 98 
(185 mg, 0.67 mmol, 1.0 eq.)  in DME (10 mL) was added to Pd(PPh3)4 (77 mg, 
0.067 mmol, 0.1 eq.) under argon atmosphere with stirring. To this was added a 
deoxygenated aq. Na2CO3 (2 M, 1.34 mL, 2.68 mmol, 4.0 eq.). The mixture was then 
heated at reflux for 18 hrs. After this time, the mixture was cooled to rt and the 
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reaction quenched with H2O (10 mL). The organic material was extracted into EtOAc 
(3 × 30 mL), the combined extract dried with MgSO4, and the solvent removed in 
vacuo. The crude product was purified by column chromatography on silica gel (10-
20% EtOAc/hexane) to afford 2-(2-allyl-1,4,8-trimethoxynaphthalen-3-yl)-3-
methoxy-5-methylbenzaldehyde 110 as an off-white solid (33 mg, 0.08 mmol, 12%). 
 
 Rf = 0.32 (20% EtOAc/Hexane); Mp. 54-56 CHCl3; IR 
(ν/cm-1): 3018, 2944, 2835, 1691,  1604, 1567, 1446, 1232, 
1187, 1055; 
1
H NMR (300 MHz, CDCl3): δ 9.55 (1H, s, 
ArCO), 7.71 (1H, dd, J = 8.4, 1.0 Hz, H-8′), 7.48 (1H, d, J = 
0.8 Hz, H-6), 7.41 (1H, t, J = 8.4, H-7′), 7.04 (1H, d, J = 0.9 
Hz, H-4), 6.93 (1H, dd, J = 7.8, 1.0 Hz, H-6′), 5.65 (1H, m, 
H-2′′), 4.72 (1H, dd, J = 10.1, 1.6 Hz, H-3′′), 4.50 (1H, dd, J = 17.1, 1.8 Hz, H-3′′), 
4.04 (3H, s, OMe), 3.86 (5H, m, OMe and H-1′′), 3.74 (3H, s, OMe), 3.45 (3H, s, 
OMe), 2.49 (3H, s, ArMe); 
13
C NMR (75 MHz, CDCl3): δ 192.7, 157.0, 156.1, 
150.6, 150.1, 139.3, 136.6, 135.0, 130.1, 129.7, 126.7, 126.0, 125.0, 121.0, 119.2, 
116.7, 115.3, 115.1, 106.6, 62.7, 60.7, 56.2, 55.6, 32.1, 21.7; HRMS (ESI+):  Found 
(M + Na)
+
 429.1657 and (M + H)
+
 407.1838, C25H26O5 (M + Na)
+
 requires 429.1673 
and (M + H)
+ 
requires 407.1854, m/z 429.1657 ((M + Na)
+
, 100%), 407.1838 [(M + 
H)
+
, 60%]. 
 
7.2.2.14 Preparation of (1,4,5-trimethoxynaphthalen-2-yl)boronic acid 114 
n-BuLi (1.5 M, 8.53 mL, 12.80 mmol, 2.0 eq.) was added dropwise to a solution of 2-
bromo-1,4,5-trimethoxynaphthalene 115 (1.90 g, 6.40 mmol, 1.0 eq.) in THF (50 mL) 
at −78 °C. The reaction mixture was stirred for 30 min at −78 °C, then B(OiPr)3 (3.61 
g, 4.43 mL, 19.20 mmol, 4.0 eq.) was added. The resulting mixture was stirred at −78 
°C for a further 30 min and then allowed to warm to rt. The reaction mixture was 
acidified with 10% aq. HCl solution and extracted with Et2O (3 × 50 mL). The 
organic layer was then dried with MgSO4 and concentrated under reduced pressure to 
afford (1,4,5-trimethoxynaphthalen-2-yl)boronic 114 acid as an off-white crystalline 
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solid (1.61 g, 6.14 mmol, 96%), which was used without further purification or 
characterization. 
 
7.2.2.15 Preparation of 3-methoxy-5-methyl-2-(1,4,5-trimethoxynaphthalen-2-
yl)benzaldehyde 116 
A deoxygenated solution of (1,4,5-trimethoxynaphthalen-2-yl)boronic acid 114 (2.50 
g, 9.51 mmol, 1.5 eq.) and 2-iodo-3-methoxy-5-methylbenzaldehyde 98 (1.75 g, 6.34 
mmol, 1.0 eq.)  in DME (80 mL) was added to Pd(PPh3)4 (10.73 g, 0.63 mmol, 10 
mol %) under argon atmosphere with stirring. To this was added a deoxygenated aq. 
Na2CO3 (2 M, 2.69 g, 12.68 mL, 25.36 mmol, 4.0 eq.) solution. The mixture was then 
heated at reflux for 18 hrs. After this time, the mixture was cooled to rt and the 
reaction quenched with H2O (100 mL). The organic material was extracted into 
EtOAc (3 × 100 mL), the combined extract dried with MgSO4, and the solvent 
removed in vacuo. The crude product was purified by column chromatography on 
silica gel (10-20% EtOAc/hexane) to afford 3-methoxy-5-methyl-2-(1,4,5-
trimethoxynaphthalen-2-yl)benzaldehyde 116 as an off-white solid (1.70 g, 5.07 
mmol, 80%).   
 
Rf = 0.24 (20% EtOAc/Hexane); Mp. 160-162 CH2Cl2; IR 
(ν/cm-1): 3002, 2939, 1686,  1598, 1287, 1118, 1003, 849; 
1
H NMR (300 MHz, CDCl3): δ 9.70 (1H, s, ArCHO), 7.75 
(1H, dd, J = 8.4, 1.0 Hz, H-8′), 7.50 (1H, d, J = 0.7 Hz, H-6), 
7.44 (1H, t, J = 7.9 Hz, H-7′), 7.08 (1H, d, J = 0.8 Hz, H-4), 
6.93 (1H, dd, J = 7.8, 0.7 Hz, H-6′), 6.69 (1H, s, H-3′), 4.00 (3H, s, 5′-OMe), 3.92 
(3H, s, 4′-OMe), 3.80 (3H, s, 3-OMe), 3.45 (3H, s, 1′-OMe), 2.49 (3H, s, ArMe); 13C 
NMR (126 MHz, CDCl3): δ 192.8 (ArCO), 157.4 (C-5′), 157.2 (C-3), 152.8 (C-4′), 
147.8 (C-1′), 139.3 (C-5), 134.7 (C-1), 131.2 (C-8b), 128.1 (C-2′), 126.9 (C-7′), 122.2 
(C-2), 119.3 (C-6), 117.2 (C-4), 115.2 (C-8′), 109.7 (C-3′), 107.2 (C-6′), 60.8 (C1′-
OMe), 56.9 (C4′-OMe), 56.6 (C5′-OMe), 56.0 (C3-OMe), 21.7 (ArMe); HRMS 
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(ESI+):  Found (M + H)
+
 367.1531, C22H23O5 (M + H)
+
 requires 367.1540, m/z 
367.1531 [(M + H)
+
, 100%]. 
 
7.2.2.16 Preparation of 2-(2-(2,2-dibromovinyl)-6-methoxy-4-methylphenyl)-
1,4,5-trimethoxynaphthalene 117 
In an oven-dried 25 mL round-bottom flask equipped with a magnetic stirring bar 
was placed PPh3 (4.98 g, 19.0 mmol, 5.0 eq.) in dry CH2Cl2 (6 mL). The mixture was 
cooled to 0 °C and CBr4 (3.15 g, 9.50 mmol) was added, and the mixture was stirred 
for 10 min at 0 °C. Aldehyde 116 (1.40 g, 3.81 mmol, 1.0 eq.) dissolved in dry 
CH2Cl2 (10 mL) was slowly added. The mixture was flushed with argon and allowed 
to stir at 0 °C for 4 hrs. The mixture was diluted with CH2Cl2 and washed with brine 
(2 × 30 mL) followed by H2O (2 × 30 mL). The aqueous layer was extracted twice 
with CH2Cl2 and the combined organic layer was dried over MgSO4. The solvent was 
evaporated under reduced pressure and the crude product purified by column 
chromatography on silica gel (15-20% EtOAc/hexane) to afford the vinyl dibromide 
117 as a foamy yellow solid (1.77 g, 3.40 mmol, 89%). 
 
Rf = 0.47 (20% EtOAc/Hexane); Mp. 133-135 (C2H5)2O; 
IR (ν/cm-1): 3108, 2912, 1599, 1213, 1173, 1103, 630.0; 
1
H NMR (300 MHz, CDCl3): δ 7.78 (1H, dd, J = 8.4, 1,0 
Hz, H-8), 7.43 (1H, t, J = 8.1 Hz, H-7), 7.14 (1H, d, J = 
0.8 Hz, H-3′), 7.09 (1H, s, =CH-), 6.91 (1H, dd, J = 7.8, 
1.1 Hz, H-6), 6.84 (1H, d, J =  0.9 Hz, H-5′), 6.55 (1H, s, H-3), 4.00 (3H, s, OMe), 
3.92 (3H, s, OMe), 3.75 (3H, s, OMe), 3.52 (3H, s, OMe), 2.46 (3H, s, ArMe); 
13
C 
NMR (75 MHz, CDCl3): δ 157.4, 157.0, 152.8, 147.3, 138.6, 137.1, 136.2, 131.6, 
126.5, 124.7, 124.2, 121.7, 118.3, 115.3, 112.1, 109.6, 106.9, 90.6, 61.2, 56.9, 56.6, 
55.9, 21.8; HRMS (ESI+): Found (M + H)
+
 520.9960, C23H23O4
79
Br2 (M + H)
+
 
requires 520.9958, m/z 520.9960 [(M + H)
+
, 50%], 522.9937 (100). 
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7.2.2.17 Preparation of 2-(2-ethynyl-6-methoxy-4-methylphenyl)-1,4,5-
trimethoxynaphthalene 118 
In an oven-dried 25 mL two-necked round bottom flask equipped with a magnetic 
stirring bar was placed the vinyl dibromide 117 (1.35 g, 2.59 mmol, 1.0 eq.) in dry 
THF (6 mL) under argon atmosphere. The mixture was cooled to −78 °C and a 1.2 M 
solution of n-BuLi in hexanes (5.40 mL, 6.48 mmol, 2.5 eq.) was added dropwise. 
The mixture was allowed to stir at −78 °C for 6 hrs and then for 1 hr at rt, at which 
time TLC showed the reaction to be complete. The mixture was quenched with water 
and extracted with Et2O (3 × 30 mL). The combined organic layer was dried over 
MgSO4 and solvent evaporated under reduced pressure. Chromatographic purification 
on silica gel (20% EtOAc/hexane) afforded the alkyne product 118 as a yellowish 
brown solid (0.83 g, 2.29 mmol, 88%).  
 
Rf = 0.27 (20% EtOAc/Hexane); Mp. 135-137 CHCl3; IR 
(ν/cm-1): 3272, 3089, 2947, 2371, 1598, 1274, 1122, 1078; 1H 
NMR (300 MHz, CDCl3): δ 7.78 (1H, dd, J = 8.5, 1.0 Hz, H-
8), 7.41 (1H, t, J = 8.2 Hz, H-7), 7.09 (1H, d, J = 0.9 Hz, H-
3′), 6.89 (1H, dd, J = 8.5, 1,0 Hz, H-6), 6.84 (1H, d, J = 0.8 
Hz, H-5′), 6.67 (1H, s, H-3), 3.98 (3H, s, OMe), 3.92 (3H, s, OMe), 3.73 (3H, s, 
OMe), 3.57 (3H, s, OMe), 2.81 (1H, s, ≡CH), 2.41 (3H, s, ArMe); 13C NMR (75 
MHz, CDCl3): δ 157.4, 157.1, 152.6, 147.7, 138.6, 131.4, 128.3, 126.2, 125.8, 125.6, 
123.2, 118.3, 115.4, 113.0, 109.9, 106.7, 82.6, 79.9, 61.4, 56.9, 56.6, 56.0, 21.5; 
HRMS (ESI+):  Found (M + H)
+
 363.1601, C23H23O4 (M + H)
+
 requires 363.1596, 
m/z 363.1601 [(M + H)
+
, 100%], 348.1370 (30). 
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7.2.2.18 Preparation of 1,7,8,12-tetramethoxy-3-methyltetraphene 119 and 
1,10,12-trimethoxy-8-methylchrysene 120 
 
Method 1: Using platinum(II) chloride 
In an oven-dried 25 mL round-bottom flask equipped with a magnetic stirring bar 
was placed the alkyne 118 (810 mg, 2.24 mmol, 1.0 eq.) in dry PhMe (10 mL). PtCl2 
(0.089 mg, 0.34 mmol) was then added and the mixture was stirred at 90 °C for 24 
hrs under argon atmosphere. The mixture was filtered through Celite and the residue 
was washed with CH2Cl2. Chromatographic purification on silica gel (15-20% 
EtOAc/hexane) afforded 1,7,8,12-tetramethoxy-3-methyltetraphene 119 as a yellow 
solid (495 mg, 1.37 mmol, 61 %) and 1,10,12-trimethoxy-8-methylchrysene 120 as a 
yellowish brown solid (171 mg, 0.515 mmol, 23%). 
 
Method 2: Using gold(III) chloride 
In an oven-dried 25 mL round-bottom flask equipped with a magnetic stirring bar 
was placed the alkyne 118 (820 mg, 2.27 mmol, 1.0 eq.) in dry PhMe (10 mL). AuCl3 
(0.103 mg. 0.34 mmol) was then added and the mixture was stirred at 90 °C for 24 h 
under argon atmosphere. The mixture was filtered through Celite and the residue was 
washed with CH2Cl2. Chromatographic purification on silica gel (15-20% 
EtOAc/hexane) afforded 1,7,8,12-tetramethoxy-3-methyltetraphene 119 as a yellow 
solid (0.460 mg, 1.27 mmol, 56 %) and 1,10,12-trimethoxy-8-methylchrysene 120 as 
a yellowish brown solid (234 mg, 0.704 mmol, 31%). 
 
Rf = 0.48 (20% EtOAc/Hexane); Mp. 80-82 CH2Cl2; IR 
(ν/cm-1): 3097, 2920, 1606, 1223, 1121, 1060, 832;  1H 
NMR (300 MHz, CDCl3): δ 8.11 (1H, dd, J = 8.6, 1.0 Hz, 
H-11), 8.03 (1H, d, J = 9.2 Hz, H-6), 7.44 (1H, t, J = 8.8 
Hz, H-10), 7.36 (1H, d, J = 9.5 Hz, H-5), 7.17 (1H, d, J = 
0.8 Hz, H-4), 6.92 (1H, d, J = 0.9 Hz, H-2), 6.89 (1H, d, J = 7.1 Hz, H-9), 4.07 (3H, 
s, OMe), 3.97 (6H, s, OMe), 3.51 (3H, s, OMe), 2.54 (3H, s, ArMe); 
13
C NMR (75 
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MHz, CDCl3): δ 158.0, 156.2, 150.9, 147.1, 138.1, 134.6, 129.7, 126.2, 125.4, 125.1, 
122.1, 119.6, 118.6, 117.4, 116.6, 115.8, 110.9, 105.2, 63.3, 60.4, 56.3, 56.2, 21.7; 
HRMS (ESI+):  Found (M + H)
+
 363.1593, C23H23O4 (M + H)
+
 requires 363.1591, 
m/z 363.1593 [(M + H)
+
, 100%], 362.1521 (55). 
 
Rf = 0.29 (20% EtOAc/Hexane); Mp. 176-178 CH2Cl2; IR 
(ν/cm-1): 3021, 2904, 1589, 1489, 1217, 1167, 1078, 742; 1H 
NMR (300 MHz, CDCl3) δ 9.20 (1H, s, H-11), 8.55 (1H, d, J 
= 9.1 Hz, H-5), 8.37 (1H, d, J = 8.5 Hz, H-4), 7.69 (1H, d, J = 
9.1 Hz, H-6), 7.56 (1H, t, J = 8.2 Hz, H-3), 7.34 (1H, d, 0.9 
Hz, H-7), 7.05 (1H, d, J = 7.8 Hz, H-2), 6.92 (1H, d, J = 0.9 
Hz, H-9), 4.15 (3H, s, OMe), 4.11 (3H, s, OMe), 4.03 (3H, s, 
OMe), 2.54 (3H, s, ArMe);  
13
C NMR (75 MHz, CDCl3) δ 
158.6, 157.4, 154.9, 136.5, 135.3, 134.0, 130.0, 126.6, 124.8, 
123.5, 122.4, 121.2, 118.9, 116.7, 116.2, 110.0, 107.8, 106.1, 
56.8, 56.2, 56.1, 21.7. HRMS (ESI+):  Found (M + H)
+
 
333.1458, C22H21O3 (M + H)
+
 requires 333.1486, m/z 
333.1458 [(M + H)
+
, 100%]. 
 
7.2.2.19 Preparation of 1,8-dimethoxy-3-methyltetraphene-7,12-dione 38 
In a 25 mL round bottom flask equipped with a magnetic stirring bar was placed 
1,7,8,12-tetramethoxy-3-methyltetraphene 119 (150 mg, 0.41 mmol, 1.0 eq.) in 
MeCN (5 mL). CAN (0.66 mg, 1.20 mmol, 3.0 eq.) in H2O (5 mL) was then added 
and the mixture stirred for 30 min. NaHCO3 was then added and the organic material 
was extracted into EtOAc (3 × 10 mL). The combined organic layer was dried over 
MgSO4 and the solvent removed in vacuo. The crude product was purified by column 
chromatography on silica gel (50% EtOAc/hexane) to give 1,8-dimethoxy-3-
methyltetraphene-7,12-dione 38 as a yellow solid (117 mg, 0.353 mmol, 86%) 
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Rf = 0.16 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3011, 2984, 
1660, 1656, 1588, 1470, 1442, 1137, 1009, 947, 754; 
1
H 
NMR (300 MHz, CDCl3): δ 8.22 (1H, d, J = 8.6 Hz, H-5), 
7.91 (1H, d, J = 8.6 Hz, H-6), 7.67 (2H, dd, J = 4.8, 0.7 Hz, 
ArH), 7.27 – 7.22 (2H, m, ArH), 6.89 (1H, d, J = 1.4 Hz, H-
2), 4.03 (3H, s, OMe), 3.97 (3H, s, OMe), 2.52 (3H, s, ArMe); 
13
C NMR (75 MHz, 
CDCl3): δ 186.6, 182.3, 159.4, 156.9, 140.3, 139.3, 137.8, 135.2, 135.0, 133.9, 132.5, 
122.7, 120.7, 120.1, 119.1, 118.5, 116.2, 111.2, 56.5, 56.0, 22.1. 
 
7.2.2.20 Preparation of 1,8-dihydroxy-3-methyltetraphene-7,12-dione 2 
In an oven-dried 25 mL two-necked round bottom flask equipped with a magnetic 
stirring bar was placed 1,8,-dimethoxy-3-methyltetraphene-7,12-dione 38 (40 mg, 
0.120 mmol. 1.0 eq.) in CH2Cl2 (5 mL) under argon atmosphere. The mixture was 
cooled to −78 °C and BBr3 (1.20 mL, 1.20 mmol, 10.0 eq.) was added dropwise. The 
reaction was then slowly warmed to RT and stirred for a further 18hrs before being 
cooled to 0 °C and quenched with water. The organic material was extracted with 
CH2Cl2 (3 × 10 mL) and the combined organic layer was dried over MgSO4 and the 
solvent removed under reduced pressure. The crude product was purified by column 
chromatography on silica gel (5% EtOAc/hexane) to afford 1,8-dihydroxy-3-
methyltetraphene-7,12-dione 2 as a brown solid (37.1 mg, 0.111 mmol, 93%)  
 
Rf = 0.58 (20% EtOAc/Hexane); IR (CHCl3): (ν/cm
–1
): 3002, 
2996, 1677, 1656, 1578, 1543, 1499, 1477, 1371, 1292, 1157, 
1080, 793; 
1
H NMR (300 MHz, CDCl3): δ 12.24 (1H, s, 
ArOH), 11.26 (1H, s, ArOH), 8.31 (1H, d, J = 8.6 Hz, H-5), 
8.13 (1H, d, J = 8.6 Hz, H-6), 7.85 (1H, d, J = 7.6 Hz, H-11), 7.73 – 7.63 (2H, m, 
ArH), 7.36 – 7.30 (2H, m, ArH), 7.14 (1H, d, J = 1.4 Hz, H-2), 2.49 (3H, s, ArMe); 
13
C NMR (126 MHz, CDCl3): δ 189.7, 187.9, 161.7, 155.3, 142.0, 139.1, 137.7, 
136.9, 134.8, 132.4, 124.8, 123.2, 121.9, 121.3, 121.2, 120.2, 120.0, 114.7, 21.3. 
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7.3 Experimental Procedures pertaining to Chapter 4 
7.3.1 Preparation of 3-methoxy-5-methyl-2-(1,4,5-trimethoxynaphthalen-2-
yl)benzaldehyde O-acetyl oxime 222 
To a solution of 3-methoxy-5-methyl-2-(1,4,5-trimethoxynaphthalen-2-
yl)benzaldehyde 116 (0.505 g, 1.38 mmol, 1.0 eq.) in MeOH (5 mL) was added 
hydroxylamine hydrochloride (0.19 g, 2.75 mmol, 2.0 eq.) and NaOAc (0.170 g, 2.07 
mmol, 1.5 eq.). The reaction mixture was heated at reflux for 2 hrs and the solvent 
was removed in vacuo. To the residue, dry CH2Cl2 (3 mL) and triethylamine (0.38 
mL, 0.28 g, 2.75 mmol, 2.0 eq.) were added at 0 °C. To this cooled solution was 
slowly added a solution of acetyl chloride (0.2 mL, 0.22 g, 2.75 mmol, 2.0 eq.) in dry 
CH2Cl2 (1 mL). The reaction mixture was stirred at rt for 18 hrs. Upon completion, 
the reaction was quenched with water (5 mL) and the mixture extracted with CH2Cl2 
(3 × 10 mL). The combined organic extracts were washed with aq. NaHCO3 (10 mL) 
and brine (10 mL) and dried over MgSO4 and the solvent removed under reduced 
pressure. The crude product was purified by column chromatography on silica gel (30 
% EtOAc/hexane) to afford the acetyl oxime 222 as a yellow solid (0.5 g, 1.18 mmol, 
86%).  
Rf = 0.17 (20% EtOAc/Hexane); Mp. 136-138 CH2Cl2; 
IR (ν/cm-1): 3004, 2945, 1764, 1581, 1449, 1374, 1201, 
1172, 752; 
1
H NMR (300 MHz, CDCl3): δ 8.03 (1H, s, -
N=CH-), 7.77 (1H, dd, J = 8.4, 0.8 Hz, H-8′), 7.67 (1H, s, 
H-6), 7.46 (1H, t, J = 8.1 Hz, H-7′), 6.97 – 6.92 (2H, m, 
ArH), 6.57 (1H, s, H-3′), 4.00 (3H, s, OMe), 3.90 (3H, s, OMe), 3.77 (3H, s, OMe), 
3.48 (3H, s, OMe), 2.46 (3H, s, ArMe), 2.08 (3H, s, -CO2Me); 
13
C NMR (75 MHz, 
CDCl3) δ 168.6, 157.5, 157.1, 155.3, 155.3, 152.9, 147.4, 139.4, 131.5, 129.6, 126.8, 
126.4, 123.5, 119.1, 115.3, 114.7, 109.6, 107.2, 61.0, 56.9, 56.6, 55.9, 21.6, 19.5; 
HRMS (ESI+):  Found (M + H)
+
 424.1757, C24H26NO6 (M + H)
+
 requires 424.1755, 
m/z 424.1757 [(M + H)
+
, 7%], 364.1542 (100), 333.1357 (30). 
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7.3.2 Preparation of 3-methoxy-5-methyl-2-(1,4,5-trimethoxynaphthalen-2-
yl)benzaldehyde O-phenyl oxime 230 
O-phenylhydroxylamine hydrochloride (0.240 g, 1.63 mmol, 1.0 eq.) was dissolved in 
anhydrous pyridine (10 mL) under argon at rt and 3-methoxy-5-methyl-2-(1,4,5-
trimethoxynaphthalen-2-yl)benzaldehyde 116 (0.60 g, 1.63 mmol, 1.0 eq.) was added 
in one portion. The reaction was stirred at rt for 18 hrs. On completion, the reaction 
was quenched with water and extracted with EtOAc (3 × 20 mL). The combined 
organic extracts were washed three times with CuSO4 to removed traces of pyridine 
followed by brine and then dried over MgSO4 and the solvent removed in vacuo. The 
crude product was purified by column chromatography (20% EtOAc/hexane) to give 
the O-phenyl oxime 230 as a yellowish brown solid (0.70 g, 1.53 mmol, 93%). 
 
 Rf = 0.35 (20% EtOAc/Hexane); Mp. 134-136 CH2Cl2; 
IR (ν/cm-1): 3036, 2939, 1578, 1455, 1374, 1298, 1075, 
749; 
1
H NMR (300 MHz, CDCl3): δ 8.12 (1H, s, -
N=CH-), 7.78 (1H, dd, J = 8.4, 0.9 Hz, H-8′), 7.63 (1H, 
d, J = 0.8 Hz, H-6), 7.43 (1H, t, J = 8.1 Hz, H-7′), 7.28 
– 7.11 (4H, m, ArH), 7.00 – 6.86 (3H, m, ArH), 6.59 (1H, s, H-3′), 3.97 (3H, s, 
OMe), 3.89 (3H, s, OMe), 3.74 (3H, s, OMe), 3.52 (3H, s, OMe), 2.47 (3H, s, ArMe); 
13
C NMR (75 MHz, CDCl3): δ 159.40, 157.47, 157.20, 152.91, 150.84, 147.52, 
139.04, 131.51, 130.92, 129.18, 126.76, 125.86, 123.90, 122.05, 118.45, 115.27, 
114.41, 113.70, 109.67, 107.11, 60.97, 56.84, 56.58, 55.82, 21.76; HRMS (ESI+):  
Found (M + H)
+
 458.1969, C28H28NO5 (M + H)
+
 requires 458.1962, m/z 458.1969 
[(M + H)
+
, 60%], 364.1548 (100), 334.1434 (30). 
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7.3.3 Preparation of 3-methoxy-5-methyl-2-(1,4,5-trimethoxynaphthalen-2-
yl)benzonitrile 224 
To a solution of the acetyl oxime 222 (0.32g, 0.76 mmol, 1.0 eq.) in toluene (10 mL) 
was added Pd(dba)2 (44 mg, 0.076 mmol, 10 mol %) and Cs2CO3 (0.248 g, 0.76 
mmol, 1.0 eq.). The reaction was stirred at 150 °C for 24 hrs. On completion, the 
reaction mixture was cooled to rt followed by the addition of EtOAc (15 mL) and 
water (15 mL). The organic layer was separated and subsequently washed with 
saturated NH4Cl solution (10 mL), water (10 mL) and brine (10 mL) and dried over 
MgSO4. The crude product was purified using column chromatography on silica gel 
(30% EtOAc/hexane) to afford the benzonitrile 224 as a yellow solid (0.17g, 0.471 
mmol, 62%) 
 
Rf = 0.13 (20% EtOAc/Hexane); Mp. 184-186 CHCl3; IR 
(ν/cm-1): 3043, 2991, 2365, 1597, 1455, 1227, 1176, 1076, 
847; 
1
H NMR (300 MHz, CDCl3): δ 7.78 (1H, dd, J = 8.4, 
1.0 Hz, H-8′), 7.43 (1H, t, J = 8.2 Hz, H-7′), 7.19 (1H, s, H-
6), 7.03 (1H, s, H-4), 6.92 (1H, d, J = 7.8 Hz, H-6′), 6.63 
(1H, s, H-3′), 3.98 (3H, s, OMe), 3.93 (3H, s, OMe), 3.77 
(3H, s, OMe), 3.55 (3H, s, OMe), 2.44 (3H, s, ArMe); 
13
C NMR (75 MHz, CDCl3): δ 
157.5, 157.3, 153.2, 147.9, 139.9, 131.5, 128.9, 126.8, 125.0, 123.6, 118.9, 118.1, 
116.5, 115.4, 114.5, 108.7, 107.4, 61.6, 57.0, 56.7, 56.1, 21.5; HRMS (ESI+):  Found 
(M + H)
+
 364.1552, C22H22 NO4 (M + H)
+
 requires 364.1544, m/z 364.1552 [(M + 
H)
+
, 100%]. 
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7.3.4 Preparation of 1,10,12-trimethoxy-8-methylbenzo[c]phenanthridine 
231 
 
Method 1: Microwave assisted method 
O-phenyl oxime 230 (110 mg, 0.24 mmol, 1.0 eq.) and EmimPF6 (60 mg, 0.24 mmol) 
were dissolved in tert-butylbenzene (3 mL) in a microwave reactor tube. The reaction 
mixture was subjected to microwave irradiation (300 W, 160 °C) for 20 min. After 
cooling, the ionic liquid was filtered off and the crude product was purified by 
column chromatography (20% EtOAc/hexane) to afford the phenanthridine 231 (46 
mg, 0.14 mmol, 58%) and the benzonitrile 224 (9.60 mg, 0.026 mmol, 11%) as 
yellow solids. 
 
Method 2: UV-induced photochemical method 
O- acetyl oxime 222 (80 mg, 0.17 mmol, 1.0 eq.) was introduced into a UV reactor 
and tert-butanol (5 mL) was added and the reaction mixture was degassed with argon. 
The solution was then subjected to UV radiation (450 W) for 20 min. After cooling, 
the crude product was purified by column chromatography (20% EtOAc/hexane) to 
afford the phenanthridine 231 (26 mg, 0.078 mmol, 46%) and the benzonitrile 224 
(11 mg, 0.031 mmol, 18%) 
 
Rf = 0.17 (20% EtOAc/Hexane); Mp. 211-213 CHCl3); 
IR (ν/cm-1): 3067, 2914, 1589, 1447, 1364, 1256, 1195, 
1076, 752; 
1
H NMR (500 MHz, CDCl3): δ 9.15 (1H, s, H-
11), 9.13 (1H, dd, J = 8.4, 0.7 Hz, H-4), 8.87 (1H, s, H-6), 
7.64 (1H, t, J = 8.1 Hz, H-3), 7.45 (1H, s, H-7), 7.12 (1H, 
d, J = 7.7 Hz, H-2), 7.03 (1H, s, H-9), 4.15 (3H, s, OMe), 4.11 (3H, s, OMe), 4.04 
(3H, s, OMe), 2.56 (3H, s, ArMe); 
13
C NMR (126 MHz, CDCl3): δ 157.8, 156.8, 
155.4, 149.0, 137.7, 137.2, 135.4, 129.6, 127.0, 122.6, 121.0, 120.6, 117.9, 117.4, 
112.7, 108.7, 103.7, 56.8, 56.1, 56.0, 21.8; HRMS (ESI+): Found (M + H)
+
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334.1447, C21H20NO3 (M + H)
+
 requires 334.1440, m/z 334.1447 [(M + H)
+
, 100%], 
335.1479 (25), 240.9883 (60). 
 
7.4 Experimental procedures pertaining to Chapter 6  
7.4.1 Preparation of 1,4-dimethoxynaphthalene 306 
To a clear solution of 1,4-naphthoquinone 305 (5.00 g, 31.63 mmol, 1.0 eq.) in THF 
(200 mL) was added TBAI (1.17 g, 1.69 mmol, 10 mol %) and Na2S2O4 (27.5 g, 
158.1 mmol, 5.0 eq.) in H2O (150 mL). The reaction was stirred at rt under argon for 
30 min followed by the addition of KOH (17.7 g, 0.316 mol, 10.0 eq.) in H2O (300 
mL). The reaction was stirred for a further 1 hr followed by the addition of Me2SO4 
(39.88 g, 30.0 mL, 0.316 mol, 10.0 eq.). The reaction mixture was then stirred for 18 
hrs before being quenched with 25% NH4OH (100 mL) and the organic material 
extracted into EtOAc (3 × 200 mL). The combined organic extracts were washed 
sequentially with distilled water (200 mL), 10% aq. HCl (200 mL) and brine (200 
mL) then dried over MgSO4, filtered through Celite and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel 
(10% EtOAc/hexane) to give the naphthalene 306 (5.18 g, 27.51 mmol, 87%) as a 
low melting off-white solid. 
 
Rf = 0.67 (20% EtOAc/Hexane); IR (ν/cm
–1
): = 3078, 2947, 2849, 
1614, 1489, 1464, 1238, 1163, 1088, 837, 812, 787; 
1
H NMR (500 
MHz, CDCl3): δ 8.32 – 8.10 (2H, m, H-5), 7.56 – 7.40 (2H, m, H-
6), 6.63 (2H, s, H-2), 3.90 (6H, s, OMe); 
13
C NMR (126 MHz, 
CDCl3): δ 149.5, 126.4, 125.8, 121.8, 103.2, 55.7. 
 
 
Chapter 7: Experimental Procedures 
 
 
 
184  
 
7.4.2 Preparation of 2-bromo-1,4-dimethoxynaphthalene 307 
To a solution of 1,4-dimethoxynaphthalene 306 (6.50 g, 34.57 mmol, 1.0 eq.) in 
CH2Cl2 was added NBS (6.15 g, 34.57 mmol, 1.0 eq.) and the reaction mixture was 
stirred under reflux for 2 hrs. On completion, the reaction was quenched with a 
saturated solution of aq. sodium sulfite (50 mL). The organic layer was collected and 
washed with water (50 mL) and brine (50 mL), dried over anhydrous MgSO4, filtered 
and the organic solvent was removed under reduced pressure. The crude product was 
purified by column chromatography (10% EtOAc/Hexane) to furnish 2-bromo-1,4-
dimethoxynaphthalene 307 as a low melting white solid (7.48 g, 28.0 mmol, 81 %). 
 
 
Rf = 0.76 (20% EtOAc/Hexane); 
1
H NMR (500 MHz, CDCl3): δ 
8.17 (1H, dd, J = 7.8, 0.7 Hz, ArH), 8.03 (1H, dd, dd, J = 7.8, 0.7 
Hz, ArH), 7.52 (1H, ddd, J = 8.3, 6.9, 1.3 Hz, ArH), 7.46 (1H, ddd, 
J = 8.2, 6.9, 1.3 Hz, ArH), 6.84 (1H, s, H-3), 3.92 (3H, s, OMe), 
3.90 (3H, s, OMe); 
13
C NMR (126 MHz, CDCl3): δ 152.2, 146.7, 129.0, 127.3, 
125.8, 125.6, 122.57, 121.8, 111.9, 107.7, 61.4, 55.8. 
 
7.4.3 Preparation of 2-(1,4-dimethoxynaphthalen-2-yl)benzaldehyde 309 
Tetrakis(triphenylphosphine)palladium(0) (2.08 g, 1.80 mmol, 0.1 eq.) and  2-
formylphenylboronic acid 308 (4.05 g, 27.02 mmol, 1.5 eq.) were added to a 
deoxygenated solution of  2-bromo-1,4-dimethoxynaphthalene (4.8 g, 17.98 mmol, 
1.0 eq.) in DME (100 mL) under argon atmosphere with stirring. To this was added a 
deoxygenated aq. Na2CO3 solution (2 M, 36 mL, 72.0 mmol, 4.0 eq.). The reaction 
mixture was then heated at reflux for 18 hrs. After this time, the mixture was cooled 
to rt and the reaction quenched with H2O (100 mL). The organic material was 
extracted into EtOAc (3 × 00 mL), followed by a brine wash (100 mL). The 
combined extract was dried over MgSO4, filtered through Celite and the solvent 
removed in vacuo. The crude product was purified by column chromatography on 
silica gel (10 % EtOAc/hexane) to afford 2-(1,4-dimethoxynaphthalen-2-
yl)benzaldehyde 309 as a yellow solid (4.25 g, 14.56 mmol, 90%).   
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Rf = 0.59 (20% EtOAc/Hexane); Mp. 190–192 °C (C2H5)2O; 
IR (ν/cm–1): 2935, 1723, 1625, 1591, 1506, 1464, 1263, 
1223; 
1
H NMR (300 MHz, CDCl3): δ 9.90 (IH, s, CHO), 
8.34 – 8.25 (1H, m, ArH), 8.17 – 8.04 (2H, m, ArH), 7.75 – 
7.65 (1H, m, ArH), 7.63 – 7.50 (4H, m, ArH), 6.74 (s, 1H), 
4.01 (3H, s. OMe), 3.40 (3H, s, OMe); 
13
C NMR (75 MHz, CDCl3): δ 192.4, 152.1, 
147.0, 142.0, 133.8, 133.6, 131.0, 128.4, 127.9, 127.2, 127.1, 126.7, 126.2, 125.4, 
122.4, 122.4, 105.9, 60.9, 55.8; HRMS (ESI+): Found (M + H)
+
 293.1169, C19H17O3 
(M + H)
+
 requires 293.1173, m/z 293.1169 [(M + H)
+
, 100%], 292.1092 (50%). 
 
7.4.4 Preparation of (2-(1,4-dimethoxynaphthalen-2-yl)phenyl)methanol 
235 
2-(1,4-Dimethoxynaphthalen-2-yl)benzaldehyde 309  (2.97 g, 10.17 mmol, 1.0 eq.) 
was dissolved in 100 mL of freshly distilled dry THF under inert conditions. LiAlH4
 
(1.15 g, 30.5 mmol, 3.0 eq.) was added carefully to the mixture at 0 °C under inert 
conditions. The reaction mixture was allowed to warm to rt and the reaction was 
stirred for 2 hrs. When completed, the reaction was cooled to 0 °C, a 2% aq. NaOH 
(50 mL) solution was added dropwise to quench the unreacted LiAlH4 and then the 
mixture was diluted with ice-cold water (50 mL). The organic material was then 
extracted into EtOAc (3 × 100 mL) and combined organic phases were washed with 
brine (100 mL), dried over anhydrous MgSO4, filtered and the solvent was removed 
in vacuo. The crude product was then subjected to column chromatography on silica 
gel (30% EtOAc/Hexane) to obtain (2-(1,4-dimethoxynaphthalen-2-
yl)phenyl)methanol 235 as a white solid (2.81 g, 9.56 mmol, 94%).  
Rf = 0.36 (20% EtOAc/Hexane); Mp. 114-115 °C (C2H5)2O; 
IR (ν/cm-1): 3442, 2931, 1626, 1593, 1505, 1491, 1455, 
1274, 1230; 
1
H NMR (300 MHz, CDCl3): δ 8.28 (1H, d, J = 
7.8 Hz, ArH), 8.10 (1H, d, J = 7.8 Hz, ArH), 7.65 – 7.32 
(6H, m, ArH), 6.62 (1H, s, ArH-3′), 4.44 (1H, d, J = 11.1 
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Hz, one of CH2OH), 4.37 (1H, d, J = 11.1 Hz, one of CH2OH), 3.93 (3H, s, OMe), 
3.61 (1H, s, OH), 3.47 (3H, s, OMe);
 13
C NMR (75 MHz, CDCl3): δ 152.0, 146.2, 
139.5, 137.9, 130.1, 129.9, 129.1, 128.4, 128.3, 127.8, 127.1, 126.2, 125.8, 122.4, 
122.1, 106.4, 64.1, 61.6, 55.7; HRMS (ESI+): Found M
+
 294.1244, C19H17O2  M
+
 
requires 294.1251, m/z
 
277.1240 (100%), 294.1244 (M
+
, 30%). 
 
7.4.5 Preparation of 12-methoxy-6H-dibenzo[c,h]chromen-6-one 238, 3-
bromo-1,4-naphthoquinone)benzaldehyde 311 and 12-methoxy-6H-
dibenzo[c,h]chromen-6-ol 310 
A solution of (2-(1,4-dimethoxynaphthalen-2-yl)phenyl)methanol 235 (900 mg, 3.06 
mmol, 1.0 eq.) in CH2Cl2 (30 mL) was oxygenated and to this solution, NBS (1090 
mg, 6.12 mmol) was slowly added under oxygen atmosphere and the reaction mixture 
was allowed to stir under oxygen at rt for 8 hrs. On completion, the reaction was 
quenched with a saturated solution of aq. sodium sulfite (30 mL). The organic layer 
was collected and washed with water (50 mL) and brine (50 mL), dried over 
anhydrous MgSO4, filtered and the organic solvent was removed under reduced 
pressure. The crude product was purified by column chromatography (10% 
EtOAc/Hexane) to isolate 12-methoxy-6H-dibenzo[c,h]chromen-6-one 238 as a light 
tan solid (356 mg, 1.29 mmol, 42%) and 2-(3-bromo-1,4-
naphthoquinone)benzaldehyde 311 as a yellow solid (324 mg, 0.949 mmol 36%). The 
spectroscopic data for 238 was found to be in agreement with that of Jones and 
Qabaja.
159
  
Rf = 0.88 (20% EtOAc/Hexane); Mp. 228-230 °C (C2H5)2O; 
IR (ν/cm-1): 2935, 2814, 1683, 1616, 1418, 1277, 1275, 938; 
1
H NMR (300 MHz, CDCl3): δ 8.58-8.43 (2H, m, ArH), 8.26 
(1H, d, J = 7.7 Hz, ArH), 8.12 (1H, d, J = 8.1 Hz, ArH), 7.95-
7.82 (1H, m, ArH), 7.69-7.55 (3H, m, ArH), 7.24 (1H, s, ArH-
11), 4.12 (3H, s, OMe);
 13
C NMR (75 MHz, CDCl3): δ 161.4, 
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152.4, 141.8, 135.5, 134.7, 130.7, 128.4, 127.7, 127.3, 126.8, 124.8, 122.1, 122.1, 
121.8, 121.4, 112.6, 95.7, 55.8; HRMS (ESI+): Found (M + H)
+
 277.0865, C18H12O3 
(M + H)
+  requires 277.0860, m/z 277.0865 [(M + H)
+
, 100%], 278.0694 (20%). 
 Rf = 0.29 (20% EtOAc/Hexane); Mp. 114-116 °C 
(C2H5)2O; IR (ν/cm
-1
): 3069, 2759, 1693, 1667, 1591, 1578, 
1268, 1246, 1129, 759;
 1
H NMR (500 MHz, CDCl3): δ 9.94 
(1H, d, J = 0.7 Hz, CHO), 8.26-8.24 (1H, m, ArH), 8.12-
8.10 (1H, m, ArH), 7.97 (1H, dd, J = 8.4, 1.3 Hz, ArH), 
7.80 – 7.78 (2H, m, ArH), 7.75 (1H, td, J = 7.5,  1.4 Hz, ArH), 7.70 (1H, td, J = 7.6, 
1.3 Hz, ArH), 7.38 (1H, dd, J = 8.4, 1.4 Hz, ArH); 
13
C NMR (126 MHz, CDCl3): δ 
191.3, 180.9, 177.8, 150.9, 136.8, 135.1, 134.3, 134.1, 134.0, 133.9, 133.6, 131.9, 
131.3, 130.2, 129.8, 127.7, 127.3; HRMS (ESI+): Found (M + H)
+
 340.9799, 
C17H10O3
79
Br (M + H)
+
 requires 340.9810. 
Note: The lactol 310 was isolated when the same reaction was done under 
atmospheric condition. 
Rf = 0.48 (20% EtOAc/Hexane); 
1
H NMR (500 MHz, CDCl3): δ 8.59 (1H, d, J = 8.3 
Hz, ArH), 8.30 (1H, d, J = 8.4 Hz, ArH), 7.72 – 7.68 (2H, m, 
ArH), 7.60 (1H, d, J = 6.9, 7.0 Hz, ArH), 7.31 (1H, td, J = 7.6, 
1.3 Hz, ArH), 7.12 (1H, s, ArH), 7.08 (1H, s, CH), 7.01 (1H, td, 
J = 7.5, 7.5, 1.1 Hz, ArH), 6.70 (1H, d, J = 7.6 Hz, ArH), 4.04 
(3H, s, OMe), 1.54 (1H, s, OH); 
13
C NMR (126 MHz, CDCl3): 
δ 150.9, 139.5, 129.4, 129.3, 128.9, 127.5, 127.0, 126.8, 126.7, 
126.5, 126.1, 122.3, 121.7, 121.5, 115.4, 98.3, 92.8, 55.8. 
 
7.4.6 Preparation of 2-(3-bromo-1,4-dimethoxynaphthalen-2-
yl)benzaldehyde 314 
A solution of 2-(1,4-dimethoxynaphthalen-2-yl)benzaldehyde 309 (410 mg, 1.42 
mmol, 1.0 eq.) in CH2Cl2 (10 mL) was oxygenated and to this solution, NBS (504 
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mg, 2.83 mmol, 2.0 eq.) was slowly added under oxygen atmosphere and the reaction 
mixture was allowed to stir under oxygen over 18 hrs at rt. On completion, the 
reaction was quenched with saturated solution of aq. sodium sulfite (15 mL). The 
organic layer was collected and washed with water (30 mL) and brine (30 mL), dried 
over anhydrous MgSO4, filtered and the organic solvent was removed under reduced 
pressure. The crude product was purified by column chromatography (15% 
EtOAc/Hexane) to isolate 2-(3-bromo-1,4-dimethoxynaphthalen-2-yl)benzaldehyde 
314 (301 mg, 0.809 mmol, 57 %)  as an off-white low melting solid and 2-(3-bromo-
1,4-naphthoquinone)benzaldehyde 311 as a yellow solid (136 mg, 0.397 mmol 28%).  
 Rf = 0.59 (20% EtOAc/Hexane); Mp. 89-91 °C CH2Cl2; IR 
(ν/cm-1): 3070, 2933, 2844, 2745, 1694, 1596, 1576, 1491, 
1351, 1146, 1080, 1040; 
1
H NMR (500 MHz, CDCl3): δ 9.82 
(1H, d, J = 0.6 Hz), 8.20 – 8.17 (1H, m, ArH), 8.13 – 8.11 (1H, 
m, ArH), 8.10 (1H, dd, J = 7.8, 1.4 Hz), 7.72 (1H, td, J = 7.5,  
1.4 Hz, ArH), 7.62 – 7.60 (3H, m, ArH), 7.42 (1H, dd, J = 7.7, 1.7 Hz, ArH), 4.03 
(3H, s, OMe), 3.48 (3H, s, OMe); 
13
C NMR (126 MHz, CDCl3): δ 191.6, 150.8, 
150.4, 140.4, 134.1, 133.5, 132.0, 129.2, 128.7, 128.2, 128.0, 127.7, 127.6, 127.2, 
123.1, 122.6, 114.7, 61.6, 61.5; HRMS (ESI+):  Found (M + H)
+
 371.0267, 
C19H16O3
79
Br (M + H)
+
 requires 371.0278.  
 
7.4.7 Preparation of 2-bromo-1,4-dimethoxybenzene 319 
To a solution of 1,4-dimethoxybenzene 318 (5.00 g, 36.19 mmol, 1.0 eq.) in CH2Cl2 
was added NBS (6.40 g, 36.19 mmol, 1.0 eq.) and the reaction mixture was stirred 
under reflux for 72 hrs. On completion, the reaction was quenched with a saturated 
solution of aq. sodium sulfite (50 mL). The organic layer was collected and washed 
with water (50 mL) and brine (50 mL), dried over anhydrous MgSO4, filtered and the 
organic solvent was removed under reduced pressure. The crude product was purified 
by column chromatography (10% EtOAc/Hexane) to furnish 2-bromo-1,4-
dimethoxybenzene 319 as a light brown oil (7.31 g, 33.66 mmol, 93 %). 
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 Rf = 0.59 (20% EtOAc/Hexane); 
1
H NMR (300 MHz, CDCl3): 
δ 7.11 (1H, dd, J = 7.1, 0.8 Hz, H-5), 6.82 – 6.79 (2H, m, H-3 
and H-6 overlapping), 3.81 (3H, s, OMe), 3.73 (3H, s, OMe); 
13
C 
NMR (75 MHz, CDCl3): δ 150.3, 119.0, 114.6, 113.6, 112.9, 
111.9, 56.8, 55.1. 
 
7.4.8 Preparation of 2',5'-dimethoxybiphenyl-2-carbaldehyde 320 
To a deoxygenated solution of 2-bromo-1,4-dimethoxybenzene 319 (4.25 g, 19.66 
mmol, 1.0 eq.) and 2-formylphenylboronic acid 308 (4.42 g, 29.49 mmol, 1.5 eq.) in 
DME (160 mL) was added Pd(PPh3)4 (1.82 g, 1.57 mmol, 8 mol %) under argon 
atmosphere with stirring. To this mixture was added a deoxygenated aq. Na2CO3 
solution (2 M, 39.3 mL, 78.64 mmol, 4.0 eq.). The mixture was then heated at reflux 
for 18 hrs. After this time, the mixture was cooled to rt and the reaction quenched 
with H2O (100 mL). The organic material was extracted into EtOAc (3 × 100 mL), 
the combined extract dried with MgSO4, and the solvent removed in vacuo. The crude 
product was purified by column chromatography on silica gel (5-10% EtOAc/hexane) 
to afford 2',5'-dimethoxybiphenyl-2-carbaldehyde 320 as an off-white solid (4.19 g, 
17.30 mmol, 88%). 
 
 
Rf = 0.48 (20% EtOAc/Hexane); 
1
H NMR (500 MHz, CDCl3): 
δ 9.79 (1H, s, CHO), 8.01 – 7.97 (1H, m, ArH), 7.64 (1H, td, J = 
7.5, 1.2 Hz, ArH), 7.48 (1H, t, J = 7.6 Hz, ArH), 7.38 – 7.34 
(1H, m, ArH), 6.94 (1H, dd, J = 8.9, 3.0 Hz, ArH), 6.90 (1H, d, J 
= 8.9 Hz, ArH), 6.87 (1H, d, J = 3.0 Hz, ArH), 3.81 (3H, s, 
OMe), 3.67 (3H, s, OMe); 
13
C NMR (126 MHz, CDCl3): δ 192.5, 153.8, 150.7, 
141.6, 134.0, 133.7, 131.0, 127.8, 127.7, 126.6, 117.3, 114.4, 111.8, 55.9, 55.8.
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7.4.9 Preparation of (2',5'-dimethoxybiphenyl-2-yl)methanol 321 
2',5'-Dimethoxybiphenyl-2-carbaldehyde 320 (3.37 g, 13.92 mmol, 1.0 eq.) was 
dissolved in freshly distilled THF (140mL) and LiAlH4 (1.58 g, 41.75 mmol, 3.0 eq.) 
was added to it at 0 °C under inert conditions. The reaction mixture was allowed to 
warm up to rt and was stirred for 2 hrs. When completed, the reaction was cooled to 0 
°C, a 2% aq. NaOH (50 mL) solution was added dropwise to quench the unreacted 
LiAlH4 and then the mixture was diluted with ice-cold water (50 mL). The organic 
material was then extracted into EtOAc (3 × 100 mL) and combined organic phases 
were washed with brine (100 mL), dried over anhydrous MgSO4, filtered and the 
solvent was removed in vacuo. The crude product was purified using column 
chromatography on silica gel (20% EtOAc/Hexane) to isolate (2',5'-
dimethoxybiphenyl-2-yl)methanol 321 as a clear oil (3.33 g, 13.64 mmol, 98%).  
Rf = 0.37 (20% EtOAc/Hexane); IR (ν/cm
-1
): 3422, 2999, 2836, 1600, 1499, 1483, 
1460, 1447, 1440, 1274, 1211; 
1
H NMR (500 MHz, CDCl3): δ 7.53 
(1H, dd, J = 7.5, 1.2 Hz, ArH), 7.36 (2H, dtd, J = 7.4, 7.4, 1.4 Hz, 
ArH), 7.26 – 7.15 (1H, m, ArH), 6.89 (2H, dt, J = 8.9, 5.9 Hz, 
ArH), 6.74 (1H, d, J = 2.9 Hz, ArH), 4.41 (2H, d, J = 10.6 Hz, 
CH2OH), 3.77 (3H, s, OMe), 3.66 (3H, s, OMe), 2.50 (t, J = 6.2 Hz, 
OH); 
13
C NMR (126 MHz, CDCl3): δ 153.9, 150.6, 139.3, 137.4, 131.1, 130.1, 
128.8, 128.1, 127.7, 117.0, 113.6, 112.8, 63.8, 56.7, 55.7; HRMS (ESI+): Found M
+
 
244.1091, C15H16O3 M
+
 requires 244.1086, m/z 244.1091 (M
+
, 15%), 227.1065 
(100%). 
 
7.4.10 Preparation of 2-methoxy-6H-benzo[c]chromen-6-one 322 and (4′-
bromo-2′,5′-dimethoxybiphenyl-2-yl)benzaldehyde 323 
NBS (1.28 g, 7.21 mmol, 2.0 eq.) was slowly added under an oxygen atmosphere to 
an oxygenated solution of (2',5'-dimethoxybiphenyl-2-yl)methanol 321 (0.88 g, 3.60 
mmol, 1.0 eq.) in CH2Cl2 (40 mL). The reaction mixture was allowed to stir under 
oxygen at rt for 8 hrs. On completion, the reaction was quenched with saturated 
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solution of aq. sodium sulfite (30 mL). The aqueous layer was extracted with CH2Cl2 
(3 × 50 mL) and the combined organic phases were washed with water (50 mL) and 
brine (50 mL), dried over anhydrous MgSO4, filtered and the organic solvent was 
removed under reduced pressure. The crude product was purified by column 
chromatography (5% EtOAc/Hexane) to afford 2-methoxy-6H-benzo[c]chromen-6-
one 322 as a white solid (0.37 g, 1.65 mmol, 46%) and (4′-bromo-2′,5′-
dimethoxybiphenyl-2-yl)benzaldehyde 323 (0.42 g, 1.29 mmol 36%). 
 Rf = 0.45 (20% EtOAc/Hexane); Mp 117-119 °C CH2Cl2; IR 
(ν/cm-1) 2938, 2812, 1679, 1609, 1420, 1278, 1224, 1003; 1H 
NMR (300 MHz, CDCl3): δ 8.41 (1H, dd, J = 7.9, 1.0 Hz, ArH), 
8.07 (1H, d, J = 8.1 Hz, ArH), 7.83 (1H, td, J = 7.8, 1.4 Hz, ArH), 
7.64 – 7.55 (1H, m, ArH), 7.50 (1H, d, J = 2.9 Hz, ArH), 7.31 
(1H, d, J = 9.0 Hz, ArH), 7.05 (1H, dd, J = 9.0, 2.9 Hz, ArH), 
3.91 (3H, s, OMe); 
13
C NMR (75 MHz, CDCl3): δ 161.3, 156.4, 145.7, 134.7, 134.7, 
130.7, 129.0, 121.7, 121.4, 118.7, 118.6, 117.1, 106.4, 55.9; HRMS (ESI+):  Found 
(M + H)
+
 227.0701, C14H11O3 (M + H)
+
 requires 227.0704, m/z 227.0701 [(M + H)
+
, 
100%], 226.0625 (30%). 
Rf = 0.61 (20% EtOAc/Hexane); IR (ν/cm
–1
): 2976, 2847, 
1691, 1596, 1206, 1198, 938, 656; 
1
H NMR (500 MHz, 
CDCl3): δ 9.78 (1H, s, CHO), 8.02-7.97 (1H, m, ArH), 7.65 
(1H, d, J = 1.2 Hz, ArH), 7.51 (1H, s, ArH), 7.34 (1H, d, J = 
7.6 Hz, ArH), 7.18 (1H, s, ArH), 6.86 (1H, s, ArH), 3.88 (3H, s, OMe), 3.69 (3H, s, 
OMe); 
13
C NMR (126 MHz, CDCl3): δ 192.1, 150.8, 150.4, 140.7, 134.0, 133.7, 
130.9, 128.2, 126.9, 126.7, 116.3, 115.2, 112.1, 57.0, 56.2; HRMS (ESI+): Found (M 
+ H)
+
 321.0120, C15H14
79
BrO3 (M + H)
+
 requires 321.0122, m/z 320.0043 (100%), 
322.0043 (97%). 
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7.4.11 Preparation of 2′-methoxybiphenyl-2-carbaldehyde 325 
To a deoxygenated solution of 2-bromoanisole 324 (4.00 g, 21.34 mmol, 1.0 eq.) and 
2-formylphenylboronic acid 308 (4.80 g, 32.09 mmol, 1.5 eq.) in DME (160 mL) was 
added Pd(PPh3)4 (2.46 g, 2.13 mmol, 10 mol%) under argon atmosphere with stirring. 
To this mixture was added a deoxygenated aq. Na2CO3 (2 M, 42.7 mL, 85.36 mmol, 
4.0 eq.). The mixture was then heated at reflux for 18 hrs. After this time, the mixture 
was cooled to rt and reaction quenched with H2O (100 mL). The organic material was 
extracted into EtOAc (3 × 100 mL), the combined extract dried with MgSO4, and the 
solvent removed in vacuo. The crude product was purified by column 
chromatography on silica gel (5-10% EtOAc/hexane) to afford 2′-methoxybiphenyl-
2-carbaldehyde 325 as an off-white solid (3.95 g, 18.63 mmol, 87%). 
 
 Rf = 0.52 (20% EtOAc/Hexane); 
1
H NMR (500 MHz, CDCl3): δ 
9.78 (1H, d, J = 0.9 Hz, CHO), 7.98 (1H, dd, J = 7.8, 1.5 Hz, 
ArH), 7.60 (1H, td, J = 7.5, 1.5 Hz, ArH), 7.44 (1H, t, J = 7.6 Hz, 
ArH), 7.39 (1H, td, J = 7.5, 1.8 Hz, ArH), 7.33 (1H, dd, J = 7.7, 
1.2 Hz, ArH), 7.26 (1H, dd, J = 7.5, 1.8 Hz, ArH), 7.06 (1H, td, J = 7.5, 1.1 Hz, 
ArH), 6.95 (1H, dd, J = 8.3, 1.0 Hz, ArH), 3.70 (3H, s, OMe); 
13
C NMR (126 MHz, 
CDCl3): δ 192.5, 156.5, 141.8, 134.0, 133.6, 131.4, 131.2, 130.0, 127.7, 126.8, 126.5, 
121.0, 110.6, 55.3. 
 
7.4.12 Preparation of (2'-methoxybiphenyl-2-yl)methanol 326 
2'-Methoxybiphenyl-2-carbaldehyde 325 (3.20 g, 15.09 mmol, 1.0 eq.) was dissolved 
in 140 mL of freshly distilled dry THF under inert conditions. LiAlH4
 
(1.71 g, 45.28 
mmol, 3.0 eq.) was added to the mixture carefully at 0 °C. The reaction was warmed 
to rt and allowed to stir at rt under inert conditions for 2 hrs. When completed, the 
reaction was cooled to 0 °C, a 2% aq. NaOH (50 mL) solution was added dropwise to 
quench the unreacted LiAlH4 and then the mixture was diluted with ice-cold water 
(100 mL). The organic material was then extracted into EtOAc (3 × 100 mL) and the 
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combined organic phases were washed with brine (100 mL), dried over anhydrous 
MgSO4, filtered and the solvent was removed under reduced pressure. The crude 
product was then subjected to column chromatography (20% EtOAc/Hexane) to 
obtain (2'-methoxybiphenyl-2-yl)methanol 326 as a clear oil (3.17 g, 14.78 mmol, 
98%).  
Rf = 0.48 (20% EtOAc/Hexane); 
1
H NMR (500 MHz, CDCl3): 
δ 7.49 (1H, dd, J = 7.4, 1.6 Hz, ArH), 7.35 – 7.27 (3H, m, ArH), 
7.16 (1H, dd, J = 7.4, 1.6 Hz, ArH), 7.11 (1H, dd, J = 7.4, 1.8 
Hz, ArH), 6.98 (1H, td, J = 7.5, 1.1 Hz, ArH), 6.92 (1H, dd, J = 
8.4, 1.0 Hz, ArH), 4.36 (2H, d, J = 11.9 Hz, -CH2-), 3.64 (3H, s, OMe), 2.66 (1H, s, 
OH); 
13
C NMR (126 MHz, CDCl3): δ 156.3, 139.3, 137.3, 131.2, 130.2, 129.0, 
128.0, 127.8, 127.4, 126.8, 120.9, 111.0, 63.3, 55.6.  
 
7.4.13 Preparation of 6H-benzo[c]chromen-6-one 327 
NBS (1.10 g, 6.17 mmol, 1.5 eq.) was slowly added under an oxygen atmosphere to 
an oxygenated solution of (2'-methoxybiphenyl-2-yl)methanol 326  (880 mg, 4.11 
mmol, 1.0 eq.) in CCl4 (100 mL). The reaction mixture was allowed to stir under 
reflux for 18 hrs. On completion, the reaction was quenched with a saturated solution 
of aq. sodium sulfite (50 mL). The aqueous layer was extracted with CH2Cl2 (3 × 50 
mL) and the combined organic phases were washed with water (100 mL) and brine 
(100 mL), dried over anhydrous MgSO4, filtered and the organic solvent was 
removed under reduced pressure. The crude product was purified by column 
chromatography (5 - 10% EtOAc/Hexane) to isolate 6H-benzo[c]chromen-6-one 327 
as a white crystalline solid (0.57 g, 2.91 mmol, 70%).  
Rf = 0.57 (20% EtOAc/Hexane); 
1
H NMR (300 MHz, CDCl3): δ 
8.39 (1H, d, J = 8.0 Hz, ArH), 8.10 (1H, d, J = 8.1 Hz, ArH), 8.04 
(1H, d, J = 7.9 Hz, ArH), 7.81 (1H, t, J = 8.7, ArH), 7.57 (1H, t, J 
= 7.1, ArH), 7.42 – 7.51 (1H, m, ArH), 7.39-7.28 (2H, m, ArH); 
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13
C NMR (75 MHz, CDCl3): δ 161.1, 151.3, 134.8, 134.7, 130.6, 130.4, 128.9, 124.5, 
122.8, 121.7, 121.3, 118.0, 117.8.  
 
7.4.14 Preparation of 2-(1,4,5-trimethoxynaphthalen-2-yl)benzaldehyde 328 
Tetrakis(triphenylphosphine)palladium(0) (0.47 g, 0.404 mmol, 10 mol %) and  2-
formylphenylboronic acid 308 (0.91 g, 6.06 mmol, 1.5 eq.) were added to a 
deoxygenated solution of  2-bromo-1,4,5-trimethoxynaphthalene 115 (1.20 g, 4.04 
mmol, 1.0 eq.) in DME (40 mL) under argon atmosphere with stirring. To this, was 
added a deoxygenated aq. Na2CO3 solution (2 M, 8.1 mL, 16.16 mmol, 4.0 eq.). The 
reaction mixture was then heated at reflux for 18 hrs. After this time, the mixture was 
cooled to rt and reaction quenched with H2O (50 mL). The organic material was 
extracted into EtOAc (3 × 50 mL), followed by a brine wash (50 mL). The combined 
extract dried over MgSO4, filtered through Celite and the solvent removed in vacuo. 
The crude product was purified by column chromatography on silica gel (10% 
EtOAc/hexane) to afford 2-(1,4,5-trimethoxynaphthalen-2-yl)benzaldehyde 328 as 
yellow solid (1.05 g, 3.27 mmol, 81%).   
Rf = 0.45 (20% EtOAc/Hexane); Mp. 98-100 °C CHCl3; IR 
(ν/cm–1): 3002, 2837, 1687, 1583, 1413, 1263, 1183, 987;  1H 
NMR (500 MHz, CDCl3): δ 9.89 (1H, s, CHO), 8.07 (1H, d, 
J = 9.4, ArH), 7.78 (1H, dd, J = 8.4, 1.0 Hz, ArH), 7.70 (1H, 
dt, J = 8.5, 1.4 Hz, ArH), 7.55 (2H, d, J = 7.7 Hz, ArH), 7.48 (1H, t, J = 8.0 Hz, 
ArH), 6.95 (1H, dd, J = 7.8, 0.6 Hz, ArH), 6.78 (1H, s, ArH), 4.00 (3H, s, OMe), 3.97 
(3H, s, OMe), 3.37 (3H, s, OMe); 
13
C NMR (126 MHz, CDCl3): δ 192.3, 157.5 
153.7, 147.0, 141.6, 133.7, 133.5, 131.3, 130.9, 128.0, 127.4, 127.1, 126.1, 118.5, 
115.2, 108.2, 107.4, 60.7, 56.9, 56.6; HRMS (ESI+): Found (M + H)
+
 323.1268, 
C20H18O4 (M + H)
+
 requires 323.1279, m/z 323.1268 [(M + H)
+
, 100%], 322.1193 
(40%). 
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7.4.15 Preparation of (2-(1,4,5-trimethoxynaphthalen-2-yl)phenyl)methanol 
329 
2-(1,4,5-Trimethoxynaphthalen-2-yl)benzaldehyde 328 (0.70 g, 2.17 mmol, 1.0 eq.) 
was dissolved in freshly distilled THF (30 mL) and LiAlH4 (0.25 g, 6.52 mmol, 3.0 
eq.) was added to it at 0 °C under inert conditions. The reaction mixture was allowed 
to warm to rt and was stirred for 2 hrs. When completed, the reaction was cooled to 0 
°C, a 2% aq. NaOH (20 mL) solution was added dropwise to quench the unreacted 
LiAlH4 and then the mixture was diluted with ice-cold water (20 mL). The organic 
material was then extracted into EtOAc (3 × 50 mL) and the combined organic phases 
were washed with brine (50 mL), dried over anhydrous MgSO4, filtered and the 
solvent was removed in vacuo. The crude product was purified using column 
chromatography on silica gel (30% EtOAc/Hexane) to isolate (2-(1,4,5-
trimethoxynaphthalen-2-yl)phenyl)methanol 329 as an off-white solid (0.68 g, 2.10 
mmol, 97%).  
 
Rf = 0.11 (20% EtOAc/Hexane); IR (ν/cm
–1
): 3384, 3012, 2930, 1584, 1417, 1237, 
1196, 1117, 1043; 
1
H NMR (500 MHz, CDCl3): δ 7.74 (1H, dd, J = 8.4, 1.0 Hz, 
ArH), 7.60 (1H, dd, J = 7.4, 1.4 Hz, ArH), 7.48 – 7.40 (1H, m, 
ArH), 7.37 (1H, dd, J = 7.4, 1.5 Hz, ArH), 6.92 (1H, dd, J = 
7.8, 0.7 Hz, ArH), 6.66 (1H, s, ArH), 4.42 (2H, s, CH2OH), 
3.99 (3H, s, OMe), 3.93 (3H, s, OMe), 3.46 (4H, s, OMe and 
OH overlapping); 
13
C NMR (126 MHz, CDCl3): δ 157.5, 153.6, 146.2, 139.4, 137.6, 
131.2, 130.0, 129.9, 129.8, 128.3, 127.8, 127.2, 118.0, 114.9, 108.5, 107.0, 64.1, 
61.4, 56.8, 56.5. 
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